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 WORKING DEFINITION OF TERMS 
Cardiovascular disorders:  This term is used broadly to include all diseases that involve the heart or 
blood vessels and include coronary artery diseases such as angina and myocardial infarction, stroke, 
heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, abnormal heart 
rhythms, heart valve disease, peripheral artery disease, thromboembolic disease, and venous 
thrombosis. 
Metabolic disorders: For purposes of this study this refers to specific disorders that increase risk of 
cardiovascular disorders such as hypertension, diabetes, dyslipidaemia and obesity. 
Conventional cardiovascular risk factors - This refers to conditions that are universally reported as to 
increase the  probability of developing cardiovascular disorders, though not necessarily causal factors 
Modifiable cardiovascular risk factors- They include smoking, hypertension diabetes, obesity, 
smoking, cigarette smoking. 
Non Modifiable cardiovascular risk factors - These include age, Sex and social economic status 
Non-conventional cardiovascular risk factors - For purposes of this study, these include trauma, 
psychological distress and chronic medical conditions. 
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Introduction: Cardiovascular disorders contribute significantly to mortality and morbidity amongst 
patient’s psychotic disorders such as schizophrenia and bipolar mood disorders. In addition to 
conventional risk factors for cardiovascular disorders (smoking, alcohol use, inadequate physical activity, 
hypertension, diabetes, dyslipidaemia, obesity and metabolic syndrome, and non-modifiable factors such 
as sex, age and social-economic status) exposure to potentially traumatic events, psychological distress, 
comorbidity of other medical conditions, and use of antipsychotics may also increase cardiovascular risk 
in patients with psychosis. There is also evidence to suggest that intervention to mitigate such 
cardiovascular risk factors are suboptimal, hence contributing to poor outcomes.  
 Despite growing interest in cardiovascular health, there remains a paucity of data on the prevalence of 
the various cardiovascular risk factors among patients with psychosis in low resource settings such as 
Sub-Saharan Africa. This is likely to differ from high resource contexts given social-cultural and economic 
differences as well as differences in the health systems.  In order to design contextually relevant 
cardiovascular risk screening, treatment and prevention guidelines that can be integrated into routine 
care of the mentally ill patients in low- and middle-income countries (LMICs), further work in this setting 
is warranted. 
Objectives: The aim of this thesis was to establish the cardiovascular risk profile among patients treated 
for psychotic disorders at Moi Teaching and Referral Hospital (MTRH) in Eldoret, Western Kenya. 
 Specific objectives were as follows: 
 1. To conduct a literature review on the burden and etiological mechanisms of cardiovascular risk in 
patients with psychosis, with a focus on LMIC. 
 2. To compare the prevalence, as well as sociodemographic and clinical correlates, of conventional 
cardiovascular risk factors (smoking, alcohol intake, poor diet, and lack of exercise, diabetes mellitus, 
hypertension, obesity, dyslipidaemia and metabolic syndrome) in patients with psychosis versus matched 
controls.   
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3. To establish the prevalence and correlates of non-conventional risk factors; psychological distress, 
traumatic events (lifetime and childhood trauma) and comorbid medical disorders in patients with 
psychosis and controls, and to delineate how these risk factors contribute to the overall cardiovascular 
risk. 
4.  To describe current psychopharmacological treatments and explore potential associations with 
cardiovascular risk among patients with psychosis. 
5. To explore the overall 10-year cardiovascular disease risk, as well as the social demographic and 
clinical correlates among patients and controls.  
6 .To determine the proportion of untreated metabolic disorders (hypertension, diabetes mellitus, and 
dyslipidaemia) in patients with psychotic disorders and matched controls. 
Methods: This was a cross-sectional descriptive survey comparing 300 patients with psychosis and 300 
controls at Moi Teaching and Referral Hospital, Western Kenya. A paper based researcher-administered 
questionnaire was used to collect data on demographic variables (age, sex, education level, and marital 
status), and risk factors (smoking, alcohol intake, diet, physical activity). We used the Composite 
International Diagnostic Interview (CIDI) to assess for presence of other chronic medical disorders. Data 
on childhood trauma were obtained using the Childhood Trauma Questionnaire (CTQ) while the Life 
Events Checklist (LEC) was used to obtain data on lifetime exposure to potentially traumatic events. Data 
on psychological distress among controls were obtained using the Kessler-10 questionnaire. 
Measurements of weight, height, abdominal circumference and blood pressure were taken from each of 
the participants. Blood was drawn for measurement of glucose level and lipid profile. Data analysis was 
undertaken using Stata version 15.  T-tests were used to compare continuous variables while Pearson 
chi-squared tests was used for categorical variables. Regression modelling was undertaken to assess 
associations between sociodemographic and clinical predictor variables and the cardiovascular risk 
factors. 
Results: Data collection took place between July 2018 and March 2019.  The mean age of patients was 
33 years and of controls was 35 years. Compared to controls, patients were more likely to be unmarried 
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(46% vs 33% p<0.001), to have lower education levels education (25.6% vs 55% p<0.001), and were 
more likely to be unemployed (24.7% vs 48%, p<0.001). Compared to controls, patients were more likely 
to have smoked in their lifetime (9.9% vs 3.3%, p= 0.006) or to be current smokers (13.8% vs 7%, 
p=0.001).  Most patients with psychosis consumed inadequate fruits and vegetables (97%); and had low 
physical activity (78%) and a good number had sedentary behaviour (48%).  
 Compared to controls, patients  had a  higher  mean random blood glucose (5.23  vs 4.79,  p=0.003),  
higher body mass index  ( 5.23 vs 4.79, p=0.001),   higher triglycerides ( 1.98 vs 1.56, p<0.001)   larger 
waist circumference ( 89.23 vs 86.39,  p=0.009)  and  lower high density lipoprotein ( 1.22 vs 1.32, 
p<0.001).  Compared to controls, patients had a higher prevalence of metabolic syndrome (28.6% vs 
19.8%, p=0.007) and obesity (15.4 vs 12.3 p=0.037).  The odds of developing metabolic syndrome in 
patients were increased by psychosis (OR=2.09, p=0.006) and increasing age (OR=1.05, p< 0.001), and 
were reduced among females (OR 0.41 p<0.001) and those participants who were widowed/separated/ 
(OR 0.38, p=0. 0 13).  The odds of having obesity in patients were increased by psychosis (OR 2.30, 
p<0.001) and female Sex (OR 2.67, P<0.001).  Many participants (73% of patients and 80% of controls) 
reported having experienced at least one traumatic event in their lifetime. There was no significant 
association between trauma and any of the cardiovascular risk factors in this study. Controls with 
evidence of psychological distress were significantly less likely to have adequate physical activity 
(p=0.002). Patients had lower rates of reported medical conditions compared to controls, and the 
presence of medical conditions was not linked to increased CVD risk. On the Framingham  risk scores, 
4.4 % of the patients had an intermediate estimated 10 year risk of developing cardiovascular disorders 
(score 10-19) and 1 % had high risk   (score >20).  The estimated 10 year cardiovascular risk was 
significantly associated with female Sex (p=0.007), age (p<0.001), current tobacco smoking (p<0.001) 
and metabolic syndrome (P<0.001).  Among the patients, 280 (94.3%) patients were on antipsychotics 
with the majority (86.5%) being treated with olanzapine.  Of all the participants with diabetes 60% among 
patients and 22% among controls were not on treatment.  Of the total number of participants with 
hypertension, 65% of patients and 47% controls were not on treatment  
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 Conclusion: In the study setting of Eldoret, Western Kenya, patients with psychosis were found to have 
high levels of lifestyle cardiovascular risk factors such as smoking, inadequate intake of fruits and 
vegetables and inadequate physical activity. They were also found to have high rates of metabolic 
disorders such as hypertension, obesity, metabolic syndrome and dyslipidaemia. There was no evidence 
of increased cardiovascular risk among participants exposed to traumatic life events, with those 
experiencing psychological distress or those with other chronic medical disorders. The use of olanzapine 
was not significantly associated with increased cardiovascular risk in this setting. There was an 
identifiable gap in the treatment of cardiovascular risk factors in this setting.   Given these findings, we 
recommend efforts to address these risk factors by development of protocols to ensure screening for 





CHAPTER 1: CARDIOVASCULAR RISK FACTORS IN THE GENERAL POPULATION 
 1.0 Introduction 
This chapter will give an introduction to cardiovascular risk factors in general population. First the chapter 
will describe the conventional cardiovascular risk factors which include modifiable lifestyle factors and 
metabolic disorders, as well as the non-modifiable risk factors such as age, sex, and social economic 
status. Second, the chapter will highlight the non- conventional risk factors; trauma, psychological 
distress and comorbid chronic medical conditions. Third, the chapter will give an overview of 
cardiovascular risk prediction, narrowing down to Framingham risk scores.  
1.1:  Cardiovascular Risk Factors 
According to the  World Health Organization (WHO),  cardiovascular disorders (CVDs) are the leading 
cause of death in the general population worldwide and  accounted for  an estimated 17.9 million deaths  
in 2016 only, a vast majority of these ( 85%)  due to heart attack and stroke (WHO, Cardiovascular 
disorders 2017).   Several factors are linked to increased CVD risk in the general population (Hennekens 
et al. 2005). The conventional/ traditional  risks factors  for CVD can be broadly divided into modifiable  
risk factors such as tobacco use, diabetes, hypertension, physical inactivity, unhealthy diet, 
dyslipidaemia, and obesity,  and non-modifiable risk factors such as age,  Sex and social economic status 
(El Fakiri 2005; Bager Tabei et al. 2014; A. S. Barnes 2013).  However there are also non- conventional 
factors which are so regarded because though they contribute to increased cardiovascular risk though,  
they have not been included into the list of the modifiable /non modifiable risk factors (Lin et al. 2018).  
1.1.1: Modifiable Cardiovascular risk factors  
The conventional modifiable risk factors for CVD can further be classified into lifestyle factors like 
smoking, inadequate exercises, poor diet and harmful alcohol use, and specific metabolic disorders such 





Life style cardiovascular risk factors 
Smoking; According to  the Centre for Disease Control and Prevention ( CDC), smoking is one of the 
leading causes of premature deaths in the world (CDC TobaccoFree 2019). A systematic analysis from 
the Global Burden of Disease Study 2015 (including data from 195 countries) reported a 25% age-
standardised prevalence of daily smoking; and  ranked  cigarette smoking among the five  leading risk 
factors  to ill health as measured  by disability-adjusted life-years DALYS (GBD 2015 Tobacco 
collaborators, 2017). It is also  recognised as one of the major contributors to  CVD related mortality in 
general population (Mallaina et al. 2013) . Smoking contributes to CVD through a number of mechanisms, 
including increased oxidative stress and promotion of a pro-inflammatory state; leading to lipid oxidation, 
thrombogenesis, accelerated atherogenesis, increases in catecholamine release and activation of the 
sympathetic nervous system , which  taken together, contribute to ischemia and arrhythmia risk, as well 
as acute myocardial infarction (MacDonald and Middlekauff 2019). Nicotine  which is delivered into the 
body from tobacco or cigarette smoking affects the  autonomic  nervous system, resulting in increased 
sympathetic activity, and   this   may in turn be  associated with increased heart rates, altered coronary 
blood flow  and  myocardial  remodelling  (Benowitz and Burbank 2016).  Among nicotine users, increased 
catecholamine release has also  been associated with fatal ventricular tachycardia and fibrillation 
resulting in sudden cardiac death  (Katz and Grosbard 2006). In addition, nicotine leads to  endothelial 
dysfunction and damage, induces vascular wall inflammation, and results in a shift towards a pro-
coagulant state in the cardiovascular system (Messner and Bernhard 2014;  Balakumar and Kaur 2009).   
Harmful Alcohol use ; While many people in the world take alcohol,  harmful drinking refers to alcohol 
consumption that results in physical or psychological harm (Reid, Fiellin, and O’Connor 1999) and is 
objectively defined as  intake of alcohol greater than 100 grams per week or more than 6 standard drink  
(Wood et al. 2018) O’Keefe, Bybee, and Lavie 2007). Globally, it has been estimated that 3.8% of all 
deaths and 4.6% of disability-adjusted life-years  are attributable  to  harmful alcohol use (Rehm et al. 
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2009;  S. Bell et al. 2017; Mostofsky et al. 2016).   Though  some literature   suggests that  lower amounts 
of alcohol may be cardio-protective,  there is no doubt that excess alcohol intake increases the risk of 
CVD (Cahill and Redmond 2012;  Carnevale and Nocella 2012; Corrao et al. 2000;  O’Keefe, Bybee, and 
Lavie 2007). A pattern of excess drinking has been associated with  increased incidence of coronary 
heart disease  (I. B. Puddey et al. 1999) (Griswold et al. 2018; Burton and Sheron 2018) . There is 
evidence for the role of alcohol  on several  specific  steps that are core  in the  process of atherosclerosis 
including effects on lipid regulation, inflammation and oxidative stress, as well as the differential effects 
on endothelial cells and vascular smooth muscle cells which then results in CVD (Cahill and Redmond 
2012;  Piano 2017).  Alcohol has  been found to increase rates of hypertension, arrhythmias and  dilated 
cardiomyopathy  (  Ricci et al. 2018;  Ian B. Puddey and Beilin 2006; Y. Zhang and Ren 2011). A 
systematic review of 26 observational studies also reported that alcohol intake exceeding 3 standard 
drinks per day was associated  with both haemorrhagic and ischemic  stroke (Patra et al. 2010).  
Inadequate physical activity and sedentary behaviour are both common contributors of many chronic 
diseases  (Kyu et al. 2016) including CVD (F. W. Booth, Roberts, and Laye 2012) which  play  a  significant 
role  in  morbidity and premature mortality in the general population (Ding et al. 2016). According to the 
WHO global strategy on diet, physical activity and health, adults aged 18–64 years should do at least 
150 minutes of moderate-intensity aerobic physical activity throughout the week or do at least 75 minutes 
of vigorous-intensity aerobic physical activity in a week or an equivalent combination of moderate- and 
vigorous-intensity activity (WHO 2011b). Inadequate physical activity has been described in literature as 
an independent  modifiable CVD risk factor  (Myers et al. 2015, (A. J. Alves et al. 2016; Siscovick et al. 
1997) .  Adequate physical activity on the other hand   has  several positive health outcomes (Penedo 
and Dahn 2005 (Vanhees et al. 2012)   and has over the years  been demonstrated to  be a cost effective 
way of promoting  cardiovascular health (Myers 2003).  For example, one meta-analysis of 36 studies (3, 
439, 874 participants and 179, 393 events, during an average follow‐up period of 12.3 years) reported 
that an increase from being inactive to achieving recommended 150 minutes of moderate‐intensity 
aerobic activity per week  was associated with lower risk of CVD mortality by 23%, CVD incidence by 
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17%, and type 2 DM  incidence by 26%  (Wahid Ahad et al. 2016). These benefits may result from direct 
and indirect cardio protective mechanisms  such as  an improvement in  other cardiovascular risk factors 
( obesity, hypertension and diabetes) , improved endothelial function, and decreased sympathetic tone 
(Prasad and Das 2009).  Physical activity  reduces total and abdominal fat resulting in improved insulin 
sensitivity, reduces risk of DM  and  results in  reduction in blood pressure (Stewart 2002).  Further , 
regular exercise improves the  endothelial integrity and  dilator function thus resulting in athero-protection,  
preventing platelets and inflammatory cells from adhering to the vascular surface (Dimmeler Stefanie and 
Zeiher Andreas M. 2003).  A  recent meta-analysis  of 16  prospective cohort studies (N= 1,005,791 
individuals followed up for 2–18·years) suggested that engaging in intense physical activity  (60-75 
minutes)  per day countered  the harmful effect of  prolonged sitting (e.g. for work purposes) (Ekelund et 
al. 2016). 
Poor Diet; A poor diet, has been associated with poor health outcomes for many non-communicable 
diseases including CVD.  Benefits of adequate fruits and vegetable intake ( which is at least half a plate 
per day)  in relation to CVD risk factors like DM and obesity is well documented (Krishnaswamy and 
Gayathri 2018), (Locke, Schneiderhan, and Zick 2018) (Bazzano, Serdula, and Liu 2003),.  Fruits and 
vegetables supply dietary fibre which is linked to lower incidence of CVD, supply vitamins and minerals 
to the diet and are sources of phytochemicals that function as antioxidants and anti-inflammatory  agents 
thus reducing the risk of CVD (Slavin and Lloyd 2012).  A national prospective cohort study including 
9,608 adults revealed that consuming fruit and vegetables more than 3 times per day compared with 1 
time/day was associated with a 24% lower ischemic heart disease mortality, 27% lower cardiovascular 
disease mortality and a 15% lower all-cause mortality after adjustment for existing cardiovascular disease 
risk factors (Bazzano et al. 2002). A similar study that followed 3,876 women for 5 years  reported a 
significant inverse association between fruit and vegetable intake and CVD risk after adjusting for age 
and smoking, with higher fruit and vegetable intake being  associated with a lower risk of MI, with an 
adjusted RR of 0.62.(S. Liu et al. 2000). A recent meta-analysis of 10 studies (N= 24,013 cases of type 
2 DM and N=434,342 controls) reported that the relative risk of Type 2 diabetes was 0.93, for an increase 
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of 1 serving of fruit per day; and the summary relative risk was 0.87, for an increase of 0.2 servings of 
green leafy vegetables consumed per day (M. Li et al. 2014).  Similarly, a systematic review and meta-
analysis of seventeen cohort studies and 563,277 participants reported an inverse relationship between 
fruit and vegetable intake, and weight gain, waist circumference and adiposity (Schwingshackl et al. 
2015). A  recent systematic review and dose-response meta-analysis of prospective studies (including  
95 unique cohort studies)  reported that – per 200 g/day of fruits and vegetables – the relative risk for 
coronary heart disease was 0.92; for stroke 0.84; for CVD 0.97; for all-cause mortality 0.90 (Aune et al. 
2017). Another meta-analysis  of  16 prospective cohort studies  in the general population  with follow-up  
periods ranging from 4.6 to 26 years reported an average reduction in risk of  all-cause mortality by 5% 
for each additional serving of fruit and vegetables per day (up to  five servings a day)  after which the risk 
of death did not reduce further ( Wang et al. 2014) . 
Metabolic disorders that increase CVD risk 
Diabetes Mellitus (DM) according to WHO,   is characterized by  persistently elevated plasma glucose 
(fasting levels above 7.0 mmol/l or random glucose above11.1mmol/l  (WHO 2006). DM increases the 
risk of CVD through various mechanisms. Diabetes Mellitus (DM) is a major contributor for both 
macrovascular and microvascular pathologic processes that increase the risk of CVD (Petrie, Guzik, and 
Touyz 2018). First,  DM  contributes to macrovascular disease through atherosclerosis which then results 
in increased risk of strokes and myocardial infarction (Dokken 2008) . Second, hyperglycaemic state in 
blood increases production of pro-inflammatory cytokines such as interleukin 6, C reactive proteins  and 
tumour necrosis factors  which result in  programmed cell death  and recruitment of invasive leukocytes 
(Fernandez-Egea et al. 2009; Garcia-Rizo et al. 2012) (Esposito Katherine et al. 2002).  Third, patients 
with DM are at risk of diabetic cardiomyopathy which is characterized by fibrosis, and hypertrophy and 
often results  in left ventricular hypertrophy, diastolic and systolic dysfunction and eventually heart failure 
(Asghar et al. 2009a; Bertoni et al. 2006).  Fourth, DM results in autonomic damage to the autonomic 
nerve fibres that innervate the heart and blood vessels ( cardiovascular autonomic neuropathy  and 
subsequent  diastolic dysfunction) resulting in abnormalities in heart rate control and vascular dynamics 
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which predispose to cardiac arrhythmias and  the risk of sudden death (Vinik, Erbas, and Casellini 2013), 
(Patil et al. 2011; Dinh et al. 2011;  Rolim et al. 2008) (B. M. Leon and Maddox 2015), and has been 
linked to  diabetic cardiomyopathy (Asghar et al. 2009b; Santra et al. 2011),  and an increased  incidence 
of myocardial infarction (Haffner et al. 1998). Insulin resistance that is associated with DM  increase the 
risk of  vascular damage (Pillinger et al. 2017; M. C. M. Ryan, Collins, and Thakore 2003;  Greenhalgh 
et al. 2017). It is worth noting that hyperglycaemia (without established DM) also increases the risk of 
mortality in the general population. For example, one systematic review reported that patients with 
glucose concentrations ≥6·1–8·0 mmol/L (but without DM) had a 3.9-fold higher risk of death, versus 
those with lower glucose concentrations (Capes et al. 2000).    
Hypertension; Hypertension, according to ‘The Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7),  is characterized by 
persistent elevation of blood pressure above a systolic pressure of 140mm/hg and a diastolic pressure 
above 90mm/hg (National High Blood Pressure Education Program 2004). Hypertension  is one of the 
strongest risk factors for CVD (Kjeldsen 2018; Lamprea-Montealegre Julio A. et al. 2018) and contributes 
significantly to incidences of  coronary heart  disease, cardiac arrhythmias including atrial fibrillation, 
cerebral stroke and renal failure (Vasan et al. 2001;Staessen et al. 1999), (Stamler, Stamler, and Neaton 
1993).   A study conducted in Taiwan (n= 77,389) showed that systolic blood pressures of 120 to 129 mm 
Hg were associated with the lowest CVD mortality risks, while systolic blood pressure ≥160 mm Hg, or  
diastolic blood pressure  ≥90 mm Hg significantly increased the CVD and expanded-CVD mortality risk 
(C.-Y. Wu et al. 2015). Hypertension contributes to CVD through various mechanisms. First, the 
persistently elevated blood pressure weakens the inner arterial wall promoting atherosclerosis and 
thrombosis which results in myocardial infarction, transient ischemic attacks and strokes. (Franklin and 
Wong 2013). Second,  hypertension results in  increases risk of left ventricular hypertrophy that results 
from chronic exposure to high blood pressure (Brook and Julius 2000; Berk, Fujiwara, and Lehoux 2007).  
Third, hypertension induced hemodynamic changes such as coronary insufficiency contributes to silent 
ischemia and risk of sudden death (Frohlich Edward D. 1999). In addition elevated blood pressure results 
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in mechanical damage to the blood vessel which results in vasoconstriction and further elevation in blood 
pressure (Drozdz and Kawecka-Jaszcz 2014). Fourth high   blood pressure affects  bioavailability of nitric 
oxide and  increases vascular smooth muscle cell proliferation which results in  stiffening of  the arterial 
wall (Tedla et al. 2017). The loss of arterial elasticity results in increased pulse pressure, which in turn 
results in increase in  the ventricular afterload, causes ventricular hypertrophy, and reduces coronary 
perfusion thus increasing the risk of cardiovascular events and mortality (Sipahioglu et al. 2012). Fifth, 
high blood pressure contributes to the risk of aneurysms (Elsa Kobeissi et al. 2019)  as well as the  
eventual rupture of blood vessels which can be fatal (Takagi and Umemoto 2017).  
Dyslipidaemia,  Dyslipidaemia is characterized by an increase in the plasma concentration of Low 
Density Lipoprotein (LDL), total cholesterol and triglycerides, as well as reduction of High Density 
Lipoprotein HDL (Saari et al. 2004).  Dyslipidaemia  is   known to increase the risk of cardiovascular 
diseases  though various pathways (Badimon, Storey, and Vilahur 2011; Toth 2016).  Products of lipid 
metabolism undergo changes that eventually lead to macrophage activation, foam cell formation and  
induction of inflammation (Tselepis and John Chapman 2002). LDL accumulates in the vascular wall   and 
gets oxidized resulting in damage of  the endothelium,  and also  triggers an inflammatory process which 
eventually results in  the process of arteriosclerosis , a common feature of  coronary artery disease, 
ischemic stroke, and peripheral vascular occlusive diseases (Marchio et al. 2019). On the other hand, 
HDL  is  reported to be cardio protective  through reversing  cholesterol transport, preventing endothelial 
dysfunction, inhibiting the homing of monocytes and preventing platelet activation and coalition on the 
vascular wall (Viles-Gonzalez et al. 2003). To illustrate this, an 8 year follow up study in Japan ( n=5245) 
reported an incidence of 17.5 % of ischemic disease  among participants with  high levels of TGS  and 
low HDL (Jeppesen Jørgen et al. 1997). The increased risk of CVD  in patients with dyslipidaemia is also 
mediated by increased rates of DM (Warraich and Rana 2017)  and  hypertension (Halperin et al. 2006).  
Obesity; Obesity is a growing challenge worldwide that affects close to 20 billion people (Hossain, Kawar, 
and El Nahas 2007). Obesity which is defined as excess accumulation of body fat is measured using the 
Body Mass Index (BMI), a function of the weight and height of an individual.  It is  categorized into 4 ; 
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underweight <18.5kg/m2, healthy weight 18.5-24.9kg/m2 , overweight, 25.0-29.9kg/m2, obese, and 
obese  ≥30kg/m2 obese  (World Health Organization 2000).  Obesity is a well-known risk factor for various 
types of CVD (Ndumele et al. 2016) and has been associated with increased CVD related deaths  (S. C. 
Smith 2007),  (Hubert et al. 1983).  Excess adipose tissue  secrete leptin which is reported to alter 
myocardial metabolism, promote cardiomyocyte hypertrophy, and contribute to  cardiac remodelling, thus 
increasing the risk of CVD (Wannamethee et al. 2011). It  increases the risk of CVD, particularly heart 
failure and coronary heart disease, by  causing changes in body composition that may alter hemodynamic 
and heart structure (Carbone et al. 2019) (Manson et al. 1990). Direct effects result from structural and 
functional adaptive changes  of the cardiovascular system to accommodate excess weight (Koliaki, Liatis, 
and Kokkinos 2019; Van Gaal, Mertens, and De Block 2006).  In addition, abnormal adipose tissue 
expansion has been linked to anti-inflammatory adipokines, resulting in the development of a chronic, 
low-grade inflammatory state and  impaired mitochondrial function all which contribute to CVD 
(Nakamura, Fuster, and Walsh 2014). Pro-inflammatory cytokines which are  produced  by perivascular 
adipose tissue result in  a reduction in  vascular nitric oxide thus resulting in  endothelial damage (Virdis 
et al. 2019). Obesity also contributes to insulin resistance (Ye 2013),  abnormal glucose and lipid  
metabolism, (Singla, Bardoloi, and Parkash 2010) as well as  hypertension (S.-Z. Jiang et al. 2016). It 
has also been found to increase both the aldosterone level and the mineralocorticoid receptor expression, 
each of which promotes interstitial cardiac fibrosis, platelet aggregation, and endothelial dysfunction 
(Csige et al. 2018).  
Due to variations in the BMI across different body builds, the waist circumference, which measures central 
obesity, is also used to assess risk of CVD. Central obesity  has been linked to  insulin resistance and 
atherosclerosis (Rader 2007). According to a study done in Cameroon,  central obesity  is one of the key 
determinants of metabolic syndrome in some populations such as  Africans (Fezeu et al. 2007).   
 Metabolic Syndrome ( MetS);  MetS, according to the National Cholesterol Education Program’s Adult 
Treatment Panel III report (ATP III) is the occurrence of a combination of abdominal obesity, impaired 
glucose tolerance, hypertriglyceridemia, decreased High density Lipoprotein HDL and hypertension 
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(Beilby 2004a). This syndrome is now recognized as a major risk factor for CVD (Tune et al. 2017; Cornier 
et al. 2008). The co-occurrence several  CVD risk factors  which constitute  MetS  makes it one of the 
greatest predictors of CVD (Robert H Eckel 2005).  An 8 year cohort study  reported that metabolic 
syndrome accounts for up to one third of CVD in men (Wilson Peter W.F. et al. 2005).  A  systematic 
review and meta- analysis  that included 87 studies, and 951,083 patients reported  that patients who 
have MetS have a 2-fold increase in CVD  events and a 1.5-fold increase in all-cause mortality (Salvatore 
Motillo et al 2010). MetS is associated with inflammation as evidence by presence of  inflammatory 
markers like C reactive protein (Steven Haffner 2005). Patients with MetS have an increased rate of 
thrombosis and atherogenesis which increases the risk of CVD  event (Grundy Scott 2016) 
 
1.1.2: Non Modifiable cardiovascular risk factors 
Factors currently classified as non-modifiable cardiovascular risk factors  include age, sex and social 
economic status (World Heart Federation 2017). 
Age is believed to contribute to increased cardiovascular risk due to associated body changes with 
advancing years as well as accumulation of various risk factors in the course of time (North and Sinclair 
2012). This may be reflective of the relationship between advancing age and increasing duration and 
intensity of exposure to other CVD  risk factors  (Dhingra and Vasan 2012b).  For example, a multi-ethnic 
cardiac magnetic resonance imaging study  in the US  examining age-related differences in left ventricular  
structure and function in 5,004 participants  reported that age was associated with left ventricular  
remodelling  which was marked by increased mass-to-volume ratio,  and accompanied by systolic as well 
as diastolic myocardial dysfunction (Susan Cheng et al. 2009). Further, a large Finnish cohort study of 
14,786 men and women reported age-related differences in cholesterol level, blood pressure, BMI, and 
DM prevalence; and, taken together, these differences accounted for approximately one-third of the age-
related increase in overall CVD  risk (Jousilahti et al. 1999). The Framingham Heart Study in which 
enrolled participants were followed up for a total of 111,777 person-years indicated that having fewer 
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individual risk factors by age 50 was associated with a lower risk of developing CVD (Lloyd-Jones et al. 
2006) 
Sex plays an important role in shaping the CVD risk profile.    WHO mortality and population data from 
26 countries worldwide, demonstrated that coronary heart disease related deaths were up to five times 
higher in men than women while differences in mortality from stroke were approximately twice as high in 
men as compared with women (Bots, Peters, and Woodward 2017). One prospective Finnish study of 
14,786 participants aged 25 to 64 years  reported that smoking, total cholesterol and BMI were each 
higher in men, though this difference was found to decrease with increasing age (Jousilahti et al. 1999). 
A meta-analysis of 37 studies of type 2 DM and fatal coronary heart disease (total N=447,064 patients) 
reported that the relative risk for fatal coronary heart disease associated with DM was 50% higher in 
females compared to men (Rachel Huxley et al 2006).  Similarly, a meta- analysis  of 64 cohort studies 
(N=representing 775,385 individuals) and 12,539 fatal and non-fatal strokes reported that the relative risk 
of  stroke associated with diabetes was 2.28 in women and 1.83 in men (Sanne A E Peters et al 2014).  
In contrast to these studies, a New Yolk study done among 1,527 participants reported that black Latino 
women had lower prevalence of CVD risk factors than men, with less hypertension, lower triglycerides 
higher HDL and a greater likelihood of a healthy lifestyle, and were more likely not to smoke and to follow 
a healthy diet, thus highlighting the need to avoid generalizing the role of Sex in CVD risk but instead 
consider differences in various settings. Sex differences in CVD risk profile are also likely in an African 
populations. For example  a study done  among  Nigerian and Ghanaian immigrants into Baltimore 
reported significant Sex differences in the CVD risk prevalence and reported that being employed and 
having health insurance were associated with lower CVD risk in women, while higher social support was 
associated with lower CVD risk in men (Commodore‐ Mensah Yvonne et al. 2016). A very recent study 
which enrolled 2,198 participants from 12 different Sub-Saharan countries reported higher rates of 
obesity and sedentary behaviour in women, and more  cardiovascular complications in men (Diop et al. 
2019). Similarly,  a Tanzanian study done among 209 participants aged between 44 and 66 years 
revealed an excess of  various CVD risk factors among women  compared to men 13%:  abdominal 
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obesity was 11%in men  and 58% in women, women had  three-fold greater odds of having metabolic 
syndrome compared to male counterparts, women had  higher  fasting blood glucose (Njelekela et al. 
2009a). The  differences in cardiovascular risk between men and women conditions is partly explained  
by the combined expression of genetic and hormonal differences  between the two sexes (Shufelt C.L. 
et al. 2018; Kautzky-Willer, Harreiter, and Pacini 2016). It   may also  be associated with  varying social  
and cultural experiences  for men and women (Mark Woodward 2019).  While initially the focus was 
mainly on the male Sex(Woodward 2019), recent evidence has described the Sex differences and 
brought to focus the cardiovascular risk issues related to female Sex (Mosca, Barrett-Connor, and Kass 
Wenger 2011).   
Social economic status ( SES) :  The social  economic status is one of the social determinants of health 
and has also been shown to influence cardiovascular health (Catalyst 2017). For example, studies  
suggest that childhood poverty (G. E. Miller et al. 2011), as well as low SES in adulthood and cumulatively 
across the lifespan, may increase the risk of metabolic disorders (Chichlowska et al. 2009). This may be 
due – in part - to psychosocial distress and resultant neuroendocrine disturbances, as well as to poor 
nutritional status associated with low SES (Agardh et al. 2011).Similarly a relationship exists between 
SES such as unemployment   and low education level and negative physical health outcomes which 
include increased CVD (Michael Marmot et al. 2008).   Some association has been reported linking   low 
SES with  presence of CVD  risk factors  like low HDL, high cholesterol, high triglycerides, and 
hyperglycaemia (E. Brunner et al. 1999).  Further, challenging social circumstances are reported to have 
an effect on behaviours such as smoking, diet, alcohol consumption, or physical activity which are known 
to increase the risk of CVD (Hemingway and Marmot 1999). For example  low education level has also 
been associated with poor lifestyles  that potentially increase the risk of cardiovascular disorders 
(Mucheru et al. 2018). It is reported that persons with  lower employment levels  are more likely to smoke, 
engage less in physical activity and  to die from coronary heart disease compared to those in higher  
employment grades (M. Marmot et al. 2001). The Whitehall II study of 10,308 government workers in 
London  aged 35–55 years reported that participants with a lower employment grade ( which translates 
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to lower SES) were more likely to die from coronary heart disease (M. Marmot et al. 2001), compared to  
those who had higher employment grade. In the same study, employment grade was inversely associated  
with current  history of smoking and physical inactivity; and with  other metabolic risk factors such as low 
HDL, high cholesterol, high triglycerides, and hyperglycaemia (E. Brunner et al. 1999). The effect of 
unemployment on cardiovascular  health may be  related to the anxiety resulting from  financial 
constraints, as well as a lack of structured activities; which may in turn increase  the likelihood of adverse 
behaviours such as smoking and harmful alcohol use  (Q. Wang, Shen, and Cochran 2016) , eventually  
increasing the  overall cardiovascular risk (Weber and Lehnert 1997;  R. L. Jin, Shah, and Svoboda 
1997). A recent  prospective cohort study (N=13,451) further demonstrated the link between 
unemployment and onset of acute cardiovascular events (Dupre et al. 2012).   Similarly, another  study 
that included 674  black and white women form Georgia, USA, reported that lower SES ( defined by 
education level, annual household income, and employment status) increased the odds of poor 
cardiovascular health (S. K. Davis et al. 2014) 
1.2: Non -conventional CVD risk factors; Trauma, Psychological distress and chronic medical 
conditions. 
Beyond the traditional CVD risk factors described in the previous section, there are other factors that 
have been described in literature as contributing significant increase in cardiovascular risk.  Some of 
these include marital status, exposure to potentially traumatic events, psychological distress and 
comorbid medical conditions. 
 1.2.1:  Marital status 
 Marital status, while not considered a key conventional cardiovascular risk factor, has been 
documented as one of the factors that influence the cardiovascular risk profile in the general population. 
One systematic review that consisted of 34 studies with more than two million participants reported that 
compared with married participants, being unmarried  was associated with increased odds of CVD ,  
widowers were more likely to develop a stroke and single  men and women with myocardial infarction 
30 
 
had increased mortality (Wong et al. 2018).  The  2014 Ghana Demographic Health Survey (GDHS) that 
included 9,356 women and 4,374 men reported higher odds of hypertension for married, cohabiting and 
previously married women, and   no significant association between any of the marital status cohorts and 
hypertension for men (Tuoyire and Ayetey 2019). In addition to affecting the risk profile, the marital status 
is reported to affect outcomes for those with established CVD. One prospective cohort study that included 
6,051 patients  undergoing cardiac catheterization for coronary artery disease who were  followed  up for 
about 3.7 years reported that  being unmarried was associated with higher risk of all‐cause mortality, 
cardiovascular death and  myocardial infarction  and these findings persisted even  after adjustment for 
medications and other socioeconomic factors (Schultz et al. 2017). Marital status has been found to be 
associated with a number of health outcomes, including CVD.  One recent prospective cohort study 
following 9,737 Iranian adults for 12 years reported a significant association between never having been 
married and higher risk of hypertension and all-cause mortality in men , widowed status was associated 
with a lower risk of Type 2 diabetes mellitus,  and lower risk of hypertension in currently or previously 
married women (Ramezankhani, Azizi, and Hadaegh 2019).  The role of marital status in CVD risk was 
also evident from the  data sixth Korea National Health and Nutrition Examination Survey (2013–2014),  
that included 3,225 women aged 40–69 years which reported  that widowed participants higher odds of 
getting MetS compared to their married counterparts (Jung et al. 2018) and in this setting, these  
differences were associated with  socioeconomic and psychological  factors (Cho et al. 2016). The Tehran 
lipid and glucose study  that followed up  5,221 participants (2060 males and 3161 females) for a  median 
of 9.6  years reported that marital transition including to or out of married status was  associated with an 
increased prevalence of CVD, especially among employed females (Hosseinpour-Niazi et al. 2014). 
Other than the status, the quality of marital status also seem to play a role in influencing the CVD risk. 
As an example, Pittsburgh Healthy Women Study that involved 413 participants reported that lower 
scores in marital satisfaction (with regard to communication, satisfaction with sexual activity, agreement 
on financial matters, and similarity of interests, lifestyle, and temperament) were associated with higher 
odds of MetS (Troxel et al. 2005).  The mechanism by which marital status may influence CDV risk profile 
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is not well researched. However it may result from the social economic benefits that a functional marriage 
may bring as described in  the marriage protection theory (Waldron, Hughes, and Brooks 1996; N. 
Goldman, Korenman, and Weinstein 1995)  thus affecting other CVD risk factors indirectly.  
1.2.2 Exposure to Potentially traumatic Events 
There is evidence indicating that exposure to  potentially traumatic events ( both lifetime and childhood) 
increase the risk of developing  physical disorders, including CVD (Atwoli et al. 2016). Exposure to  these 
traumatic events  both in adulthood or childhood may  result in significant changes in the  Hypothalamus 
Pituitary Adrenal ( HPA ) axis  (De Bellis and A.B. 2014).  In such cases, chronic  HPA  axis activation  
results in  increased   release of catecholamines Second, HPA-axis dysregulation - as associated with 
chronic psychological distress – may result in immunological alterations and altered cytokine expression 
and other inflammatory markers such as the C- reactive protein , and  alterations may, in turn, contribute 
to the development of obesity  and MetS (Bose, Oliván, and Laferrère 2009). (Rozanski, Blumenthal, and 
Kaplan 1999).   These inflammatory processes also contribute significantly  to endothelial dysfunction 
(Black and Garbutt 2002), (Black 2006). Third, a stress-specific coronary syndrome, known as transient 
left ventricular apical ballooning cardiomyopathy or stress cardiomyopathy (Steptoe and Kivimäki 2012) 
may arise as a result of sympathetic nervous system hyper activation (Esler 2017).  Stress related 
alteration in  cortisol also  contribute to increased risk of    obesity, raised blood pressure and  insulin 
resistance (Joseph and Golden 2017) (Dong et al. 2004) . In addition  to these physiological changes,  
patients with posttraumatic stress disorder may resort to use of   tobacco , alcohol and other drugs of 
abuse, physical inactivity,  overeating, as strategies  to alleviate anxiety and hyperarousal symptoms, 
further increasing the CVD risk (Edmondson and Cohen 2013; Dedert et al. 2010)  (Halonen et al. 2015; 
C. Lee, Tsenkova, and Carr 2014; C. R. Davis et al. 2014).. A systematic review of 78 observational 
studies reported that posttraumatic stress resulted increased  heart rate and  raised blood pressure 
ultimately increasing CVD risk (Dedert et al. 2010). A well-powered prospective study following  49,978 
women  over 20-year period also reported increased odds of CVD events (including myocardial infarction 
and stroke) among those who had endorsed >4 PTSD symptoms (Sumner Jennifer A. et al. 2015). Data 
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from 10 countries participating in the WHO World Mental Health surveys (n=18,630)  reported that  two 
or more early childhood adversities were significantly associated with  hypertension in adulthood (Stein 
et al. 2010). Further, there is evidence to suggest that childhood trauma not only  increases the overall 
risk of developing metabolic syndrome, but also affects the number of specific symptoms that one  
develop  (Etain et al. 2008b; Kesebir 2014).  A cross-sectional study   among patients with schizophrenia 
reported that exposure to trauma in childhood was associated with a sensitized state in adulthood 
characterized by elevated emotional and psychotic reactions to small daily life stressors, and this is  likely 
to affect the cardiovascular system in the long term (Lardinois et al. 2011).  
1.2.3 Psychological distress and cardiovascular risk 
Psychological distress  encompasses  negative  emotional experiences such as stress, anger, hostility, 
anxiety and depression experienced by an individual in response to a specific stressor or demand that 
results in harm to the person  (Ridner 2004) . Psychological distress may contribute to increased risk of 
CVD and  may, also influence the course and outcomes  in those who develop CVD (Januzzi et al. 2000). 
First, stress has been found to be associated with pathophysiological changes in the cardiovascular 
system, which may result in cardiac dysregulation, myocardial ischemia, cardiac wall  abnormalities, 
myocardial infarction and sudden death (Dimsdale 2008a).The suggested  biological mechanisms 
underlying this include sympathetic activation, stimulation of the hypothalamic–pituitary axis, 
hyperventilation-induced coronary spasm, oxidative stress and  increased inflammatory mediators 
(Olafiranye et al. 2011), (Esler Murray 2014).. The association between psychological distress and CVD 
risk has been well-documented in the current literature. For example, one study of 6,292 Japanese men 
reported that participants who displayed anger suppression and depressive symptoms had 1.5  increased 
odds of developing hypertension (Ohira 2010).  Acute or chronic psychological distress  has also been 
found to be associated with 40-60% increased risk of CVD, independent of conventional risk factors such 
as dyslipidaemia and hypertension (B. E. Cohen, Edmondson, and Kronish 2015),(W. Jiang 2015).  
Further, a number of cardiovascular events (including sudden death, myocardial infarction and 
myocardial ischemia) may be associated with psychological distress (Dimsdale 2008a).In addition  
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chronic stress may also be experienced in the absence of an actual threat, in the context of prior unsafe 
social networks or situations (Brosschot, Verkuil, and Thayer 2017). This may result  in a chronically 
active  sympathetic nervous system, which eventually also affects the cardiovascular system (Öhlin et al. 
2004).  Finally, psychological distress may increase CVD  risk through poor lifestyle such as   increase 
cigarette smoking, reduced  physical activity, and increased alcohol intake, which may be part of negative 
coping skills in distressed individuals (Hamer, Molloy, and Stamatakis 2008).  
1.2.4: Comorbid medical conditions and cardiovascular risk. 
Co-occurrence of more than one medical condition (comorbidity also referred to as multimorbidity) is 
common in the general population  (Navickas et al. 2016;  Colombo, García-Goñi, and Schwierz 2016). 
As a  result, the presence of several chronic conditions may be associated with increased disability, 
decreased quality of life, and increased risk of death (Johnston et al. 2019).  According to a recent 
systematic review of 68 studies including data both from high-income and LMICs (Nguyen et al. 2019), 
the pooled prevalence of multimorbidity in the general population was found to be 33%. A  large cross-
sectional  Dutch study (N=60,000 patients in general practice) also reported that the prevalence of  
multimorbidity was highly influenced by age, ranging from 10 % in young people to 78% in patients older 
than 80 years (van den Akker et al. 1998). Multimorbidity is also associated with a decline in general 
functioning of the affected individual.  For example, one systemic review   of 37 studies  and (n=1,371,631 
participants) reported that this decline was associated with the number of conditions affecting individual 
patients, as well as the severity of each condition (Ryan et al. 2015).  Ultimately, multimorbidity may result 
in higher hospital utilization and increased  financial burden (J. T. Lee et al. 2015).  
Non-communicable as well as infectious diseases may play a role in increased CVD risk.  As an example 
HIV-associated inflammation and immune activation are important mediators increasing  cardiovascular 
risk  2 fold among those affected (Triant 2013; Mesquita et al. 2019). One prospective study of 2,960 
Brazilian patients reported an increase in smoking, hypertension and obesity among HIV-positive 
patients, with an overall incidence rate of 6.75 per 1000 person-years (Diaz et al. 2016).   A similar  study 
following 3,384 HIV-infected individuals reported a CVD  incidence rate  of  11.10/1000 person years – 
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this was 4-fold higher at < 3 months’ post-hospitalization for severe infections (Mesquita et al. 2019). HIV-
positive patients are also likely  to have  a higher risk of cardiovascular disorders  due to the interactions 
between traditional risk factors and the HI virus (Cerrato et al. 2015). For example, HIV-associated 
inflammation and immune activation (Triant 2013),  as well increased rates of  dyslipidaemia, 
hypertension and smoking, may account – in part – for  the increased  risk of CVD among HIV-positive 
patients  (Freiberg and So‐Armah 2016) .  At the same time, mental illness increases the  risk for HIV 
acquisition and  the risk of negative health outcomes among (Remien et al. 2019).  Infections such as 
Helicobacter Pylori which causes stomach ulcers may trigger the release of various pro-inflammatory 
mediators such as  cytokines, bacterial lipopolysaccharide, heat shock proteins get into the systemic 
circulation,  and trigger  immune response in the arterial wall and contribute to atherosclerosis (Dunne 
2004) (Whincup et al. 1996)   Pasceri et al. 1998). This bacterium may also trigger the release of toxigenic 
nutrients such as vacuolating cytotoxic gen A, a  nutrient  which has been found to be involved in the 
formation of cholesterol patches in arteries, thus promoting atherosclerosis (Jamkhande, Gattani, and 
Farhat 2016).  
Chronic inflammatory disorders such as allergies and asthma produce pro-inflammatory markers which 
may contribute to atherogenetic plagues thus increasing risk of CVD.  For example, a systemic review  
and meta-analysis  of 406,426 participants reported  a  relative risk for CVD   among patients with asthma 
of 1.33 in women, 1.55 in men,  and  for both sexes combined (Mingzhu Xu, Jialiang Xu, and Xiangjun 
Yang 2017).  Similarly, a multi-ethnic study following 6,792 participants  for 9.1 years reported  that 
patients with persistent asthma had a greater risk of CVD events than non-asthmatics (hazard ratio: 1.6), 
which persisted after adjustment for age, sex, ethnicity, CVD risk factors, and antihypertensive and lipid 
medication use (Tattersall Matthew C. et al. 2015). The mechanism of increased CVD risk among patients 
with asthma may be linked to inflammation -  asthma is an inflammatory disorder; and its pro-inflammatory 
markers (e.g. leukotrienes) may contribute to atherogenetic plagues, thus increasing risk of CVD 
(Spanbroek et al. 2003) 
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A number of studies have also explored the association between Tuberculosis (TB) could also potentially 
increase CVD risk in affected individuals. A review of co-morbidity between infectious and chronic 
diseases in SSA  reported that DM was associated with a 3-fold incident risk of tuberculosis (TB); and it 
is hypothesized that the TB may also increase the risk of developing the DM(Young et al. 2009a).  
1.3: Estimating the 10 year risk of cardiovascular disorders 
In order to quantify risk and to guide intervention, algorithms have been developed to estimate the 
absolute CVD risk ( the probability that one develops a cardiovascular event in a defined period)  and 
such estimates are determined by the synergistic effect of several  cardiovascular risk factors present 
(Benowitz and Burbank 2016). An assessment of total risk of developing CVD  which is based on the 
sum of all major risk factors has been found to be useful in clinical practice as it helps in identification of 
high-risk patients who require immediate attention and intervention, gives a clue to a patient’s motivation 
to adhere to risk-reduction therapies, and can aid modification of intensity of risk-reduction efforts based 
on the total risk estimates (Grundy et al. 1999).  Scores of the   absolute 10  year CVD risk of developing 
cardiovascular disorders  has been widely accepted as a guide  for determining  who to initiate on  
medication such as lipid-lowering statins  in order to reduce the CVD risk (David P. J. et al. 2015). 
Several of these scoring systems have been described in literature. They include the QRISK that was 
developed mainly for the United Kingdom (Collins and Altman 2010), the ASSIGN  algorithm (Iglesia et 
al. 2011) , Reynolds risk score (Ridker et al. 2007) and the Framingham Risk Score ( FRS).FRS is  Sex 
specific multivariable risk factor algorithm  that was initially  developed for the  Framingham study 
(n=8,491 mean age 49 years,  women = 4522 women)  among participants  who attended a routine 
examination between 30 and 74 years of age and were free of CVD,  and it is used to assess general 
CVD risk and risk of individual CVD events including coronary, cerebrovascular, and peripheral arterial 
disease as well as  heart failure (D’Agostino Ralph B. et al. 2008).  The FRS  assesses the  CVD  risk 
level over 10 years by considering  several  risk factors; age, sex, total cholesterol, high density lipoprotein 
cholesterol, smoking habits, and systolic blood pressure (Jahangiry, Farhangi, and Rezaei 2017). The 
scores are then categorized as low (<10), intermediate (10-19) or high >20.  The FRS  has been found 
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to  be useful in assessing people in need of interventions to mitigate  CVD risk such initiating statin 
treatment (Bosomworth 2011).  
1.4:  CVD Risk Factors in the Context of Low and Middle Income countries 
Evidence indicates a rising trend of CVD risk factors in Africa and other LMIC in general populations. A 
WHO commissioned review of literature  on the emerging non-communicable disease epidemic in Africa 
reported a rise in the prevalence of CVD risk factors over 6 years, (between 1998 and 2004 ); 
hypertension ( 3% to 30%) and diabetes ( 1% to 20%)  as reported  by  (Mufunda et al. 2006).  Further  
a systematic  review   of 1,201 studies on NCD in SSA reported a wide variation in prevalence: diabetes 
mellitus from 0 to 16%, hypertension from 6 to 48%, obesity from 0.4 to 43% and current smoking from 
0.4 to 71%  and an over representation in some countries such as South Africa (Dalal et al. 2011).   
While the burden and outcomes of cardiovascular disorders can largely be reduced using cost effective 
methods, outcomes in many LMICs are poor with higher CVD related mortality rates being reported 
compared to high income countries. For example, the Prospective Urban Rural Epidemiologic (PURE) 
cohort study that  included  150,000 adults in 17 high-, middle-, and low-income countries where 
participants were followed over  4 years reported  that the rates of major CVD events were  higher in  
LMIC compared to  high income countries ( 6.43 vs 3.99 per 1000 person years),  the case fatalities rates 
were also higher, (17.3% vs 6.5%)  and  the  use of preventive medications to mitigate these risks was 
significantly more common in high-income countries than in middle- or low-income countries (Yusuf et al. 
2014). Further WHO estimates that about 75% of  the reported  CVD deaths  in the general population  




Figure 1: World map showing ischemic heart disease mortality rates  
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Figure 2: World map showing cerebrovascular disease mortality rates  
 
 Age standardized, per 100,000) 
Cerebrovascular disease mortality   (per 100 000) 
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  Both Figure 1 and 2 are reprinted with permission from Global Atlas on cardiovascular disease 
prevention and control. ISBN:9789241564373  page 17.  
 (https://www.who.int/cardiovasculardiseases/publications/atlas cvd/en/ (WHO 2011a) 
Several factors may contribute to poorer CVD-related outcomes in LMICs, compared to developed 
countries. First, there is lack of integrated care programs for early detection and treatment of CVD risk 
factors, thus limiting access to effective and equitable health care services. This is likely compounded by 




A large body of evidence exists on the factors increasing CVD risk – both in the general population .These 
include conventional modifiable and non- modifiable cardiovascular factors, as well as other non-
conventional risk factors such as trauma exposure and psychological distress. Low and middle income 
countries suffer from the high burden of the CVD risk and yet the systems in these settings are not optimal 





CHAPTER 2:  BURDEN AND ETIOLOGICAL MECHANISMS OF CARDIOVASCULAR RISK 
FACTORS AMONG PATIENTS WITH PSYCHOSIS.  
2.0: Introduction 
This chapter will describe the cardiovascular risk factors, as well as the etiological mechanisms for the 
excess risk among patients with psychosis. First the chapter introduces the subject of comorbidity of 
mental illness and cardiovascular disorders and how this comorbidity impacts outcomes. Second, the 
chapter  describes the  burden of each of the CVD risk factors and the reasons of their occurrence among 
mentally ill patients as currently documented in literature is highlighted, and the overlapping etiological 
mechanisms between mental illness and CVD risk factors. Third   the chapter reports on documented 
evidence for the role of antipsychotics in increasing cardiovascular risk.  Fourth, the chapter gives an 
overview of use Framingham risk scores to assess CVD risk among patients with psychosis. Fifth the 
chapter highlights the treatment gap for CVD risk factors among patients with mental illness. Lastly the 
chapter provides a summary of the gaps in the literature in Low and Middle income countries (LMICs), a 
conceptual framework and a list of the objectives of the study.   
2.1: Multimorbidity and Excess Mortality among Patients with Mental Illness. 
Patients with psychotic disorders  such as schizophrenia have a 2 to 3 fold increased risk of dying 
compared to the general population and  comorbid medical conditions play an important role in the excess 
mortality in this group (Saha, Chant, and McGrath 2007).  A review  including 17 large studies  done 
among patients with bipolar disorders indicated a two fold increase in risk of premature death  due to  
general medical conditions (Roshanaei-Moghaddam and Katon 2009).  Similarly, a large longitudinal 
study done among 270,770 patients with psychiatric disorder in Denmark, Finland, and Sweden reported 
a reduced life expectancy ( approximately 15 years shorter for women and 20 years shorter for men) in 
patients  compared to the general population,   and mortality due to medical conditions was increased 




Co-occurrence of mental illness and physical conditions  has been widely documented (Soreca et al. 
2008; Kilbourne et al. 2004; ,C. P. Carney, Jones, and Woolson 2006) and may result in poor outcomes 
for  both the  physical and the mental illness (E. C. Harris and Barraclough 1998; Fagiolini and Goracci 
2009a). The prevalence of medical conditions among the patients with mental illness is  higher than 
among the general population in many settings (Janssen et al. 2015). According to the World Mental 
Health Survey of 17 countries (n=47,609 individuals, followed for 2,032,942 person-years), patients with 
mental illness were up to 3.5 times  more likely to develop other physical conditions (K. M. Scott et al. 
2016). Similarly, a large  population-based study among patients  with schizophrenia and  schizoaffective 
disorder in the USA  (n=1,074 cases and N=726,262) also reported that patients  were twice more likely 
to have another chronic medical condition compared to controls (C. P. Carney, Jones, and Woolson 
2006).  Further, a national survey  that included 1,037,946 patients attending primary care facilities in the 
United Kingdom linked multimorbidity with worsening health-related quality of life; and reported that the 
presence of a comorbid mental illness had a more adverse effect on health-related quality of life  than 
any single comorbid physical condition (Mujica-Mota et al. 2015). This is in line with findings from the  
Patient Outcomes Research Team ( Port ) study  in   the US, which reported that comorbid physical and 
mental illness not only led to higher mortality, but also resulted in poorer perceived health status and 
worsening mental illness  (Dixon et al. 1999). 
Recent evidence indicate an excess risk of CVD among mentally ill patients compared to the general 
population (Barnett et al. 2007; McIntyre et al. 2005;  Gardner-Sood et al. 2015; Mitchell, Vancampfort, 
Sweets, van Winkel, et al. 2013). These disorders are the leading physical disorders that contribute to 
mortality in patients with mental illness,  as evidenced  among patients receiving community psychiatry 
services across six  states in the US (Colton and Manderscheid 2006). A recent  meta‐analysis of 
3,211,768 patients and 113,383,368 controls reported that the pooled CVD prevalence in patients with 
severe mental illness ( SMI) was 9.9%,  while  the cumulative CVD incidence was 3.6% (Correll et al. 
2017).  These  disorders are  believed to contribute significantly to the excess mortality that has been 
reported among patients  with psychosis (Muhammad Chachal et al 2016), (Hennekens et al. 2005;  
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Risgaard et al. 2015), competing  only with suicide (Ösby et al. 2000).  For example, a cohort study done 
in the United Kingdom  including 46,136 participants  with severe mental illness (SMI) and 300, 426 
without SMI, the hazard ratio for coronary heart disease mortality in people with SMI compared with 
controls was 3.22 and for stroke deaths, the hazard ratio was 2.53 (Osborn et al. 2007). Similarly a study 
that included 147,193 veteran affairs psychiatric patients in the US reported that  11,809 (8%)  of these 
patients died from heart disease (Kilbourne Amy M. et al 2009). This therefore emphasizes the need for 
attention to CVD risk factors in order to reduce the mortality associated with CVD in this population. 
 
Other comorbidities may also have a bearing The CVD risk profile of patients with psychosis. For example 
patients with psychosis have an  increased risk of acquiring/transmitting TB, and with poorer adherence 
to anti-TB treatment; while a TB diagnosis may also increase the risk of psychiatric comorbidity (Doherty 
et al. 2013;,Pachi et al. 2013; Unwin 2016).  TB among patients with psychosis may also have indirect 
effects on cardiovascular risk.  For example, TB and diabetes mellitus have been found to be highly co-
morbid -  (Alebel et al. 2019). the TB bacterium may in fact alter carbohydrate metabolism by causing 
insulin deficiency and persistent  hyperglycaemia (Young et al. 2009a; L. Bell et al. 2007). In addition, 
mental illness may increase the risk of smoking, which in turn may increases the risk both of TB and of 
CVD (Boon et al. 2007).  
2.2:  Conventional Cardiovascular Risk Factors among Patients with Psychosis 
According to one narrative  review, up to 9.7 million cases of CVD annually  are attributable to well 
established CVD risk factors (Tzoulaki et al. 2016). Among patients with psychosis each of these risk 
factors exist in varying proportions, have different etiological mechanisms and have distinct pathways by 
which they contribute to the increased risk of developing CVD.  
Socio-economic factors: The relationship between psychosis  and low Social- economic Status (  SES)  
has been  described in literature (Hudson 2005) , with some evidence indicating  that  poverty and income 
inequality influence the  prevalence and severity of psychosis  in men and women across the life course 
(Lund et al. 2018). Poverty may also indirectly increase the risk of psychosis  and the association has 
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been described for  lower education levels, lack of employment, high cost of managing the disease, 
stigma and discrimination  (Callander and Schofield 2015).  An alternative explanation of the link between 
SES and cardiovascular health is that psychosis  may impair one’s ability to participate in income-
generating activities, as  demonstrated by large observational  studies in Norway (Kaspersen et al. 2016),  
Finland, Poland, Spain (Leonardi et al. 2018),  and  the Netherlands (Leijten et al. 2015).  Resultant job 
loss due to psychosis may then result in increased psychological distress, and ultimately increased CVD 
risk in affected individuals.   
Smoking:  Smoking   is very common among patients with psychotic disorders (Wojtyna and Wiszniewicz 
2013). There is evidence to suggest that more than half  of patients on treatment schizophrenia and 
bipolar disorders  smoke (J. de Leon and Diaz 2005; McClave et al. 2010; Uçok et al. 2004;  Cooper et 
al. 2012).  A recent meta-analysis which included 31 studies indicated a smoking rate of 58% among 
patients with mental illness (Myles et al. 2012a). Another study which compared  the patients with 
psychosis and the  general population reported that  patients with schizophrenia are twice more likely to 
smoke (Ohi et al. 2019; Myles et al. 2012b).  In addition to the number of cigarettes smoked per day by  
people with psychotic disorders, there is  also evidence of   higher nicotine intake as demonstrated by  
shorter inter puff  periods and more puffs per cigarette amongst patients with mental illness (J. M. Williams 
et al. 2011).   
The exact mechanisms underlying increased tobacco use in mentally ill patients remains complex and 
likely bidirectional  (Quigley and MacCabe 2019).  First, smoking itself may be a primary causative factor 
for psychosis, or may interact with other precipitating factors.  A meta-analysis of  3,717 studies (total of 
N=14,555 tobacco users and N=273,162 non-users) reported that 57% of   patients presenting with their 
first episode of psychosis were smokers; that  smoking   increased  the  risk of a psychotic disorder three 
fold; and that smoking was associated with an earlier age of onset of psychosis (Gurillo et al. 2015a).  
Second, patients with psychosis may smoke to self-medicate, i.e. to alleviate the negative experiences 
resulting from psychosis (such as anxiety and exaggerated startle reflex) (Choi, Ota, and Watanuki 2015). 
Third   patients may also smoke to counter the cognitive impairment associated with psychosis, given 
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that nicotine  has been shown to have  cognitive-enhancing abilities by increasing dopamine release in 
the prefrontal cortex (Jasinska et al. 2014; Ghiasi et al. 2013). A meta-analysis including 41 double-blind, 
placebo-controlled laboratory studies  found positive effects of smoking in  fine motor functioning , alerting 
attention-accuracy and response time, orienting attention, short-term episodic memory, accuracy, and 
working memory response time (Heishman, Kleykamp, and Singleton 2010). Fourth, increased smoking 
in patients with psychosis may be mediated by specific genetic polymorphisms. For example, 
polymorphism of  the IL-1beta-511C/T gene  has been found to be associated with increased severity of 
nicotine dependence among male smokers with schizophrenia (Zhang et al. 2015). A polygenic analysis 
from the Psychiatric Genomics Consortium (PGC) Schizophrenia group has also revealed several shared 
genes between smoking and mental illness (J. Chen et al. 2016). Finally,  nicotine use among mentally 
ill patients may be compounded by  accompanying social difficulties,  as demonstrated  by a higher  
prevalence of smoking among socially disadvantaged patients (L. Hahn, Rigby, and Galletly 2014).  
In addition the  direct neurobiological mechanisms through which smoking increases CVD risk there are 
also a number of indirect mechanisms through which smoking may increase CVD risk among patients 
with psychosis. For example, smoking has been found to increase the activity of the cytochrome CYP 
1A2 enzymes, thus decreasing the concentration of certain psychoactive agents such as clozapine and 
olanzapine,  and increasing the clearance of fluphenazine and haloperidol (Šagud, Mihaljevi, and Vuksan 
2009).  As a result, dosages above the recommended therapeutic limits may be administered, resulting 
in higher risk of metabolic side effects associated with these drugs (McCloughen 2003; Tsuda, 
Saruwatari, and Yasui-Furukori 2014) 
 Harmful Alcohol use 
While generally substance use disorders are very common among patients with mental illness (Toftdahl, 
Nordentoft, and Hjorthøj 2016),  harmful alcohol use is one of the most commonly used substance  among 
patients with  psychotic disorders (Yang et al. 2018).  One meta-analysis  of 123 studies (N=165,811 
participants)  reported that 24% of patients with schizophrenia had a co-morbid alcohol use disorder 
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(Hunt et al. 2018); and 46.2% patients with bipolar I mood disorder have been reported also to have  an 
alcohol use disorder (Sonne and Brady 2002). This , according to a nationwide  prospective study done 
in Denmark  that included 41,470 people with schizophrenia, 11,739 people with bipolar disorder, and 88 
270 people with depression, is associated with higher standardized mortality rations ( 2 to 8 times higher)  
compared to patients without alcohol use (Hjorthøj et al. 2015). 
The pathways underlying comorbid alcohol use disorder and psychotic disorders is likely multifaceted, 
including shared etiological mechanisms.  Alcohol use may itself precipitate psychosis, and mental illness 
may increase the risk of alcohol use as self-medication (Sonne and Brady 2002). Alcohol  has been found 
to target dopaminergic, glutamatergic and GABAergic transmission,  all which are also involved in the 
pathophysiology of psychosis (Thoma and Daum 2013). Patients with schizophrenia may also tend to 
overvalue drug-like rewards (augmented by alterations in nicotinic, cholinergic, GABAergic, 
glutamatergic, and cannabinoid receptor function); and to devalue the potential negative consequences 
of substances, and this may be further complicated by detrimental decision-making and impulsive 
behaviour  (Krystal et al. 2006). Distortions in reward processing and altered responses to substances of 
abuse may also increase the likelihood that individuals with schizophrenia will self-medicate in order to 
blunt or alleviate their psychotic symptoms (Potvin, Stip, and Roy 2003). Further, the  greater euphoria 
and stimulatory effects in response to alcohol observed among patients with schizophrenia may also 
promote alcohol consumption among these patients (D’Souza et al. 2006).  Genetic studies of both 
alcohol use and schizophrenia suggest a combination of multiple common and rare variants which may 
contribute to this co-morbidity (Polimanti, Agrawal, and Gelernter 2017;  Levey et al. 2014; K. Wang, Luo, 
and Zuo 2014).  
Inadequate physical activity; Current evidence indicates  that patients with mental illness tend to have  
more sedentary behaviour  and also perform less vigorous physical activity compared to the general 
population (Davy Vancampfort et al. 2017).. For example, a meta-analysis of 292 publications reported 
that  patients with schizophrenia were less physically active than the general population (Ohi et al. 2018).  
A systematic review and meta-analysis including 2,033 participants with psychosis reported patients 
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spent on average 11hours in sedentary behaviour and this was about 2.8 hours more than the general 
population (Stubbs, Williams, et al. 2016).  This less that optimal level of physical activity is likely to have 
implications both for physical health and for overall quality of life among patients with  psychosis, (Martín-
Sierra et al. 2011).   
Several explanations have been put forth as contributors toward low physical activity level in this 
population. One large study of  204,186  adult patients with psychosis from 46 LMICs  attributed the lower 
physical activity levels in these patients to certain symptoms and sequelae of psychosis, including 
impaired cognition, depression, mobility difficulties and self-care challenges, (Stubbs et al. 2017a). 
Reduced physical self-perception due to psychotic illness,  as well as impaired physical capacity and 
health-related muscular fitness, may also play a role  in reducing the ability of patients with psychosis to 
engage in adequate physical activities (Davy Vancampfort, Probst, et al. 2013). In addition, patients with 
schizophrenia have been found to have reduced cardiorespiratory fitness compared to healthy controls, 
(Heggelund et al. 2011; Strassnig, Brar, and Ganguli 2011), which may be worsened by the presence of 
other CVD risk factors such as obesity (D. Vancampfort, Sweers, et al. 2011) and DM (Davy Vancampfort, 
De Hert, et al. 2013). Low activity level may also  precede the onset of illness as reported by a Finish 
birth cohort study which demonstrated that  adolescents who later developed  psychosis had low level of 
physical activity prior to the onset of the illness (Koivukangas et al. 2010) . The sedating effects of 
antipsychotics is also likely to reduce patients’ physical activities  thus increasing the time spent in 
sedentary behaviour  and hence increasing the  CVD risk further (D. D. Miller 2004).  
Poor diet: Evidence suggests that patients with mental illness have high rates of poor diet. For example, 
a well powered self-reported health behaviours study conducted among 1, 935 Australian adults reported 
poor intake of fruits and vegetables  among patients who scored  highly on a psychological distress scale 
(D. Scott et al. 2013). This is collaborated by a  systematic review  of 31 articles assessing the dietary 
patterns of patients with schizophrenia  which reported that these individuals often followed a poor diet 
(e.g. with increased intake of saturated fats and reduced intake of fruits and vegetables), thus augmenting 
the  risk of metabolic disturbances (Dipasquale et al. 2013a).   
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Several factors contribute to poor dietary habits among patients with psychosis specifically.  A case–
control study that  recruited patients with first episode psychosis from South-East London  reported a 
positive association of poor dietary habits and unemployment (Samele et al. 2007). Poor  dietary habits  
among mentally ill patients have also  been  attributed to substance use (which – as discussed previously 
– is highly comorbid in this population);  to the negative symptoms of psychosis; or to economic 
challenges (Tune et al. 2017).  According to  an observational study of 1244 adults in Australia, another 
potential contributor of poor diet is low knowledge levels  among patients with psychosis on  physical 
health behaviours which is associated with poor dietary habits (Stanton, Scott, and Happell 2016).   
Further, cultural factors also play a role in shaping dietary habits as demonstrated by a case control study 
in Bahrain (n=240) that  reported similar dietary habits  between patients with schizophrenia and controls 
,a finding  they attributed to  the  practice of serving certain fruits and vegetables in every meal and in 
community cerebrations (Jahrami et al. 2017).  
Diabetes: Hyperglycaemia  and DM  are common among  patients with schizophrenia and schizoaffective 
disorder (D. Cohen et al. 2006), with  a recent meta-analysis (N=438,245 individuals) reporting  a 
prevalence of DM of 10.2% (Davy Vancampfort et al. 2016). This is in agreement with findings of a study 
done in Wales among 3,170 patients with schizophrenia which reported a double incidence of DM among 
the patients compared to the general population (Le Noury et al. 2008).  Similarly, a 10-year nationwide 
population-based prospective cohort study  that was conducted in Taiwan among 367 patients with 
bipolar mood disorder, 417 patients with major depressive disorder , and 1,993 patients with 
schizophrenia reported that patients with bipolar mood disorder and schizophrenia had significantly  
increased risks of initiation of anti-diabetic and anti-hyperlipidaemia treatment  compared to controls and 
patients with major depressive disorder (Bai et al. 2013). 
The relationship between DM and mental illness  is bidirectional  with DM increasing risk of mental illness 
and  mental illness medication increasing risk of DM (Balhara 2011). There is also evidence that there 
are several shared etiological pathways that contribute to the comorbidity (Y. Liu et al. 2013).  The use 
of antipsychotics -  particularly olanzapine and clozapine - has been linked to increased prevalence of 
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DM (Lamberti et al. 2004; Lamberti et al. 2005; Guo et al. 2006). Antipsychotics may contribute to 
impaired glucose control  through pancreatic  beta cell dysfunction,  reduced  insulin sensitivity , increased 
hepatic glucose production and decreased peripheral glucose utilization (Chintoh et al. 2009). However, 
there is also evidence of impaired glucose levels in up to 15% of  patients who have not been exposed 
to such neuroleptics, suggesting an alternative etiological mechanism for DM in patients with psychosis 
(Mukherjee et al. 1996). One hypothesis is linked to the deficiency of insulin-like growth factor in patients 
with schizophrenia, which is believed to contribute to insulin resistance and thus also to impaired glucose 
tolerance (Gastaldelli, Gaggini, and DeFronzo 2017;  Venkatasubramanian et al. 2007; Kirkpatrick et al. 
2012). Further, a positive family history of DM has been found to be associated with a positive family 
history of schizophrenia, suggesting potentially shared heritability (Nuevo et al. 2011), (Foley et al. 2016). 
In addition , a functional genetic variant of the melatonin receptor 1B (MTNR1B) gene, which increases 
vulnerability for elevated fasting plasma glucose, has been reported to be shared between bipolar mood 
disorder  and schizophrenia (Hukic et al. 2016).  
Hypertension: The prevalence of hypertension is estimated to be up to two times higher  among patients 
with mental illness  compared to the general population (Sugai et al. 2016a; Ayerbe et al. 2018).  Other 
evidence indicates that hypertension is one of the most common  medical   comorbidities in patients with 
schizophrenia (Nishanth et al. 2017)  and  bipolar mood disorder (Goldstein et al. 2009).  A recent meta-
analysis reported an increased incidence of hypertension in patients with bipolar mood disorders (Ayerbe 
et al. 2018) with a Japanese nationwide survey indicating a 2 to 3 fold increased risk among patients with 
schizophrenia (Sugai et al. 2016a).  Data from the 2001‐2002 National Epidemiologic Survey on Alcohol 
and Related Conditions (NESARC) study reported that the prevalence of hypertension among patients 
with bipolar mood disorder is 22% (Goldstein et al. 2009).  
 The mechanism underlying increased risk of hypertension in patients with psychosis are varied. 
Antipsychotic use resulting in disrupted dopamine activity may be a significant contributor to the increased 
risk of hypertension in patients with schizophrenia (B. B. Alves et al. 2019) . This may be underpinned by 
the absence of inhibitory tone on sympathetic outflow (mediated by D2 dopamine receptors) in the 
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vascular smooth muscle (Li et al. 2001). In addition, emotional distress which is common  in patients with 
psychosis  results in  HPA axis dysregulation  hence  contributing to development of  hypertension (Ojike 
et al. 2016).  Given the high heritability both of hypertension (30-60% (Kupper et al. 2005; Shih and 
O’Connor 2008),  and of schizophrenia (81%) (Sullivan, Kendler, and Neale 2003), genetic risk factors 
may also contribute to their co-morbidity (Kotchen et al. 2000) .  
Obesity; Studies done in high income settings indicate that patients with schizophrenia are  twice as 
likely to experience obesity  and dyslipidaemia, compared to the general population (Cameron et al. 2017; 
Association 2004). A small but growing evidence base suggests that this trend may also exist in general 
populations in SSA. For example, one population-based cross-sectional survey by Kavishe et al. of 2,011 
participants  from rural Tanzania and Uganda reported high rates of hypertension,  cigarette smoking, 
harmful  alcohol use , and increased  BMI (Kavishe et al. 2015). 
 The high rates of obesity reported among patients with psychosis has been linked to a shared biological 
vulnerability between mental illness and abnormal metabolic processes, unhealthy lifestyles and 
antipsychotic use (Bradshaw and Mairs 2014).  As is the case for DM, it is likely that co-morbid obesity  
and psychosis is largely attributable to antipsychotic use, particularly clozapine and olanzapine 
(Gianfrancesco et al. 2003; Wirshing 2004; Rummel-Kluge et al. 2010a). In this regard, a number of 
studies that have been conducted among  patients with first episode psychosis   before medication  
initiation  have consistently demonstrated lower prevalence  of obesity among unmedicated patients 
compared to patients on antipsychotics (Padmavati, McCreadie, and Tirupati 2010), (Sengupta et al. 
2008). Another mechanism that could explain the high prevalence of obesity among patients with 
psychosis is  dopamine dysregulation as described in the  dopamine theory of schizophrenia (Howes and 
Kapur 2009). Impairment in dopaminergic pathways that regulate neuronal systems associated with 
reward sensitivity and control  of food intake may   result  in overeating and hence obesity in this population 




   Dyslipidaemia; Several studies have demonstrated a derangement in lipids among patients with 
psychosis (Koro et al. 2002). A study done among 1,642 Australians with psychosis and 8,866 controls 
showed that patients with psychosis had lower a HDL-cholesterol than controls (18). Another survey 
conducted in South Africa among 84 long-term mentally ill patients reported that half of the participants 
had high Low Density Lipoprotein (LDL) (Maaroganye et al. 2013).  A similar study of 276 participants in 
Durban, Kwazulu-Natal reported high LDL and  low HDL among the mentally ill persons (Saloojee, Burns, 
and Motala 2016a).  
The  dyslipidaemia  among patients with psychosis has strongly been linked to use of antipsychotics 
especially atypical antipsychotics with olanzapine and clozapine being on the lead (Attux, Quintana, and 
Chaves 2007; Birkenaes et al. 2008; J. de Leon et al. 2007).  In support of the role of medication in 
altering the lipid metabolism, a comparative meta-analysis including twenty-six studies with 2,548 
patients who were taking medication and 19 studies with 1,325 unmedicated patients reported that the 
dyslipidaemia is more prevalent after medication initiation (Lange and Steck 1994). Antipsychotics are 
believed to alter lipid metabolism by promoting  synthesis and accumulation of total cellular cholesterol 
by reducing the cholesterol level within the cell endoplasmic reticulum (Mitchell, Vancampfort, De Herdt, 
et al. 2013a). Another potential mechanism of antipsychotic  medication on lipid metabolism is the 
upregulation  of  genes controlled by the sterol regulatory element-binding protein (SREBP) transcription 
factors(J. Fernø et al. 2005 ; Johan Fernø et al. 2009).  
Metabolic syndrome; Patients with psychosis  demonstrate a higher prevalence of (MetS) compared 
with the general population (Toalson et al. 2004, (Jakovljević et al. 2007; McEvoy et al. 2005;  Ohaeri 
and Akanji 2011).  According to one large meta-analysis (N=256,920 individuals), the prevalence of MetS 
was reported to be 32.5% among patients with schizophrenia and related disorders (Mitchell, 
Vancampfort, Sweers, et al. 2013)  and 37.3% among patients being treated for bipolar mood disorder 
(Davy Vancampfort, Vansteelandt, et al. 2013).  
51 
 
In patients with mental illness, the strongest evidence of association has been with prescribed  medication 
(Ventriglio et al. 2015). Other contributors to high  rates of MetS among patients with mental illness  can 
be linked to the individual risk factors such as DM and dyslipidaemia in these patients (Davy Vancampfort, 
Vansteelandt, et al. 2013), (Beilby 2004b). Others have hypothesized that sleep disturbance in psychosis 
could lead to impaired energy balance due to impairment of sleep regulated hormones like leptin and 
ghrelin (Garaulet and Madrid 2009). Important to note however, is that the  prevalence of MetS in 
neuroleptic-naïve psychotic patients and in those with first-episode psychosis has been found to be 
approximately 10%,  thus suggesting additional etiological mechanisms (Mitchell, Vancampfort, De Herdt, 
et al. 2013b). The risk at diagnosis is however likely to be worsened as the illness takes a more chronic 
course as indicated by a meta-analysis that included123 publications which  reported a higher  prevalence 
of MetS among more chronic patients with schizophrenia compared to first episode and unmedicated  
schizophrenia (Mitchell et al. 2013).   
2.3: Psychopharmacological treatment and cardiovascular risk 
Mental illness in itself has an association with CVD risk as demonstrated by presence of CVD risk factors 
like diabetes, dyslipidaemia and obesity even before the onset of antipsychotic use (Osby et al. 2014; 
Bushe and Holt 2004.  However the use of antipsychotics  in these patients markedly affects metabolism 
leading to weight gain, dyslipidaemia and  diabetes mellitus (DB Allison, JL Mentore, M Heo 1999; Ballon 
et al. 2014).  
Antipsychotics, both first generation and second generation, remain the main mode of treatment for 
schizophrenia, bipolar disorders and other psychotic disorders (Lally and MacCabe 2015). Unfortunately, 
most antipsychotics are associated with an increase in CVD risk factors such as obesity, weight gain, 
hypertension  and DM (Rojo et al. 2015),  thus  the need to  understand, assess, and subsequently 
manage metabolic complications of antipsychotics  in order to mitigate the excess CVD related morbidity 
and mortality  among patients using these drugs (Abosi et al. 2018). A recent meta-analysis of 307 clinical 
trials reported that almost all antipsychotics assessed resulted in increased body weight and BMI, 
particularly with longer duration of antipsychotic use - (the exceptions in this case were amisulpride, 
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aripiprazole and ziprasidone, which remained weight-neutral with increasing duration of antipsychotic 
use).  However, different antipsychotic show different alteration in metabolic profile, with olanzapine being 
most implicated.  For example an observational  Chinese study comparing  risperidone, olanzapine,  
ziprasidone chlorpromazine, haloperidol and trifluoperazine  showed that olanzapine was associated with 
the highest increment in  cholesterol and triglycerides (Edwin Lee, Lai-Yin Chow, and Chi-Ming Leung 
2011) .Further, antipsychotic-naïve patients  exhibited the greatest incremental weight gain and increase 
in BMI with increased duration of medication use (Maarten Bak et al. 2014). This is similar to  findings of 
a small Spanish longitudinal study (N=170) of patients with first episode psychosis, which  demonstrated 
that metabolic  changes occurred early in treatment,  with maximal increases of weight gain and lipids 
occurring in the first year , and stabilizing thereafter (Pérez-Iglesias et al. 2014). Though most of the 
literature is from developed nations, findings of increased CVD risk with antipsychotic use has also been 
reported in LMIC settings. For example an observational study conducted in Ethiopia among 356 patients 
reported that 56% of the patients developed cardiovascular related side effects (Wubeshet, Mohammed, 
and Desse 2019). 
A number of mechanisms underlie antipsychotic-induced metabolic changes and increased CVD risk. 
For example, antipsychotics may affect glucose homeostasis by perturbing both the central and 
peripheral nervous systems that are involved in glucose metabolism (Kowalchuk et al. 2018). 
Antipsychotic-induced weight gain as well as  alteration of lipid and glucose metabolism results from 
blockade of serotonin ( 5HT2c) and histamine (H1, H3) receptors in the nervous system (Shen- Chieh 
Chang et all 2012; Wesley Kroeze 2003; Chao Deng 2010; Gavin P Reynolds et all 2006). Antipsychotics  
also result in results in increased appetite and weight gain, as well as binding at  5-HT1A, muscarinic M3, 
dopamine D2 which has been linked to  insulin resistance  (Shen- Chieh Chang et all 2012). The  
antipsychotic-related metabolic effects are seen in patients using most antipsychotics but are more 




It has also  been suggested that reduction in prolactin levels that occurs with use  of  atypical 
antipsychotics due to reduction in serotonin level also plays a role in aetiology of DM (Oberweis and 
Gragnoli 2012). In addition,  antipsychotics may increase the risk of weight gain and obesity by inducing 
a hypermetabolic state (increasing appetite and caloric intake), which is a result of  alteration of  
neurotransmitters  such as histamine( H), adiponectin, serotonin( 5HT) and dopamine (D) which play a 
role in obesity (Manu et al. 2015).  It has also been reported that the antagonistic effects of antipsychotics 
on 5-HT2C, muscarinic, and H1 receptors alter the gut microbiota composition, which in turn leads to 
changes in appetite and emotions and eventually increased weight gain (Bretler et al. 2019).  Further,  
given that antipsychotics target dopamine receptors, and that  D1, D3 and D4 receptors interact directly 
with the renin‐angiotensin‐aldosterone system whereas D2 and D5 receptors interact with the 
sympathetic nervous system to regulate blood pressure, use of dopaminergic agonists or antagonists 
has the potential to interfere with  the regulation of blood pressure thus increasing CVD risk (Gonsai et 
al. 2018; B. B. Alves et al. 2019). Molecular studies have also indicated that second generation 
antipsychotics interfere with  energy glucose metabolism at the mitochondrial level ( the cellular organelle 
responsible for energy production) thus  accelerating development of MetS (del Campo et al. 2018) .  
Antipsychotic-related weight gain has also been linked to certain variants in genes coding for 
antipsychotic pharmacodynamics targets such as the dopamine and serotonin receptors. A meta-analysis 
of 72 articles (N=6700 participants) reported at least 9 genes and 13 Singel Nucleotide Polymorphisms 
(SNPs ) associated with antipsychotic-induced weight gain (J.-P. Zhang et al. 2016).  Antipsychotic effect 
on cardiovascular risk factors may also augment an already existing vulnerability. For example one 
Chinese study that compared antipsychotic naïve patients with schizophrenia and the general population 
reported that patients with schizophrenia are more likely to have insulin resistance and dysfunction of 
lipid metabolism when compared to the control population, even before onset of treatment (S. Chen et 
al. 2013).  
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2.4: Exposure to Potentially Traumatic Events among Patients with Psychosis 
There is evidence that patients with psychosis are more likely to experience  potentially traumatic events  
in their lifetime, when compared to  the general population (Mueser et al. 2002) (Floen and Elklit 2007b).. 
There is  also evidence to suggest that traumatic experiences increase the risk of schizophrenia and 
bipolar mood disorders- particularly among those with genetic predisposition - by increasing stress 
vulnerability, and dysfunction in the HPA axis (Okkels et al. 2017; Shevlin et al. 2008). A study done in 
South Africa among patients with first episode psychosis demonstrated that both the witnessing of a 
seriously violent act (and a history of sexual assault were associated with high positive symptoms in 
patients (Burns et al. 2011).  In addition, childhood trauma is also  common among patients with 
psychosis but the etiological mechanisms remain poorly understood (Etain et al. 2008a; Craig Morgan 
and Fisher 2007; Friedman and Tin 2007). Childhood trauma has also been found to be associated with 
the development of mental illness later in life (Larkin and Read 2008;  Spataro et al. 2004). One  meta-
analysis of 36 studies ( n=81,253) reported   that such exposure  to trauma may increase the risk of 
psychosis by almost three fold (Varese et al. 2012). This risk is likely  due to distressing interpretations 
of ambiguous external events (Whitfield et al. 2005a; Larkin and Read 2008).  In addition childhood 
trauma has been linked with impairment in working memory, executive function, verbal learning, and 
attention in schizophrenia patients (2019). The Adverse Childhood Experiences study (ACE) documented 
the positive relationship between the dose of traumatic experience in childhood and the severity of 
negative mental health outcome in adulthood (Whitfield et al. 2005b). Similarly, data from the second 
British National Survey of Psychiatric Morbidity suggested that patients with psychosis were more likely 
to report traumatic experiences in their childhood than were those without psychosis, with sexual abuse 
being most frequently reported (Bebbington et al. 2004) Data from the environmental risk longitudinal 
twin study in United Kingdom , which followed  2,232 twin children reported a three-fold increase in risk 
of psychotic symptoms among patients who were maltreated in childhood (Arseneault et al. 2011). One  
brain imaging study  of children who were maltreated postulated that childhood trauma may contribute to 
psychopathology by resulting in changes in brain regions involved in emotional regulation, ability to 
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accurately attribute thoughts or intentions and self-awareness (Teicher et al. 2014). An Irish prospective 
cohort study involving 1,112  adolescents  reported a bidirectional relationship  between trauma and 
psychotic experiences,  a  dose-response relationship between severity of bullying and risk of psychotic 
experiences as well as  incidence of psychotic experiences decreasing significantly in individuals whose 
exposure to trauma ceased over the course of the study (Kelleher et al. 2013). 
2.5: Estimating the Overall Cardiovascular Risk in Patients with Psychosis 
Framingham Risk Score (FRS) is  the most commonly used in  patients with mental illness (Foguet-Boreu 
et al. 2016) (Lloyd-Jones et al. 2004;  Wilson Peter W. F. et al. 1998).   The Clinical Trials of Antipsychotic 
Treatment Effectiveness (CATIE) schizophrenia study,   reported significantly elevated  FRS scores 
among  patients with schizophrenia compared to controls, both for males  (9.4% in patients vs 7.0% in 
controls) and females (6.3% vs. 4.2%) (Goff et al. 2005).  Similarly, a  Lebanon study of 329 patients with 
schizophrenia reported that 31.6% of the participants  had intermediate risk of developing CVD, while 
7.6% had high risk (Haddad et al. 2017). A Chinese study ( 83 patients and 243 controls ) also reported 
that patients with  schizophrenia  had a higher mean 10-year CVD risk (4.6%), compared to controls 
(3.1%) (Tay, Nurjono, and Lee 2013).  
2.6: Treatment Gap for Cardiovascular Risk Factors among Patients with Psychosis 
While the burden of CVD risk factors is high among patients with psychosis, there is evidence for 
interventions that have potential to reduce this in this population.  For example a UK  wellbeing support 
program that was initiated among 966 patients with SMI reported a significant improvement in physical 
activity and a reduction in smoking(S. Smith et al. 2007). A Chinese randomized controlled trial that 
involved  128 adults with schizophrenia  assigned to  12 weeks of  either placebo, 750 mg/d of metformin 
alone, 750 mg/d of metformin and lifestyle intervention, or lifestyle intervention only, demonstrated that a 
combination of metformin and lifestyle intervention (psychoeducational, dietary and exercise programs) 
was effective in reducing weight, BMI and waist circumference (Wu Ren Rong 2008). In addition,  a study 
done in Boston comparing the quality of care between 214 patients with schizophrenia   and 3594 controls   
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indicated that patients with schizophrenia can actually receive high quality care for DM  in well-organized 
settings (Weiss et al. 2006). 
Despite the recognized burden of CVD among patients with psychosis and evidence for interventions 
that could reduce this burden, current systems for the assessment and treatment of these disorders in 
this group are limited (Hennekens 2007).  According to data from the CATIE: Schizophrenia study, rates 
of non-treatment were  30.2% for diabetes mellitus, 62.4% for hypertension, and 88.0% for dyslipidaemia 
(Nasrallah Henry et all 2006). A study of patients with Type 2 DM including 100 patients with 
schizophrenia, 101 with a major depressive mood disorder, and 99 without SMI reported that patients  
were less likely to be prescribed  for cholesterol-lowering statin medications, angiotensin-converting 
enzyme inhibitors, and angiotensin receptor blocking agents than diabetes patients without SMI and that 
patients with both diabetes and SMI are treated less aggressively for high cardiovascular risk than 
diabetes patients without mental disorders (Kreyenbuhl et al. 2006). Similarly, a study of psychiatric 
inpatients in Southampton (n=100)  reported low documented screening for cardiovascular risk factors, 
with only 32% of patients having blood pressure on record,  16% with measured glucose, 19% with lipids 
assessed and 2% with weight recorded in a one-year period (Holt et al. 2010). Further, a study in 
Maudsley  (n=606 ) reported that 11% of patients with diabetes mellitus had not been previously 
diagnosed (David Taylor, Corina Young, Radia Mohamed, Carol Paton, Rebecca Walwyn 2005).  
Similarly, a population-based record-linkage study of 210,129 users of mental health services in Western 
Australia   reported  that - compared to the general population - patients with psychosis were less likely 
to receive interventions for acute cardiovascular events such as revascularization (David M. Lawrence et 
al. 2003).  
The low  rate of screening ,diagnosis and treatment for cardiovascular risk factors amongst patients with 
psychosis  many settings may be due to a number of interrelated factors  (D. J. Smith et al. 2013; DE 
HERT et al. 2011; Druss et al. 2001).  First , there may be   lack of co-located medical and mental health 
services, and cultural challenges such as providers' adopting a biomedical – rather than a holistic – 
approach to patient care (Druss and Newcomer 2007), (Druss 2007).  Second , patients with psychosis 
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tend to exhibit lower utilization of healthcare services and higher use of emergency services, which may 
suggest missed opportunities for recognition and management  of CVD risk factors (Motsinger et al. 2006; 
Thomas R. E. Barnes et al. 2007). In such settings, physical examination may not be comprehensive as 
clinicians may  focus instead on the presenting emotional or behavioural disturbance, neglecting 
symptoms that may indicate cardiovascular ill health  (R. Carney, Bradshaw, and Yung 2015).  Third, 
impaired cognition that is associated with psychosis may  also adversely  affect health seeking behaviour 
and reporting of  CVD related physical symptoms  (Räsänen et al. 2003; Mensah et al. 2015). Third, due 
to the mental illness most patients are less likely to adhere to medication prescribed to control the cardio 
metabolic disorders thus contributing to poorer outcomes. Fourth, both perceived and experienced stigma 
for mental illness may contribute to the patients  not receiving adequate care for the cardiovascular risk 
factors  (Knaak, Mantler, and Szeto 2017). 
However, even when healthcare facilities are accessed by patients with psychosis, screening for physical 
disorders in these settings is limited. For example, despite the American Diabetes Association (ADA) 
consensus statement recommending metabolic monitoring for patients treated with second generation 
antipsychotics (SGA, ) screening   rates among mentally ill patients in the US   have been found to be as 
low as 20% for glucose and 10% for lipids (Morrato et al. 2009) . This is similar to  findings of a UK-based 
clinician audit, which reported recorded measurement within the previous year for blood pressure in 26% 
of patients (total N=1966), for obesity in 17%, for blood glucose (or HbA1c) in 28% and for plasma lipids 
in 22%; with all four  measures documented in only 11% (Thomas R. E. Barnes et al. 2007; Motsinger et 
al. 2006). Label warnings of antipsychotics  may also not be effective in increasing screening rates - in a 
cross-state US cohort study of 109,451 individuals receiving Medicaid who were initiated on SGA 
treatment, labelled warning was not associated with a significant increase in glucose testing; and only  
marginally increased lipid testing rates (1.7%; p=0.02) (Morrato et al. 2010). These gaps in care likely 
contributes to excess CVD related mortality and morbidity in this population.  
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2.7 : Study Justification 
While there is substantial literature on the prevalence and determinants of CVD risk factors in the 
developed world, there is a notable underrepresentation of data available from LMICs and SSA; and the 
literature on the burden of conventional cardiovascular risk factors among patients with psychosis in SSA 
is scanty. There are also minimal data for SSA on the role of trauma and psychological distress in shaping 
cardiovascular risk profile; and on the contribution of comorbid medical conditions to cardiovascular risk   
among patients with psychosis. Data on prescription patterns in SSA and how this affects the 
cardiovascular risk profile among patients with mental illness is not existent.  Efforts to address the 
cardiovascular risk factors among mentally ill patients in LMIC and SSA, are also not well documented in 
literature. The current study therefore addresses the knowledge gap on the risk of CVD among patients 
treated for psychosis in a SSA setting.  
 The dearth of evidence emerging from LMICs and SSA has likely contributed to limited clinical programs 
addressing the cardiovascular health of mentally ill patients in these settings. In future, the burden and 
sequelae of CVDs may largely be reduced through simple and cost-effective methods such as lifestyle 
modification (e.g. smoking cessation, improved diet and physical activity, substance use interventions); 
as well as timely treatment for disorders such as hypertension, DM, and hyperlipidaemia. However, in 
order to design contextually relevant screening, treatment and prevention guidelines that may ultimately 
be integrated into routine care of the mentally ill in SSA, further work on the prevalence of CVD risk 
factors is needed.  
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2.8: Study aim and objectives 
The aim of this study was to assess the cardiovascular risk profile among patients treated for psychotic 
disorders at Moi Teaching and Referral Hospital (MTRH) in Eldoret, Western Kenya. 
To achieve this aim, the specific objectives of the study were as follows: 
1. To compare the prevalence, as well as sociodemographic and clinical correlates, of conventional 
cardiovascular risk factors (smoking, alcohol intake, poor diet, and lack of exercise, DM, 
hypertension, obesity, dyslipidaemia and metabolic syndrome) in patients with psychosis versus 
matched controls.   
2. To explore the prevalence and correlates of non-conventional risk factors; psychological distress, 
traumatic events (lifetime and childhood trauma) and comorbid medical disorders in patients with 
psychosis and controls, and to delineate how these risk factors contribute to the overall 
cardiovascular risk. 
3. To describe current psychopharmacological treatments in patients with psychosis and explore 
potential associations with cardiovascular risk among patients with psychosis. 
4. To estimate the overall 10-year cardiovascular disease risk, as well as the social demographic 
and clinical correlates among patients and controls.  
5. To establish the proportion of untreated metabolic disorders (hypertension, diabetes mellitus, and 
dyslipidaemia) in patients with psychotic disorders and matched controls. 
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2.9: Conceptual Frame work 
 
 
Figure 3 : Conceptual Framework 






















































 A number of inter-related factors have been found to contribute to cardiovascular risk among patients 
with psychosis. Figure 3 above summarizes the various aspects of the CVD risk profile of patients with 
psychosis. There are shared biological, socio-economic,  and environmental factors that contribute to the 
risk of both psychosis and CVD risk factors (De Hert, Detraux, and Vancampfort 2018). Antipsychotic 
medication augment these factors thus increasing the CVD risk further (Newcomer and Haupt 2006). 
Additionally,  individual, social and systemic factors may impede  optimal implementation of interventions, 
thus  resulting in increased morbidity and mortality in patients with psychosis (Ringen et al. 2014). 
Understanding these interrelated factors is the first step in planning for programs to mitigate CVD risk 
factors. This study therefore is an important step in informing programs to promote cardiovascular health 





CHAPTER 3: MATERIALS AND METHODS 
3.0: Introduction 
This chapter will highlight the research design. It will also give a description of the study site, and the 
study population. A detailed description of the study procedures will be provided as well as the data 
analysis that was undertaken. 
3.1: Study Design 
 This was a cross-sectional descriptive survey comparing a group of patients with psychotic disorders 
(patients) and a group of participants without psychotic disorders (controls). This study was nested within 
the Neuropsychiatric Genetics of African Populations (NeuroGAP) study,  which aims to explore the 
genes that are associated with psychotic disorders in African populations (Dalvie et al. 2015; Stevenson 
et al. 2019). (https://www.broadinstitute.org/stanley-center-psychiatric-research/NeuroGAP/NeuroGAP-
psychosis). In summary, NeuroGAP is an ongoing multi-site case control study, in which data collection 
is being undertaken in South Africa, Uganda, Ethiopia and Kenya in collaboration with Harvard School of 
public health. For the current thesis, patients who had already been recruited for NeuroGAP were eligible 
for inclusion.  
The patient group comprised of persons being actively followed up for the treatment of either 
schizophrenia, schizoaffective disorder or bipolar mood disorders at Moi Teaching and Referral Hospital 
(MTRH). Clinical diagnoses were obtained from patient records, as documented by the primary doctor, 
and confirmed using a subset of questions adapted from the Mini International Neuropsychiatry Interview 
(MINI). The MINI is a short semi-structured interview for diagnosing mental illness in line with the 
Diagnostic and Statistical Manual, version 5 (DSM 5 (Lecrubier et al. 1997). The MINI has been shown 
to be reliable and  comparable to the Structured Clinical Interview for DSM (SCID) and the Composite 
International Diagnostic Interview (CIDI), but with a shorter administration time (Sheehan et al. 1997) 
The control group consisted of members of the public who had never been treated for a mental illness. 
They were recruited from patients attending general clinics in MTRH, hospital visitors and relatives of 
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patients, who were believed to live in the same geographic region as the study group participants. They 
were matched with the study group for age and Sex in order to ensure similar distribution of confounders. 
3.2: Study Setting  
The study was conducted at Moi Teaching and Referral Hospital (MTRH). MTRH is located in Eldoret 
town, Uasin Gishu County, and it is the fifth largest town in Kenya, situated in the Western part of the 
country (see Figure 4).   
 
Figure 4:  Map of Kenya showing the location of Eldoret 
Source: Uploaded by World Environment 2019;  9(1): 19-27 (Wilfred Omollo 2019) 
MTRH is the second largest referral hospital in Kenya and has a catchment population of >15 million. 
The hospital serves as a referral facility for peripheral hospitals in the Western part of Kenya and as the 
primary care centre for the local community. Further, MTRH serves patients both from rural and urban 
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settings, including diverse ethnic groups. Thus, this study setting was appropriate to maximize 
generalizability of research findings. 
 
Figure 5 : Inpatient mental unit of MTRH and NeuroGAP team 
 The photo includes members of the Moi NeuroGAP study team, as well as visiting members from the Stanley 
Centre at the Broad Institute.   
 (With permission) From Left to Right:  Stella Gichuru, NeuroGAP study coordinator; Amantia Ametaj, post doc 
fellow NeuroGAP, Broad Institute; Eunice Jeptanui, one of the three NeuroGAP research assistants;  Edith 
Kwobah, author; Carter Newman, Broad institute;  Anne Stevenson , Broad Institute.  
The hospital serves as a referral facility for peripheral hospitals in the Western part of Kenya and as the 
primary care centre for the local community. Further, MTRH serves patients both from rural and urban 
settings, including diverse ethnic groups. Thus, this study setting was appropriate to maximize 
generalizability of research finding MTRH has a well-established mental health service providing both 
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inpatient and outpatient services. There is a booked psychiatric outpatient clinic that operates every 
Wednesday and - according to the hospital records - serves an average of 75 patients per week and 300 
patients per month.  This clinic is complemented by a daily walk-in mental health clinic that serves an 
average of 20 patients daily. The inpatient service is a ward (see Figure 5 above) with a 70-bed capacity 
which admits severely ill patients. According to hospital records, more than 70% of the patients treated 
in this facility have psychotic disorders.  At MTRH the patients with mental illness are managed by a 
multidisciplinary mental health team (psychiatrists, mental health clinical officers, nurses, psychologists 
and occupational therapist). A patient presenting with a medical condition in addition to the mental illness 
is either managed by the psychiatrist or referred to a medical outpatient clinic which runs on a different 
day of the week.  
3.3 Study Population 
The study targeted all adult patients who at the time of recruitment, were on management for 
schizophrenia, schizoaffective disorder or bipolar mood disorder. The control group targeted adults who 
had never been treated for mental illness. 
3.4: Inclusion and Exclusion Criteria  
Patients were eligible for inclusion if they were (i) aged 18 years or older; (ii) had been on follow up in the 
MTRH outpatients’ service for a minimum of 6 months   and   (iii) the diagnosis (as made by a psychiatrist) 
was either schizophrenia, schizoaffective disorder or bipolar mood disorder. Diagnoses were obtained 
from patient records after an assessment by the primary psychiatrist and were then confirmed using the 
MINI.  Patients receiving medical treatment for acute alcohol or drug intoxication were excluded. Pregnant 
women were  excluded due to evidence that substantial CVD-related changes may occur in pregnancy 
including insulin resistance, raised serum glucose and changes in lipid metabolism  (Lain and Kristine Y, 
Catalano, Patrick 2007). Those who did not have capacity to consent on the University of California, San 
Diego Brief Assessment of Capacity to Consent (UBACC) were also excluded from participation. The 
UBACC (see Appendix 1c) is a 10-item scale with good internal consistency, interrater reliability and 
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concurrent validity  (Jeste et al. 2007). It also has a relatively brief administration time and simple 
language, in order to optimize ease of administration in study settings such as this.  For each of the 
responses on the 10 UBACC items a patient is  given a score of 0 (implying no understanding),1 (partial 
understanding) and 2 (full understanding) of the concept, a total  score less than 14.5 indicates cognitive 
inability to consent (Megan M. Campbell et al. 2017). 
Controls were eligible for inclusion if they were adults aged 18 years and older and had provided informed 
consent to participate. Individuals known to have a mental illness and those taking any psychiatric 
medication at the time of recruitment (as determined by self-report or medical record review) were 
excluded. Individuals receiving medical treatment for acute alcohol or drug intoxication, as well as 
pregnant women, were also excluded.  
3.5: Participant recruitment 
 Being a nested study, all participants who were recruited into this cardiovascular study had already 
completed the NeuroGAP study interview.  These were patients who were attending booked outpatient 
consultant clinic at MTRH.  Routinely, and in order to ensure timely services during the clinic day, files of 
all booked patients are retrieved on Tuesdays (i.e. the day before the outpatient clinic) and transported 
from the records library to the outpatient clinic reception desk. Research assistants were thus able to 
review these retrieved files on Wednesday mornings. Files with a documented diagnosis of any of the 
psychotic disorders of interests were tagged with a study sticker. On the clinic day, all participants with a 
marked file were then identified from the waiting bay, given more information on both studies and 
requested to participate.  Patients had the option of participating only on the NeuroGAP study or both 
studies.  Those who agreed to participate were taken to a private room for clarifications on the study 
procedures and consenting.  Clarification was made on the two studies.  All participants were requested 
to provide written informed consent (see Appendix 1). 
Like participants, controls who were recruited also participated in the NeuroGAP study. Recruitment of 
control participants took place every day of the week apart from Wednesdays, which was dedicated to 
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recruitment of patients. Posters were displayed on the hospital notice boards informing members of the 
public of the study; and asking those who were interested to contact the research assistant on the 
telephone number provided (see Appendix 2). In addition, controls were also recruited from hospital 
waiting bays. Clarification was made on the two studies, and participants had the option of participating 
only on the NeuroGAP study or both studies.  Those who expressed interest in participating were given 
more details about the study; and upon agreeing to participate, written informed consent was provided.  
 3.6: Sample size and sampling procedure 
For this study, convenience sampling was undertaken. The target sample size  was 286 participants in 
the study group and 286 participants in the control group, based on prior sample size calculations i.e.: N 
= 10 k/p , where k is the number of covariates and p is the proportion of cases in the population (Peduzzi 
et al. 1996). Using an estimated prevalence of MetS in the general population in Kenya  of approximately 
35% (Kaduka et al. 2012) and 10 covariates in the data collection tool: N = 10×10/0.35  = 285.7. This 
sample size is comparable to one prior study conducted in South Africa by Saloojee and colleagues, 
which employed a design similar to this  (Saloojee, Burns, and Motala 2016a). In order to allow for missing 
data and quality control procedures, we aimed to recruit 300 patients and 300 controls.  
3.7: Data Collection tools  
 Demographic data were obtained on age, sex, level of education, employment status, smoking, marital 
status, other physical medication, dietary habits and exercise. Items assessing diet and exercise were  
adapted from the WHO Steps Survey, a tool used to measure risk factors for non-communicable disease 
(“WHO , The STEPS Instrument and Support Materials” ). The Alcohol use Identification Test ( AUDIT – 
C)  was used to screen for  harmful alcohol use  (Bradley et al. 2007b).  The AUDIT-C comprises three 
questions, each scored on a 5-points Likert scale (minimum score = 0; maximum score = 4), with the total 
score ranging from 0 to 12. A score of  4 in men and 3 in women is optimal for identifying an alcohol use 
disorder (Bush et al. 1998), (Bradley et al. 2007a) 
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Exposure to lifetime  potentially traumatic events was  assessed using the  Live Events Checklist  ( LEC)  
for DSM 5, a tool  with acceptable psychometric properties   (Gray et al. 2004) and has been used in a 
African setting (Mhlongo et al. 2018). A history of childhood trauma was assessed using the Childhood 
Trauma Questionnaire-Short Form (CTQ-SF) a reliable and valid self-report measure for assessing 
exposure to childhood abuse and/or neglect in patients with schizophrenia (Kim et al. 2013). The CTQ is 
a 28-item retrospective inventory comprising five subscales - three assessing abuse (emotional, physical, 
and sexual) and two assessing neglect (emotional and physical). Each subscale score ranges from 5 (no 
history of abuse or neglect) to 25 (very extreme history of abuse and neglect), (Bernstein et al. 2003),  
(Devi et al. 2019).   
For patient only information on primary psychiatric diagnosis, current psychotropic medication and any 
other medication was obtained from patient self-report and from hospital records. In both groups, the 
WHO Composite International Diagnostic Interview (CIDI) screener for chronic diseases was used to 
establish presence of other chronic physical disorders  (“About the WHO WMH-CIDI – WHO WMH-CIDI”) 
(https://www.hcp.med.harvard.edu/wmhcidi/about-the-who-wmh-cidi/) 
Psychosocial distress in the control group only was assessed using the Kessler-10 (K10), a tool validated 
for use in individuals with no known mental illness.   Each item is scored on a Likert scale ranging from 
1 (none of the time) to 5 (all of the time). Total scores range from 10 to 50; those scoring under 20 are 
likely to be well; those scoring 20-24 are likely to have a mild distress; those scoring 25-29 are likely to 
have moderate distress; and those scoring 30 and over are likely to have  severe distress (Gavin Andrews 
and Tim Slade 2001) 
  In addition to the interviews, measurements for weight, height, abdominal circumference and blood 
pressure were taken; and blood was drawn for blood sugar and a non-fasting lipid profile.  A non-fasting 
assessment was undertaken due to anticipated difficulties in ensuring or ascertaining a fasted state 
among mentally ill participants. There is evidence to suggest that in assessing for cardiovascular risk , 
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non- fasting lipid profile is adequate, time saving, and patient-friendly  and a fasting test is then 
recommended only for those with triglycerides > 5 mmol/L (Mora 2016;  Nordestgaard 2017) 
 For clarity, it is important to highlight that though some of the tools we used were also used on the 
NeuroGAP study whose protocol has been published  (Stevenson et al. 2019), the social demographic 
questionnaire was modified. In addition we had extra tools like the CTQ, and we collected blood while 
this was not done in NeuroGAP. CVD study the tools were printed into hard copy for ease of data access 
and retrieval  for analysis, while the Neuro-Gap study data collected into an IPad and submitted to Broad 
Institute, and  needed a specific approval mechanism to analyse the data. 
Table 1 below gives a summary of the data collection tools: 
Table 1: Summary of data collection tools used in CVD and NGAP study 






1.  Social Demographic Questionnaire    modified 
2.   AUDIT-C   × 
3.  Kessler 10 ×   
4.  Childhood Trauma Questionnaire-Short Form   × 
5.  Live Events Checklist      
6.  Current psychotropic medication  ×  
7.  CIDI  screener for chronic diseases    
8.  Anthropometric measurements and blood 
pressure  
   modified 
9.  Blood for lipid Profile and Glucose levels.   × 
 
  Administered 
× Not administered. 
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3.8: Study   procedures 
Data were collected by three trained NeuroGAP research assistants - a graduate psychologist, a graduate 
nurse and a clinical officer (equivalent to a physician assistant in other settings), all who were not primary 
care providers for these patients.  They were trained on research ethics and the protection of human 
subjects.   
The research assistants explained in detail the purpose of the study and the procedures to be undertaken. 
They then confirmed that the individual was ready to participate.  For the controls, the consent form was 
given to participants to review and sign. For the patients, the UBACC was administered in order to 
ascertain capacity to consent. The UBACC was administered a maximum of 4 times with more 
explanations for questions where one scored 0. If the participant scored above 14.5 the participant was 
deemed fit to consent. If the scores remained below 14.5 on the 4th attempt, the patient was not 
interviewed. The consent form was signed in duplicate, allowing the participant to retain one copy, while 
the other copy was attached to the data collection tool and was kept by the research assistant. The 
participant was also assigned a unique study identifying number, which was included on the signed 
consent and the study questionnaire. 
Following informed consenting, the research assistants then administered the complete study interview 
battery (as described above). Upon completion of the interview, two readings of blood pressure were 
taken using an Omron compact upper arm blood pressure monitor.   To draw blood,   a tourniquet was 
placed around the arm, a vein was identified, the injection site was sterilized using alcohol swab and 10 
millimetres of blood was drawn into a 10 ml plain vacutainer. The vacutainer was labelled using the 
participant’s study ID. 
The participant was then asked to remove footwear to enable accurate measurement of weight and 
height. The weight of the participant was measured with a 762 dial bathroom floor scale and recorded in 
kilograms. The height (in centimetres) was measured with a mechanical roll-up measuring tape with feet 
together, heels against the measuring wall and knees straight. Finally, the waist circumference was 
measured on the exposed abdomen with the participant standing and both arms lifted.  It was measured 
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in centimetres at the midpoint between the iliac crests and the lower rib laterally and passing over the 
umbilicus anteriorly. The participant was then given a chance to ask any questions and once these were 
addressed the participant was thanked, and the session came to an end. 
Research assistants delivered blood samples to the Academic Model Providing Access to Healthcare 
(AMPATH) reference laboratory for analysis immediately after completion of the interview. They also 
followed up with the laboratory, collected the results, and attached them to each participant’s 
questionnaire. The laboratory results were then reviewed by the study psychiatrist. Any participant with 
elevated blood pressure, elevated glucose, or dyslipidaemia was contacted via mobile telephone by the 
psychiatrist and the results discussed.  In instances of elevated blood pressure or elevated glucose, for 
which intervention was urgently needed, the psychiatrist initiated treatment with medication before 
referring the patient to the medical outpatient clinic of MTRH. In cases in which measurements were 




3.9: Data management and analysis  
Data were entered into REDcap, (Research Electronic Data Capture) a secure, web-based software 
platform designed to support data capture for research studies and also provides  an intuitive interface 
for validated data capture,  audit trails for tracking data manipulation, and automated export procedures 
for seamless data downloads to common statistical packages  (P. A. Harris et al. 2009).  Once in REDcap, 
the data were then cleaned and exported into Stata version 15 for analysis (Statistical Software: Release 
14. College Station, TX: StataCorp LP).  
The Wilcoxon sum rank tests a non- parametric   test was used to assess whether the distribution of age 
differed between patients and controls; while Pearson chi squared tests were used to assess associations 
between categorical variables.   Fisher’s exact tests was only used in cases where the expected cell 
counts were small.   
The frequencies of various cardiovascular risk factors were calculated (i.e. smoking, alcohol intake, 
psychosocial distress, trauma, poor diet and lack of exercise, diabetes, hypertension, dyslipidaemia and 
metabolic syndrome); and Person’s chi squared tests was used to determine the differences in these 
frequencies between patients with psychosis versus controls. T-tests were undertaken to determine the 
differences in the means of lipids, blood sugar and blood pressure between the patients and the controls. 
Table 2 below shows the cut-off parameters that were used for analyses of outcome variables.  
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Table 2:  Cut off Parameters for metabolic disorders 
   Disorder Cut-off parameter 
Diabetes  
(WHO 2006). 
Random blood sugar ≥11.1 mmol/l  or treatment for diabetes 
Hypertension (B. 
Williams et al. 2018) 
 
On treatment for hypertension with a documented diagnosis, or 
newly-diagnosed hypertension, i.e. 3 or more readings of systolic 
blood pressure ≥140 mmHg, or diastolic blood pressure ≥90 mmHg 
Dyslipidaemia 
according to 
†NCEP ATP III 
Cholesterol 
guidelines (Expert 
Panel on Detection, 
Evaluation, and 
Treatment of High 
Blood Cholesterol in 
Adults 2001) 
Total cholesterol > 200 mg/dl or > 5.17mmol/l) and/or increased LDL 
cholesterol > 100 mg/dl or >2.59 mmol/l and/or decreased HDL 
cholesterol < 40mg/dl or <1 mmol/l) 
 
Obesity Overweight: BMI >25-30 
Obese: BMI >30-40 
Morbidly obese: BMI>40. 
Central obesity =  waist circumference > 88cm in women and 
> 102cm in men. 
Metabolic 
syndrome 
According to the 
Adult Treatment 
Panel III (Grundy et 
al. 2004) 
 
Abdominal obesity > 102 cm in men, > 88cm in women. 
TGS  ≥150mg/dl 
HDL < 40mg/dl or <1mmol/l in men, < 50mg/dl or <1.3mmol/l in 
women. 
BP ≥130/≥85mmHg or current treatment for hypertension 
Fasting glucose- ≥110mg/dl or current treatment for diabetes. 





 In computing FRS   we used the age, sex, total cholesterol, high density lipoprotein cholesterol, smoking 
habits, DM and systolic blood pressure. The scores were then categorized as low (<10), intermediate 
(10-19) or high >20. T-tests were used to determine the differences in the means of the Framingham 10-
year estimated risk for cardiovascular disorders between the patients and the controls. Logistic 
regression modelling was then undertaken to explore the predictors of FRS statistically higher among 
patients than controls. 
In analyses of trauma and cardiovascular risk, the prevalence of a number traumatic experiences was 
calculated. Pearson Chi-squared tests were carried out to establish differences in the prevalence of 
trauma exposure between patients and controls.   
Prescription patterns were explored by calculating the proportions of participants being treated with 
specific medications of interest. Chi squared tests (or and Fishers exact tests where applicable) were 
carried out to determine the association between olanzapine use and a number cardiovascular risk 
factors. 
The treatment gap was assessed by calculating the number of participants with untreated hypertension, 
diabetes mellitus and dyslipidaemia, as a proportion of the total number of individuals with any of these 
conditions in both groups (patients and controls).  The proportion of those who had never been treated 




3.10: Ethical Considerations 
Ethics review and approval was obtained from the MTRH/Moi University School of Medicine Institutional 
Research and Ethics Committee (IREC/2017/90) and from the Human Research Ethics Committee of the 
University of Cape Town (HREC/286/2017).  This was renewed annually during the study period. 
Permission to carry out the proposed procedures was also obtained from the management of MTRH. 
Informed Consent was provided by all participants (see Appendix 1). As previously discussed, ability to 
consent was assessed using the UBACC. Participation was entirely voluntary and participants were free 
to withdraw at any point of the study without forfeiting any benefits of receiving required care. 
Compensation of 10 US dollars for transport expenditure and time inconvenience (a total of about 2.5 
hours was required to complete both interviews) was offered by NeuroGAP Study. Confidentiality was 
maintained by using assigned study ID numbers and entering only de-identified data into REDCap. The 
study posed minimal risk of pain during blood sample collection; as well as psychological distress due to 
painful memories of traumatic life events being potentially elicited. All participants with abnormal results 
were reviewed by the study psychiatrist, initiated on medication where urgently needed, and referred to 
the relevant medical outpatient clinic for physician review. Participants who developed psychological 
distress secondary to the interview process were also assessed by the psychiatrist, managed and 
referred appropriately. All study documents were safely stored in a lockable cabinet; and soft copies of 
the data was stored in a password-protected electronic database with controlled access.  All potentially 
identifiable data were appropriately de-identified before analysis.  
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CHAPTER 4: RESULTS 
4.0: Introduction 
Data were collected between July 2018 and March 2019. A total of 1,700 participants were treated for 
psychosis at the MTRH psychiatry outpatient clinic during the study period. During the same period, the 
hospital served about 200 000 patients for other medical conditions and had several visitors.  After 8 
months of data collection, a total of 600 participants consented and were recruited into the study - 300 
patients with psychosis and 300 controls.  Three patients were excluded from analyses as two had 
epilepsy-induced psychosis and one had substance-induced psychosis.  
This chapter will give a detailed report of relevant study findings. First, sociodemographic characteristics 
of the study participants will be described.  Second, findings of the prevalence and correlates of 
conventional cardiovascular lifestyle risk factors and metabolic disorders will be presented. Third, the 
results pertaining to the three non-conventional cardiovascular risk factors (i.e. exposure to traumatic 
events, psychological distress and comorbid medical conditions) will be reported.  Fourth, the estimated 
10-year risk of developing cardiovascular disorders in this study sample will be described. Fifth, 
prescription patterns and associated cardiovascular risk will be reported. Finally the treatment gap for 
CVD risk factors in patients with mental illness will be presented.  
 4.1:  Conventional non modifiable CVD risk factors and other demographic characteristics.   
Participants in this study sample were relatively young, with a mean age of 33 years among the patients 
and 35 years among the controls. Patients were more likely to be unmarried (47% vs 33%, p<0.001).    
While most participants had formal education (77% patients and 82% controls), patients were less likely 
to have tertiary education compared to controls (26% vs 56%, p<0.001), with most having only primary 
school education. Further patients were more likely to be   unemployed (48% vs 24.7% of controls) and 
controls were more likely to be in formal employment (48% vs 14.5% of patients), and these differences 




Table 3: Socio-demographic characteristics of the study participants 
Variable Total Patients Control p-value 






Male 265 (44.4) 139 (46.8) 126 (42.0) 
 






Married 269 (45.1) 103 (34.7) 166 (55.3) 
 
Never married 239 (40) 139 (46.8) 100 (33.3) 
 
Widow/separated/divorced 89 (14.9) 55 (18.5) 34 (11.3)   
Highest level of Education 
 
 <0.0011 
None 35 (5.9) 23 (7.7) 12 (4) 
 
Primary 147 (24.6) 106 (35.7) 41 (13.7) 
 
Secondary 172 (28.8) 92 (31) 80 (26.7) 
 






Unemployed 217 (36.3) 143 (48.1) 74 (24.7) 
 
Formal 187 (31.3) 43 (14.5) 144 (48) 
 
Self 193 (32.3) 11(17.4) 82 (27.3)   
1 Chi square test    2 Fishers’ exact test 3 Wilcoxon rank sum test   
4.2. Lifestyle factors 
Compared to controls, patients were more likely to have ever smoked (13.8% patients vs 7 % controls, 
p=0.006) or to be current smokers (9.8% vs 3.3%, p=0.001. Most patients with psychosis had consumed 
inadequate fruits and vegetables (97%); had inadequate physical activity (78%) and had   significant 
78 
 
sedentary behaviour (48%). However, significant differences in physical activity and dietary habits were 
not demonstrated between patients and controls), Table 4. 
Table 4: Lifestyle risk factors 
  Total Cases Control p-value 
Variable Freq %) Freq (%) Freq (%)   
Current smoker   
 
0.0011 
No 558 (93.5) 268 (90.2) 290 (96.7) 
 






No 535 (89.6) 256 (86.2) 279 (93) 
 






No 579 (97) 289 (97.3) 290 (96.7) 
 






No 11 (1.8) 7 (2.4) 4 (1.3) 
 
Yes 586 (98.2) 290 (97.6) 296 (98.7)   
Inadequate  exercise   
 
0.0841 
No 114 (19.1) 65 (21.9) 49 (16.3) 
 
Yes 483 (80.9) 232 (78.1) 251 (83.7)   
Time spent sitting    
 
0.9061 
<  3 hours  in a day 311 (52.1) 154 (51.9) 157 (52.3) 
 
More than 3 hours in a day 286 (47.9) 143 (48.1) 143 (47.7)   
1 Chi square test    2 Fishers’ exact test 
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 4.3: Metabolic disorders 
Metabolic disorders were common among patients, with abnormal LDL being the most prevalent (65%) 
followed by elevated triglycerides (47%) and abnormal BMI (45%), Figure 6. 
 
Figure 6: Prevalence of metabolic disorders among patients  
Met Syndrome - Metabolic Syndrome       
BMI -Abnormal Body mass index              
LDL - Low High density Lipoproteins    
HDL - High density Lipoproteins  
TGS - Triglycerides                                     
Cho l- Cholesterol 
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As shown in Table 5 below, there were significant differences in the means of a number of metabolic risk 
parameters.   Compared to controls, patients  had  higher mean  random blood sugar (5.23  vs 4.79,  
p=0.003),  BMI ( 5.23 vs 4.79 p=0.001), TGs ( 1.98 vs 1.56,p<0.001)  and  waist circumference ( 89.23 
vs 86.39  p=0.009) ), but were found to have  lower HDL  ( 1.22 vs 1.32, p<0.001). 
Table 5: A comparison of the means of metabolic parameters   
Variable 
Total Patient Control 
t-test  
p-value 
Mean (SD) Mean (SD) Mean (SD)   
Systolic BP 119.19 (14.98) 119.6 (13.76) 118.78 (16.1) 0.504 
Diastolic BP 76.04 (11.17) 76.09 (10.11) 76 (12.15) 0.916 
RBS1 5.01 (1.85) 5.23 (2) 4.79 (1.67) 0.003 
BMI2 24.82 (6.13) 25.63 (7.15) 24.03 (4.81) 0.001 
HDL3 1.27 (0.48) 1.22 (0.49) 1.32 (0.46) 0.008 
LDL4 2.98 (0.92) 3.01 (0.98) 2.95 (0.85) 0.405 
Chol5 4.46 (1.79) 4.59 (2.37) 4.34 (0.89) 0.089 
TG6 1.77 (1.29) 1.98 (1.41) 1.56 (1.12) 
              
<0.001 
Waist  
circum7 87.81 (13.31) 89.23 (13.43) 86.39 (13.06) 0.009 
  




Compared to controls, patients were more likely to have elevated total cholesterol (23.6 vs 14.7, 
p=0.006), higher triglycerides (47.1 vs 30.3, p<0.001), higher rates of MetS (28.6 vs 19, p=0.007) and 
obesity (45.1 vs 35.6, p=0.037), Table 6.  
Table 6: Comparing prevalence of cardio metabolic disorders of patients and controls 
  Patients Controls P-value 
Variable Freq (Col%) Freq (Col%)   
Diabetes    0.798
2 
No 287 (96.6) 291 (97)  
Yes 10 (3.4) 9 (3)   
Hypertension    0.412
1 
No 243 (81.8) 253 (84.3)  
Yes 54 (18.2) 47 (15.7)   
Metabolic Syndrome    0.007
1 
No MetS 262 (71.4) 243 (81.0)  















































































After adjusting for other variables in a logistic regression model, factors associated with increased odds 
of having MetS were psychosis (OR=2.09, p=0.006), and age (OR=1.05, p< 0.001). Factors that were 
associated with decreased odds of MetS were female Sex (OR 0.41 p<0.001), and being 
widowed/separated/divorced (OR 0.38, P=013), Table 7. 








Psychosis 2.09 0.006 1.23 3.55 
Age in yrs 1.05 <0.001 1.02 1.07 
Male 1.00       
Female 0.41 <0.001 0.25 0.67 
Never married 0.52 0.031 0.28 0.94 
Widow/separated/divorced 0.38 0.013 0.17 0.81 
Primary education 0.48 0.112 0.19 1.19 
Secondary education 0.43 0.071 0.17 1.07 
Tertiary education 0.60 0.270 0.24 1.48 
Currently smoking 1.18 0.701 0.51 2.76 
Harmful alcohol 0.94 0.925 0.24 3.72 
Physical exercise 0.80 0.442 0.45 1.42 




After adjusting for other variables in a regression model, factors associated with increased odds of having   
elevated BMI   were psychosis (OR 2.30, p<0.001), age (OR1.05, p<0.001) and female Sex (OR 2.67, 
p<0.001) Table 8. Having never been married (or being windowed/ separated/ divorced) was associated 
with decreased odd of having an abnormal BMI (OR 0.44, p= 0.003). 
Table 8:   Factors associated with abnormal BMI 
Variable Odds Ratio P-value [95% Conf. Interval 
Psychosis 2.30 <0.001 1.55 3.43 
Age in years 1.05 <0.001 1.02 1.07 
Female 2.67 <0.001 1.82 3.92 
Never married 0.52 0.005 0.33 0.82 
Widow/separated/divorced 0.44 0.003 0.26 0.75 
Primary 0.86 0.703 0.39 1.90 
Secondary 0.91 0.807 0.41 2.00 
Tertiary 1.43 0.374 0.65 3.14 
Currently smoking 0.94 0.871 0.43 2.03 
Harmful alcohol use 1.48 0.457 0.53 4.11 
Poor diet 0.86 0.830 0.21 3.49 
Inadequate physical exercise 0.90 0.639 0.57 1.41 
Spent >3 hours  sitting  1.05 0.770 0.74 1.51 
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4.4.   Trauma and cardiovascular risk  
4.4.1.:  Lifetime Exposure to potentially traumatic events  
Among all participants, physical assault was the most commonly reported potentially traumatic live event 
(30%), followed by transport accidents (28.3%) and life threatening illness or injury (28.1%), Table 9.  
Patients reported significantly lower prevalence of a number of traumatic events compared to controls, 
including natural disasters (p=0.009), fire explosion (p=0.005), transport accidents (p<0.001), accident at 
work or home (p=0.001), life threatening injury (p=0.008), exposure to war (p=0.022), severe human 
suffering (p=0.007), sudden violent death 0.029) and other unspecified stressors (p=0.002). 
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Table 9 : Exposure to potentially traumatic life events 
Event 
Total  Patients Control 
P-
value Freq (%) Freq (%) Freq (%) 
Natural disaster 71 (11.9) 25 (8.4) 46 (15.3) 0.009 
Fire or explosion 120 (20.1) 46 (15.5) 74 (24.7) 0.005 
Transportation accident 169 (28.3) 61 (20.5) 108 (36) <0.001 
Serious accident at work, home or 
recreation 63 (10.6) 19 (6.4) 44 (14.7) 0.001 
Exposure to toxic substance 22 (3.7) 11 (3.7) 11 (3.7) 0.981 
Physical assault 182 (30.5) 86 (29) 96 (32) 0.419 
Assault with a weapon 91 (15.2) 39 (13.1) 52 (17.3) 0.153 
Sexual assault 41 (6.9) 21 (7.1) 20 (6.7) 0.845 
Other sexual experience 37 (6.2) 15 (5.1) 22 (7.3) 0.247 
Combat or exposure to war 33 (5.5) 10 (3.4) 23 (7.7) 0.022 
Captivity 9 (1.5) 4 (1.3) 5 (1.7) 0.748 
Life threatening illness or injury 168 (28.1) 69 (23.2) 99 (33) 0.008 
Severe human suffering 97 (16.2) 36 (12.1) 61 (20.3) 0.007 
Sudden violent death 74 (12.4) 28 (9.4) 46 (15.3) 0.029 
Sudden accidental death 70 (11.7) 29 (9.8) 41 (13.7) 0.138 
Serious injury, harm or death you 
caused  10 (1.7) 4 (1.3) 6 (2.0) 0.534 




As shown in Figure 7 below, 73% of patients and 80% of controls reported having experienced at least 
one traumatic event in their lifetimes. 
 
 

































Among patients, there was a significant association between exposure to potentially traumatic life events 
and smoking Table 10 
Table 10: Lifetime traumatic life events and other cardiovascular risk factors- patients 
Variable 
Traumatic life events 
controls   
P-
value 
None One More than One 
Freq (Col %) 
Freq (Col 
%) 
Freq (Col %) 
MS 
   
0.875 
No MS 63(80.8) 53(779) 122(80.8)  
MS 15(19.2) 15( 22.1) 29(19.2)  
Diabetes    0.954 
No 75(96.2) 66(97.1) 146(96.7)  
Yes 2(3.8) 2(2.9) 5(3.3)  
Hypertension    0.743 
No 62(79.5) 55(80.9) 128(83.4)  
Yes 16(20.5) 13(19.1) 25(16.6)  
HDL    0.106 
Normal 57(73.1) 44(64.7) 89(58.9)  
Elevated 21(26.1) 24(35.3) 62(41.1)  
LDL    0.052 
Normal 19(24.4) 29(42.6) 56(37.1)  
Elevated 59(75.6) 39(57.4) 95(62.9)  
Cholesterol    0.449 
Normal 61(78.2) 55(80.9) 111(73.5)  
Elevated 17(21.8) 13( 19.1) 40(26.5)  
Current smoker    0.035 
No 76(97.4) 61(89.7) 131(86.8)  
Yes 2(2.6) 7 (10.3) 20 (13.2)  
Harmful alcohol    0.661 
No 77(98.7) 66(97.1) 146(96.7)  
Yes 1(1.3) 2(2.9) 5(3.3)   
88 
 
There was no significant association between exposure to potentially traumatic life events and any of the 
cardiovascular risk factors of interest was demonstrated among controls, Table 11 
Table 11 Lifetime traumatic life events and other cardiovascular risk factors- controls 
Variable 
Traumatic life events    
P-
value 
None One More than One 
Freq (Col %) 
Freq (Col 
%) 
Freq (Col %) 
MS 
   
0.391 
No MS 49(81,7) 55(90.2) 155(86.6)  
MS 11(18.3 6(9,8) 24(13.4)  
Diabetes    0.968 
No 58 (96.7) 59(96.7) 174(97.2)  
Yes 2(3.3) 2( 3.3) 5( 2.8)  
Hypertension    0.556 
No 49(81.7) 54(88.5) 150(83.8)  
Yes 11(8.3 7 (11.5) 29( 16.2)  
HDL    0.990 
Normal 43(71.7) 43(70.5) 127(70.9)  
Elevated 17(28.3 18(29.5) 52(29.1)  
LDL    0.343 
Normal 20(33.3) 17(27.9) 68(38.0)  
Elevated 40(66.7) 44( 72.1) 111(62.0)  
Cholesterol    0.895 
Normal 51 ( 85.0) 51(83.6) 154(86.0  
Elevated 9 (15.0) 10(16.4) 25(14)  
     
Current smoker    0.712 
No 57(95.) 59( 96.7) 171(95.5)  
Yes 3( 5.0) 2(3.3) 8(4.5)  
Harmful alcohol    0.712 
No 60 (100 59 (96.7 171 (95.5)  




4.4.2: Childhood trauma 
Severe physical abuse was reported among 9% of controls and 8.8% of patients.  Severe emotional 
abuse was reported among 5.7% of patients and 4.3% of controls, while severe sexual abuse was 
reported in 4.7% of patients and 6.3% of controls. Almost half of the participants (49.2% of controls and 
56.1) of patients endorsed items on the CTQ pertaining to childhood neglect; about half reporting physical 
neglect. No significant differences in overall reported childhood trauma was found between patients and 
controls Table 12. 





  Freq (Col %) Freq (Col %) 
Childhood trauma    
Emotional abuse   0.295
2 
None 214 (72.3) 208 (69.6)  
Low 47 (15.9) 64 (21.4)  
Moderate 18 (6.1) 14 (4.7)  
Severe 17 (5.7) 13 (4.3)   
Physical abuse   0.979
2 
None 206 (69.6) 212 (70.7)  
Low 42 (14.2) 39 (13)  
Moderate 22 (7.4) 22 (7.3)  
Severe 26 (8.8) 27 (9)   
Sexual abuse   0.055
2 
None 243 (82.1) 219 (73)  
Low 17 (5.7) 31 (10.3)  
Moderate 22 (7.4) 31 (10.3)  
Severe 14 (4.7) 19 (6.3)   
Emotional neglect   0.234
2 
None 130 (43.9) 155 (51.8)  
Low 122 (41.2) 101 (33.8)  
Moderate 34 (11.5) 32 (10.7)  
Severe 10 (3.4) 11 (3.7)   
Physical neglect   0.683
2 
None 149 (50.2) 153 (51.2)  
Low 50 (16.8) 57 (19.1)  
Moderate 56 (18.9) 46 (15.4)  





 On the CTQ, patients endorsed wearing dirty clothes significantly more than controls ( 51.5% vs 39.7% 
, p=0.004) and endorsed 3 questions on sexual abuse  significantly less than controls;  sexual touch (10.4  
patients vs 18.0 controls ),  being forced to do or watch sexual things (7.7 patients  vs13% controls , 
p=0.035),  and being molested (7.1  patients vs12.3% controls , p=0.031) Table 13.  
Table 13: Childhood trauma exposure (itemized by the CTQ) 
When I was growing up  Total Patients Controls 
p-
value 
  Freq (%) Freq (%) Freq (%)   
Physical Neglect     
1. I didn’t have enough to eat. 244 (40.9) 117 (39.4) 127 (42.3) 0.465 
2. I knew there was someone to  
take care of me and protect me 580 (97.2) 288 (97) 292 (97.3) 0.789 
4. My parents were too drunk or high to take care 
of me. 133 (22.3) 69 (23.2) 64 (21.4) 0.592 
6. I had to wear dirty clothes. 272 (45.6) 153 (51.5) 119 (39.7) 0.004 
26. There was someone to take me to the doctor 
if I needed it. 573 (96) 286 (96.3) 287 (95.7) 0.695 
Emotional Neglect     
5. There was someone in my family who helped 
me feel important or special. 573 (96) 286 (96.3) 287 (95.7) 0.695 
7. I felt loved. 569 (95.3) 284 (95.6) 285 (95) 0.719 
13. People in my family looked out for each other. 549 (92.1) 277 (93.3) 272 (91) 0.298 
19. People in my family felt close to each other. 554 (93) 278 (93.9) 276 (92.0) 0.360 
28. My family was a source of strength and 
support. 588 (98.5) 293 (98.7) 295 (98.3) 0.748 
Emotional abuse     
3. People in my family called me things like 
“stupid”, “lazy”, or “ugly”. 210 (35.2) 108 (36.4) 102 (34) 0.545 
8. I thought that my parents wished I had never 
been born. 88 (14.8) 45 (15.2) 43 (14.4) 0.791 
14. People in my family said hurtful or insulting 
things to me. 179 (30) 87 (29.4) 92 (30.7) 0.734 
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18. I felt that someone in my family hated me. 187 (31.3) 96 (32.3) 91 (30.3) 0.600 
25. I believe that I was emotionally abused. 162 (27.1) 88 (29.6) 74 (24.7) 0.173 
Physical abuse     
9. I got hit so hard by someone in my family that I 
had to see a doctor or go to the hospital. 95 (15.9) 50 (16.8) 45 (15) 0.540 
11. People in my family hit me so hard that it left 
bruises or marks. 103 (17.3) 52 (17.6) 51 (17) 0.855 
12. I was punished with a belt, a board, a cord, or 
some hard object. 216 (36.2) 108 (36.4) 108 (36) 0.926 
15. I believe that I was physically abused. 137 (22.9) 72 (24.2) 65 (21.7) 0.454 
17. I got hit or beaten so badly that it was noticed 
by someone like a teacher, neighbour, or doctor. 87 (14.6) 38 (12.8) 49 (16.3) 0.220 
Sexual abuse     
20. Someone tried to touch me in a sexual 
way, or tried to make me touch them. 85 (14.2) 31 (10.4) 54 (18.0) 0.008 
21. Someone threatened to hurt me or tell lies 
about me unless I did something sexual with 
them. 42 (7) 23 (7.7) 19 (6.3) 0.500 
23. Someone tried to make me do sexual 
things or make me watch sexual things. 62 (10.4) 23 (7.7) 39 (13) 0.035 
24. Someone molested me. 58 (9.7) 21 (7.1) 37 (12.3) 0.031 
27. I believe that I was sexually abused 49 (8.2) 24 (8.1) 25 (8.3) 0.911 
Minimization     
10. There was nothing I wanted to change about 
my family. 338 (56.7) 163 (55.1) 175 (58.3) 0.421 
16. I had the perfect childhood. 543 (91.3) 272 (92.2) 271 (90.3) 0.419 





No significant association between childhood trauma and any of the other cardiovascular risk factors of 
interest was found in the study sample, Table 14. 





Freq (Col %) Freq (Col %) 
MS   0.533 
No MS 63(77.8) 175( 81.0)  
MS 18(22.8) 41(19.0)  
Diabetes   0.599 
No 79(97.5) 208(96.3)  
Yes 2(2.5) 8(307)  
Hypertension   0.110 
No 71(87.7) 172(79.6)  
Yes 10(12.3) 44(20.4)  
HDL   0.160 
Normal 57(70.4) 133(61.6)  
Elevated 24(29.6) 83(38.4)  
LDL   0.710 
Normal 27(33.3) 77(35.6)  
Elevated 54 (66.7) 139 (64.4)  
Cholesterol   0.780 
Normal 61(75.3) 166(76.90  
Elevated 20(24.7) 50(23.1)  
Current smoker   0.690 
No 74(91.4) 194(89.8)  
Yes 7(8.6) 22(10.2)  
Harmful alcohol   0.884 
No 79(97.5) 210( 97.2)  




No significant association between childhood trauma and any of the other cardiovascular risk factors of 
interest was found in the study sample, Table 15. 





Freq (Col %) Freq (Col %) 
MS   0.646 
No MS 67(84.8) 192(86.9)  
MS 12(15.2) 29(13.1)  
Diabetes   0.776 
No 77(97.5) 214(96.8)  
Yes 2(2.5 7(3.2)  
Hypertension   0.822 
No 66(83.5) 187(84.6)  
Yes 13(16.5) 63(28.5)  
HDL   0.753 
Normal 55(69.6) 158(71.5)  
Elevated 20(30.4) 63(28.5)  
LDL   0.923 
Normal 28(35.4) 77(34.8)  
Elevated 51(64.6) 144(65.2)  
Cholesterol   0.878 
Normal 67(84.8) 189(85.5)  
Elevated 12(15.2) 32(14.5)  
Current smoker   0.231 
No 78(98.7) 212(95.9)  
Yes 1(1.3) 9(4.1)  
Harmful alcohol   0.318 
No 75(94.9) 215(97.3)  




4.5: Psychological distress among controls  
As shown on Figure 8 below, 11%   of the controls had mild distress, 5.7% had moderate distress and 
3.3 % had severe distress.  
 
Figure 8 .Psychological distress among controls as measured using K10 Scores 
 Well: under 20. Mild:  20-24.  Moderate: score 25-29. Severe: 30 and above 
Those participants who did score highly on the psychological distress scale were significantly less likely 
to have adequate physical activity (p=0.002), Table 16. A significant association between psychological 






Well Mild Moderate Severe
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Table 16: Psychological distress and cardiovascular risk factors 
  Total Distress No distress P-value 
Variable Freq (%) Freq (%) Freq (%)   
Sex       0.2191 
Male 126 (42) 21 (35) 105 (43.8) 
 
Female 174 (58) 39 (65) 135 (56.3) 
 
Marital status       0.1072 
Married 166 (55.3) 26 (43.3) 140 (58.3) 
 
Never married 100 (33.3) 26 (43.3) 74 (30.8) 
 
Widow/separated/divorced 34 (11.3) 8 (13.3) 26 (10.8) 
 
Education level       0.0012 
None 12 (4) 4 (6.7) 8 (3.3) 
 
Primary 41 (13.7) 1 (1.7) 40 (16.7) 
 
Secondary 80 (26.7) 10 (16.7) 70 (29.2) 
 
Tertiary 167 (55.7) 45 (75) 122 (50.8) 
 
Currently smoking       0.4212 
No 290 (96.7) 57 (95) 233 (97.1) 
 
Yes 10 (3.3) 3 (5) 7 (2.9) 
 
Harmful alcohol       0.1082 
No 290 (96.7) 56 (93.3) 234 (97.5) 
 
Yes 10 (3.3) 4 (6.7) 6 (2.5) 
 
Poor diet       0.1312 
No 4 (1.3) 2 (3.3) 2 (0.8) 
 
Yes 296 (98.7) 58 (96.7) 238 (99.2) 
 
Inadequate Exercise        0.0022 
No 49 (16.3) 2 (3.3) 47 (19.6) 
 
Yes 251 (83.7) 58 (96.7) 193 (80.4) 
 
Time spent sitting       0.4881 
Less than 3 hours  157 (52.3) 29 (48.3) 128 (53.3) 
 
More than 3 hours 143 (47.7) 31 (51.7) 112 (46.7) 
 
MS       0.7372 
No MS 259 (86.3) 51 (85) 208 (86.7) 
 
MS 41 (13.7) 9 (15) 32 (13.3)   
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4.6: Comorbid chronic medical conditions  
 In general, patients with psychosis reported a lower prevalence of medical conditions compared to those 
without psychosis.  Specifically, patients were found to have significantly lower prevalence of reported 
tuberculosis (1% in patients vs 4.4% in controls, p=0.025), HIV (4.7% in patients vs 14.4%in controls 
p<0.001), seasonal allergies (17% in patients vs 27%in controls p=0.015), asthma (2.7% in patients vs 
7.4% in controls, p=0.032) and ulcers (10.4% in patients vs 20.1% in controls p=0.002). Table 17 
Table 17:  Reported medical conditions as   captured on CIDI screener. 
Variable 
Total Patients Control   








Ever been admitted to the 
hospital 
 
   
0.0181 
No 408 (31.4) 217 (73.1) 191 (64.1)  
Yes 187 (100) 80 (26.9) 107 (35.9)   
Number of previous 
hospitalizations     
0.0162 
1 115 (18) 58 (73.4) 57 (54.8)  
2 33 (10.9) 11 (13.9) 22 (21.2)  
3 20 (3.8) 9 (11.4) 11 (10.6)  
4 7 (4.4) 1 (1.3) 6 (5.8)  
5 8 (100) 0 (0) 8 (7.7)   
Arthritis or rheumatism     0.228
2 
Yes 11 (97.8) 3 (1) 8 (2.7)  
No 582 (0.2) 294 (99) 288 (96.6)  
Don't know 1 (0.2) 0 (0) 1 (0.3)  
Refused to answer 1 (100) 0 (0) 1 (0.3)   
Chronic back or neck 
problems     
0.6452 
Yes 39 (93) 17 (5.7) 22 (7.4)  
No 554 (0.3) 279 (93.9) 275 (92)  
Don't know 2 (0.2) 1 (0.3) 1 (0.3)  
Refused to answer 1 (100) 0 (0) 1 (0.3)   
Frequent or severe 
headaches     
0.1872 
Yes 98 (83.1) 43 (14.5) 55 (18.4)  
No 495 (0.3) 254 (85.5) 241 (80.6)  
Don't know 2 (0.2) 0 (0) 2 (0.7)  
Refused to answer 1 (100) 0 (0) 1 (0.3)   
Any other chronic pain     0.414
2 
Yes 36 (93.5) 14 (4.7) 22 (7.4)  
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No 557 (0.3) 282 (94.9) 275 (92)  
Don't know 2 (0.2) 1 (0.3) 1 (0.3)  
Refused to answer 1 (100) 0 (0) 1 (0.3)   
Seasonal allergies eg hay 
fever     
0.0152 
Yes 132 (77) 51 (17.2) 81 (27.1)  
No 459 (0.7) 243 (81.8) 216 (72.2)  
Don't know 4 (0.2) 3 (1) 1 (0.3)  
Refused to answer 1 (100) 0 (0) 1 (0.3)   
A stroke     0.171
2 
Yes 4 (98.8) 0 (0) 4 (1.3)  
No 589 (0.3) 296 (99.7) 293 (98)  
Don't know 2 (0.2) 1 (0.3) 1 (0.3)  
Refused to answer 1 (100) 0 (0) 1 (0.3)   
A heart attack     0.574
2 
Yes 2 (99.3) 1 (0.3) 1 (0.3)  
No 592 (0.2) 296 (99.7) 296 (99)  
Don't know 1 (0.2) 0 (0) 1 (0.3)  
Refused to answer 1 (100) 0 (0) 1 (0.3)   
Heart disease     0.297
2 
Yes 6 (98.5) 1 (0.3) 5 (1.7)  
No 586 (0.3) 295 (99.3) 291 (97.7)  
Don't know 2 (0.2) 1 (0.3) 1 (0.3)  
Refused to answer 1 (100) 0 (0) 1 (0.3)   
Asthma     0.032
2 
Yes 30 (94.6) 8 (2.7) 22 (7.4)  
No 563 (0.2) 288 (97) 275 (92.3)  
Don't know 1 (0.2) 1 (0.3) 0 (0)  
Refused to answer 1 (100) 0 (0) 1 (0.3)   
High Blood Pressure     0.597
2 
Yes 44 (92.1) 19 (6.4) 25 (8.4)  
No 548 (0.3) 277 (93.3) 271 (90.9)  
Don't know 2 (0.2) 1 (0.3) 1 (0.3)  
Refused to answer 1 (100) 0 (0) 1 (0.3)   
Tuberculosis     0.025
2 
Yes 16 (96.8) 3 (1) 13 (4.4)  
No 576 (0.3) 292 (98.3) 284 (95.3)  
Don't know 2 (0.2) 2 (0.7) 0 (0)  
Refused to answer 1 (100) 0 (0) 1 (0.3)   
COPD or emphysema      0.390
3  
Yes 4 (99) 1 (0.3) 3 (1)  
No 589 (0.2) 296 (99.7) 293 (98.3)  
Don't know 1 (0.2) 0 (0) 1 (0.3)  
Refused to answer 1 (100) 0 (0) 1 (0.3)   
Diabetes or high blood 
sugar     
0.6082 
Yes 11 (97) 4 (1.3) 7 (2.3)  
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No 577 (1) 290 (97.6) 287 (96.3)  
Don't know 6 (0.2) 3 (1) 3 (1)  
Refused to answer 1 (100) 0 (0) 1 (0.3)   
Ulcer in your  stomach or 
intestine     
0.0022 
Yes 91 (84) 31 (10.4) 60 (20.1)  
No 500 (0.7) 265 (89.2) 235 (78.9)  
Don't know 4 (100) 1 (0.3) 3 (1)   
HIV infection or AIDS     <0.001
2 
Yes 57 (86.7) 14 (4.7) 43 (14.4)  
No 517 (3.5) 275 (92.6) 242 (80.9)  
Don't know 21 (0.2) 8 (2.7) 13 (4.3)  
Refused to answer 1 (100) 0 (0) 1 (0.3)   
Epilepsy or seizures     0.125
2 
Yes 10 (97.5) 8 (2.7) 2 (0.7)  
No 581 (0.7) 286 (96.3) 295 (98.7)  
Don't know 4 (0.2) 3 (1) 1 (0.3)  
Refused to answer 1 (100) 0 (0) 1 (0.3)   
Cancer     0.133
2 
Yes 3 (89.7) 0 (0) 3 (1)  
No 534 (9.6) 272 (91.9) 262 (87.6)  
Don't know 57 (0.2) 24 (8.1) 33 (11)  
Refused to answer 1 (100) 0 (0) 1 (0.3)   
Other Conditions     0.769
2 
No 583 (1.9) 291 (98.3) 292 (98)  
Yes 11 (100) 5 (1.7) 6 (2)   
1 Chi-square test    2 Fishers’ exact test 
There was no significant association between comorbid medical conditions and metabolic syndrome or 





4.7: Pharmacological treatment patterns   and cardiovascular risk 
The vast majority (94.3%) of patients were being treated with an antipsychotic medication at the time of 
assessment, while the remaining patients were treated with antidepressants only. As shown in Figure 9, 
below, most (86.5%) patients were treated with olanzapine. 
 
 





Olanzapine Haloperidol Chropromazine Zuclopenthixol
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Neither olanzapine use, nor olanzapine dosage was significantly associated with increased 
cardiovascular risk, Table 18; and an inverse relationship between olanzapine use and hypertension 
(p=0.029) was in fact noted. 




None <=10 >10 
Freq (Col %) Freq (Col %) Freq (Col %) 
MS   0.376
1 
No MS 25 (62.5) 134 (72) 53 (74.6)  
MS 15 (37.5) 52 (28) 18 (25.4)   
Diabetes    0.1922 
No 38 (95) 178 (95.7) 71 (100)  
Yes 2 (5) 8 (4.3) 0 (0)   
Hypertension    0.0292 
No 27 (67.5) 154 (82.8) 62 (87.3)  
Yes 13 (32.5) 32 (17.2) 9 (12.7)   
HDL    0.6781 
Normal 28 (70) 118 (63.4) 44 (62)  
Elevated 12 (30) 68 (36.6) 27 (38)   
LDL    0.3241 
Normal 14 (35) 60 (32.3) 30 (42.3)  
Elevated 26 (65) 126 (67.7) 41 (57.7)   
Cholesterol    0.9481 
Normal 31 (77.5) 141 (75.8) 55 (77.5)  
Elevated 9 (22.5) 45 (24.2) 16 (22.5)   
BMI    0.2612 
Underweight 2 (5) 5 (2.7) 0 (0)  
Normal 17 (42.5) 96 (52.5) 39 (55.7)  
Overweight 10 (25) 57 (31.1) 22 (31.4)  
Obese 10 (25) 24 (13.1) 9 (12.9)  
Morbid obesity 1 (2.5) 1 (0.5) 0 (0)   
 
1 Chi square test    2 Fishers’ exact test  
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4.8:  10 year estimated risk of developing cardiovascular disorders 
 In this study the scores of the Framingham 10-year estimated risk of developing CVD among patients 
with psychosis was 3.16, which was comparable to that in the control group (2.93), Table 19. 
Table 19:  Framingham risk scores  
FRS N Mean SD t-test p-value 
Control 300 2.93 4.55 0.534 
Patients 297 3.16 4.23  
Total 597 3.04 4.39  
 
 Most patients (94.6%) had a low risk score (<10), 4.4 % had an intermediate risk and 1% had high risk 
for CVD in this study, Table 20. 
 Table 20: A comparison of   Framingham Risk Score severity  
 
Framingham Score 
Total Patients Control p-value 
 Freq (%) Freq (%) Freq (%) 
Low risk 563 (94.3) 281 (94.6) 282 (94.0) 1.000 
Intermediate 27 (4.5) 13 (4.4) 14 (4.7) 
 




In terms of Sex comparisons of the FRS, Female patients were found to have a significantly higher risk 
compared to controls (p=0.008); while no difference between male patients and male controls was 
evident, Table 21 
Table 21: Framingham 10 year cardiovascular disease risk by Sex 
 
Sex Arm N Mean SD t-test p-value 
Male 
Control 126 4.55 6.13                0.317 
Patients 139 3.86 5.19 
Female 
Control 174 1.76 2.29 0.008 
Patients 158 2.54 3.03 
Total  597 3.04 4.39  
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In a linear regression model adjusted for covariates, the estimated 10-year cardiovascular risk among 
patients was significantly associated with female Sex (p=0.007), age (p<0.001), current tobacco smoking 
(p<0.001) and metabolic syndrome (p<0.001), Table 22. It was not found to be associated with harmful 
alcohol use, or with olanzapine dose. 
Table 22:  Factors associated with higher 10 year FRS scores among patients 
Variable  Coefficient p value 95% Confidence 
interval 
Female vs male 0.888 0.007 1.528       -0.248 
Age in years 0.239 <0.001 0.2090      0. 268 
Employment ; formal vs none 0.476 0.307 -1.413       0.460 
Education: secondary vs none 0.184 0.770 -1.433      1.064 
Obese vs normal weight 0.466 0.176 -0.210       1.142 
Current tobacco use 3.817 <0.001 2.717       4.917 
Harmful alcohol use  0.884  0.369  _1.051      2.819 
Metabolic syndrome 3.092  <0.001 2.319        3.865  
Olanzapine dose    
< 10mg vs none 0.438 0.337  0.458     1.335 
>10mg vs none 0.367 0.478 0.651        1.385 
Childhood trauma  0.668 0.058 -0.022       1.359 
Traumatic life events   -0/218 0.550 -0.937       0.500 
 
4.9: Treatment Gap for CVD risk factors. 
Out of 10 patients who had DM, 6 (60%) were not previously diagnosed hence were not on treatment. 
Out of 9 controls who had DM, 2(22%) were not previously diagnosed hence were not on treatment. Out 
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of all the 54 patients who we found to have hypertension, 35 (65%)  were not on treatment, while out of 
the controls 47 controls who had hypertension  22 ( 47%)of them were not on treatment. Table 23.  
We found no record of treatment with lipid lowering drugs; or of any other medication to reduce the 
adverse cardiovascular effects of antipsychotic treatment in this study sample.  
Table 23:  Proportion of treated and untreated cardio metabolic disorders 
  
Variable 
Patients  Controls P-value 
Freq (Col %) Freq (Col %) 
Diabetes  Mellitus  
 
0.1152 
Treated 4 (40%) 7 (78%) 
Untreated 6 (60%) 2 (22%) 
 
Total Diabetes  10 (100 %) 9 (100%) 
 
 Hypertension   
 
0.0691 
Treated 19 (35%) 25 (53%) 
Untreated  35 (65%) 22 (47%) 
Total Hypertension  54 (100%) 47 ( 100)  
 Patient records were reviewed for documented evidence of treatment of the cardiovascular risk factors.  This was 
complemented by patients’ self-report of other medication they were taking; and was compared with the laboratory tests and 




CHAPTER 5: DISCUSSION 
5.0 Introduction 
The purpose of this chapter is to interpret and describe the significance of the key study findings, in light 
of existing literature on cardiovascular risk factors and psychosis. First, we discuss   sociodemographic 
characteristics of the participants, highlighting the overall young age of the study sample, and the impact 
on cardiovascular risk. Second, we explore the prevalence and correlates of both conventional and non-
conventional cardiovascular risk factors, noting the high prevalence of several factors among the 
participants. Third, we discuss antipsychotic use and its association with cardiovascular risk, highlighting 
the unexpected absence of a significant association between olanzapine and increased cardiovascular 
risk. Fourth, we discuss the overall estimated 10-year risk of developing CVD, noting the significant 
relationship between age, sex, metabolic syndrome and cigarette smoking on the FRS. Fifth, we describe 
the interventions for metabolic disorders among mentally ill patients in the study setting, as well as 
treatment gaps identified in this study. Sixth, we summarize methodological limitations which should be 
considered when interpreting the findings of this study. Finally, we discuss the translational potential of 
these findings; and how these may impact on clinical care; as well as directions for future research in this 
field.  
5.1: Conventional non-modifiable CVD risk factors and other social demographic characteristics 
 5.1.1: Age  
The overall young age ( below 40 years of age)  of participants in this study may be attributed to the fact 
that generally   Kenya has a very young population with more than three quarters of Kenyan citizens 
being  younger than  30 years of age  (World population Review 2019).  In this study age was positively 
correlated with MetS, abnormal BMI and FRS.  Evidence suggests that age affects  the  overall CVD  risk  
because several  CVD risk factors are more common among  older than younger populations resulting in 
a cumulative effect (Gurven et al. 2012; Pinto 2007a). As an example population-based retrospective 
cohort study in Canada  amongst 379, 003 Canadians with diabetes and 9, 018, 082 persons without 
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diabetes reported that  patients with diabetes  get into a high CVD risk after the age of 40 (G. L. Booth et 
al. 2006). Similarly, a study done in South Africa reported that MetS prevalence was significantly higher 
in patients aged above  55 years(Saloojee, Burns, and Motala 2016b). Further hypertension is reported 
to increase with age, due to age related alteration in sodium haemostasis, arterial stiffness and increased 
pulse pressure (Frame and Wainford 2018; Baker et al. 2016). Given that age is  a key predictor of CVD 
risk both in our study and in other studies  (Dhingra and Vasan 2012a; Sniderman and Furberg 2008) , 
the findings of this study should be interpreted in that context, bearing in mind that an older population of 
mentally ill patients may display a different cardiovascular risk profile. 
5.1.2: Sex 
This study demonstrated that sex may play a significant role in shaping the cardiovascular risk profile of 
patients with psychosis. While a number CVD risk factors were common in both men and women, female 
sex was positively correlated with a higher BMI and increased risk scores. These findings  are in 
agreement with a study done among 169 patients with in Baltimore among patients with severe mental 
illness which  reported a  positive correlation between female sex and abnormal BMI (Dickerson et al. 
2006). Similarly, higher rates of obesity were reported among female patients with severe mental illness 
in a  study involving 272 patients in Maryland (Daumit et al. 2003). While in our study we found MetS to 
be positively correlated with male sex, other studies have reported higher rates of Mets among females. 
For example,  an observation study done  among 500 patients in India reported a positive  correlation 
between  Mets and female sex (Beigh and Jain 2012).  Similarly, a Mexican study showed that females 
patients with psychosis were 3 times more likely to  develop  metabolic syndrome compared to men 
(Díaz-Domínguez et al. 2013). The sex differences in this study supports the existing literature which 
recommends a Sex sensitive approach to diagnosis and interventions of CVD risk factors.  
5.1.3:  Socioeconomic and marital status:  
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In understanding the cardiovascular risk profile of the study participants, this study explored three aspects 
of social economic environment that may play a key role in determining health outcomes: employment 
status, education level and marital status (WHO ;  S. M. Marmot 2018). 
 There were higher rates of unemployment among patients with psychosis compared to controls. These  
findings are in agreement with other  studies that  have demonstrated that people with mental illness are 
more likely to be unemployed compared to their healthy counterparts (Mallett et al. 2002). This is in 
agreement with a study done among 546  African-Caribbean participants  (224 patients with psychosis 
and 322 controls)  which demonstrated that unemployment  is common among patients with psychosis 
(Reininghaus et al. 2008).  Although this was not demonstrated in this  study,  other studies have reported 
an  indirect link between unemployment and physical as well as mental  health (Tøge 2016;  Batic-
Mujanovic et al. 2017;   López del Amo González, Benítez, and Martín-Martín 2018).    
Patients had lower level of education compared to those who had no psychosis.  In this study, having a 
secondary education was associated with lower odds of having metabolic syndrome.  This is in line with 
other literature  that has described a relationship between  education level  and physical and mental 
health  (Kurtze, Eikemo, and Kamphuis 2013).  For example, a  Chinese observational study  that involved  
10,054 community residents reported that patients with lower educational level had a higher risk of 
developing metabolic syndrome (Zhan et al. 2012).   However it is in contrast to the Interheart  African 
study that was conducted among  (578) were matched to 785 controls by age and sex in 9 SSA countries,  
which showed that high education level was associated with  increased risk of CVD. Similarly  A  
nationwide Spanish cohort study ( n=9,226) reported that  DM, hypertension and  BMI  mediated the 
association between education and CVD incidence, accounting for 26% of the association (Dégano et al. 
2017).  Further,  a Mendelian randomization study that included 217,  013 white British participants 
reported that  every additional standard deviation of education (3.6 years) was associated with a 13% 
lower risk of coronary heart disease  in observational analysis and a 37% lower risk in Mendelian 
randomization analysis and that BMI, systolic blood pressure and smoking were the main mediators 
(Carter et al. 2019). It is believed that educated persons are more likely to access screening and 
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treatment for  cardiovascular risk factors compared to those with lower educating, implying that better  
educated people are likely to have better  health outcomes (Oguoma et al. 2015) 
Patients in this study were more likely never to have been married or to be separated compared to those 
who had no psychosis. This is consistent with findings of   case control  study done in Denmark ( n=5,341)  
which  demonstrated that patients with schizophrenia were more likely not to be married  both at diagnosis 
and even several years later after initiation of treatment (Agerbo et al. 2004).  Similarly a recent  
observational study conducted in Ethiopia among 245 patients with severe mental illness indicated that 
marital status was associated with presence of metabolic syndrome components (Teshome, Kassa, and 
Hirigo 2020).  Mental illness is believed  to result in a state of   social disadvantage   associated with the 
symptomatology of  the disease, like the cognitive impairment , difficulty with social interactions, as well 
as  the stigma  for mental illness, which affects their ability to get into marital commitments (C. Morgan 
et al.  2008.). Being married has been associated with better quality of life due to the social support that 
it brings (Salokangas et al. 2001), and married psychotic patients tend to present with less severe 
symptoms compared to those who are not married (Nyer et al. 2010) . In the current study those who 
were divorced, separated or windowed had reduced odds of having metabolic syndrome and abnormal 
BMI. This is contrary to other studies that have found that unmarried people (divorced, widowed, or 
separated) have higher odds of developing metabolic syndrome. For example , the   sixth Korea National 
Health and Nutrition Examination Survey  that involved 3,225 women aged 40–69 years reported that  
the OR for metabolic syndrome in the widowed  participants compared to the  married group was 4.8, 
possibly related to   social  economic factors and other health behaviours  (Jung et al. 2018). At the same 
time, the conditions in the marriage can also shape the cardiovascular health of the individuals. As an 
example,  the Stockholm female coronary risk study  showed a nearly 3 time increase in cardiac events 
associated with marital distress (Orth-Gomér et al. 2000).. 
These findings imply that in implementing any efforts to improve the cardiovascular profile of patients 
with psychosis, it is important to also explore the role the social economic and marital circumstances play 
in shaping the individuals cardiovascular profile.     
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5.2: Conventional modifiabl CVD risk factors  
5.2.1: Lifestyle risk factors 
Smoking 
  In this study, 13.8 % of patients reported cigarette smoking. This finding  is  comparable to the 
prevalence of smoking  in the general population in Kenya which is 13.5% according to  the WHO STEP 
survey (Ngaruiya et al. 2018).   However it is lower that what other studies among patients with psychosis 
have reported. This is lower than findings of a study done among patients with schizophrenia in Nigeria 
which reported a lifetime prevalence of 25% (Aguocha et al. 2015).  Similarly, a review and meta-analysis 
including 61 studies comprising 72 samples and an overall sample of 14,555 tobacco users and 273,162 
non-users reported  a 57%  prevalence of smoking amongst patients with first episode psychosis (Gurillo 
et al. 2015b).  The lower prevalence in the current study may be due to underreporting of nicotine use 
that may be associated with both perceived and internalized stigma for substance use in the study setting.   
When compared to controls, this study reported a significantly higher prevalence of smoking among 
patients and that cigarette smoking was associated with higher FRS. The higher prevalence among 
patients versus controls is in line with a well stablished evidence base. Several  studies  across the globe 
have  demonstrated that  patients with psychotic disorders have very high rates of smoking  (Gurillo et 
al. 2015b; Addington et al. 2014; Vanable et al. 2003)  with patients being 4 to  6 times more likely to  
smoke compared to those without psychosis (Hartz et al. 2014). 
The findings of this study agree with other literature that smoking is a common cardiovascular risk factor 
among patients with psychosis supporting the need for continuous efforts to promote smoking cessation 
in order to improve the cardiovascular health of this group.  
 Harmful alcohol use 
In the current study, only 2.7% of the patients with psychosis had harmful alcohol use as defined by an 
Audit score greater than 4 in men and 3 in women. This prevalence is notably lower than expected, given 
that a community based  study   done in the same region of Western Kenya indicated that the prevalence 
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of harmful alcohol was 12% (Kwobah et al. 2017).  In addition a large body of evidence indicates a higher 
burden of harmful alcohol use among patients with psychosis than in the general population affecting 
more than one third of patients  with schizophrenia (Menezes et al. 1996).  A study done in Ethiopia 
among patients with bipolar mood disorder reported that 24.5% had alcohol use disorder (Tensae et al. 
2018).   Similarly meta-analysis that included 60 studies estimated that the prevalence of harmful alcohol 
use among patients with schizophrenia is 20% (Koskinen et al. 2009). Evidence  suggests  that the higher 
prevalence of alcohol in  patients with bipolar mood disorders as well as schizophrenia  is part of  self-
medication to relieve distressing symptoms  (Maremmani et al. 2018; James M. Bolton, Jennifer 
Robinson, and Jitender Sareen 2009).  This discordant finding in our study sample highlights the 
methodological limitation of self-reported assessments for alcohol use and the stigma that surrounds 
alcohol use in the study setting.  Other studies have demonstrated that many persons who use alcohol 
are likely to underreport  their drinking especially  when they are drinking heavily (Boniface, Kneale, and 
Shelton 2014) mainly  due to perceived  stigma (Northcote and Livingston 2011). The findings of this 
study underscore the need for a more objective way of assessing for harmful  alcohol use among patients 
with psychosis ( such as blood or urine tests) in order to avoid under estimating the role excess alcohol 
use plays in shaping the cardiovascular risk profile in this population.  
Poor dietary habits 
In this study most patients with psychosis reported eating less than one serving of fruits in a week, and 
having less than 3 servings of vegetables in a week.  This finding is in line with the 2015 national survey 
of 2015 in Kenya that reported that  99% of the participants had less than the recommended intake of 
fruits and vegetables (Haregu et al. 2018).  This pattern of  low intake of fruits and vegetables is  similar 
to findings of the second Australia national survey on psychosis (Margolese et al. 2004) which showed 
that 74% of the patients had very low intake of fruits and vegetables. This  has been attributed to the 
symptoms of the illness especially the negative symptoms and the cognitive impairment,  as well as the  
low financial abilities which would limit the purchasing power for healthy meals (L. A. Hahn et al. 2014) .  
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While only fruits and vegetables intake was used to assess diet in this  study, existing evidence report 
other poor forms of dietary habits among patients with psychosis, which may result in increased 
cardiovascular risk (Dipasquale et al. 2013b). These include  consuming diet with excess salt and 
saturated fats further increasing the cardiovascular risk  (Nenke et al. 2015). According to a German 
study the patients with schizophrenia were more likely to eat a snack for dinner , consume instant meals 
and eat healthy groceries more rarely (Roick et al. 2007). This  pattern of poor dietary habits  may be due 
to many  factors including social dysfunction which is common among these patients (Mucheru et al. 
2017a). According to the survey of high impact psychosis in Australia, patients who are isolated and 
lonely were more likely to miss essential meals like breakfast and also eat diet with low fruits and 
vegetable levels compared to the general population (Mucheru et al. 2017b). Other factors that may result 
in poor dietary habits are financial constraints as demonstrated by a  study done in  South East London 
which  associated the poor diet with unemployment (Samele et al. 2007).   
These findings are  important as they highlights the importance of including in the care of mentally ill 
patients in this setting,  efforts to improve intake of healthy diet in order to promote cardiovascular health. 
Inadequate physical activity and sedentary behaviour 
This study reports a very high rate of inadequate exercise in terms of physical activities per week as well 
as hours spent sitting. This is consistent with the 2015 WHO Steps survey that reported that up to 80% 
of the population  in Kenya do not engage in adequate physical activity (Wekesah et al. 2018). A review 
including 2,033 people with psychosis revealed that many patients with psychosis may spend up to 9 
hours of their wakefulness  in sedentary state and at least 2 hours more is spent in sedentary state 
compared to the general population (Stubbs, Williams, et al. 2016).   The WHO mental health survey 
conducted  among 204,186 participants from  several LMICs  reported that  the low physical activity  was 
common among patients  with a diagnosis of psychosis ,especially male patients, and this was associated 
with  mobility difficulties, self-care difficulties , depression , cognitive  impairment,   changes in sleep and 
energy levels in that order (Stubbs et al. 2017b). A  review including 25 articles associated   low physical 
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activity in patients with psychosis with  negative symptoms such as anhedonia ,side‐effects of 
antipsychotic medication, lack of knowledge on cardiovascular disease risk factors, lack of belief in the 
health benefits, a lower self‐efficacy, and social isolation (D. Vancampfort et al. 2012).  A different review    
including 35 studies representing 3,453 individuals with schizophrenia associated the low physical activity 
levels  with old age as well as depressive symptoms (Stubbs, Firth, et al. 2016).  The level of physical 
activity is also affected by obesity which is prevalent in patients with psychosis, as well as patients 
perceptions in terms of perceived competence physical self‐worth(D. Vancampfort, Probst, et al. 2011). 
These findings mean that there is work to be done in this kind of setting to identify and implement ways 
of promoting physical activity among patients with psychosis in order to reduce risk of CVD. 
5.2.2: Metabolic disorders 
Diabetes Mellitus; The prevalence of DM in our study sample (3.4%) was low but   comparable to the 
findings of the National  Steps  survey on NCD risk factors that was carried out in Kenya in 2015 among 
4069 participants aged between 18 and 69 years, which  reported a  2.4% diabetes (Mohamed, Mwangi, 
et al. 2018).  This is also within the range that was reported by one review that included 143 articles which 
indicated that  the prevalence of diabetes  in patients with psychotic disorders ranges  widely ,from 1·26% 
to 50% across studies (median 13%) (Ward and Druss 2015).  Other contrasting studies indicate a higher 
prevalence among patients with mental illness compared to the general population.  One observational 
study done in Taiwan that involved 246 patients with schizophrenia reported that the prevalence of DM 
was 9.8% (Chi-FaHunga, Ching-Kuan, and WuabPao-Yen 2005). Another   large population based 
Canadian study ( 28,755 patients  with psychotic disorder and  2,281,636 controls)   reported a 10% 
prevalence of diabetes among patients with psychosis compared to 6% among controls (Bresee et al. 
2010).  Similarly a smaller study done in Singapore among patients with schizophrenia reported a 
prevalence of 19.1%.(Shafie et al. 2018).  One possible contribution to the lower prevalence in the current 
study sample could be the use of random blood sugar cut off while in essence some of the patients may 
actually have been in a fasting state, having not eaten for more than 6 hours. While in this   current study 
there was no relationship between DM and FRS, the Framingham study established that the presence of 
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DM increases the risk of cardiovascular disease twice in men and three times in women compared to 
those with no diabetes (W B Kannel and McGee 1979).   
These findings point to the need for better assessments of presence of DM, for example by use of HB1Ac, 
before conclusions that indeed patients with psychosis in this setting have a low prevalence of DM. 
High blood Pressure; This study found that 18.2% of the patients with psychosis had elevated blood 
pressure.  This is lower than  a prevalence of  24%  that was reported by the  national survey in Kenya 
in 2015 (Mohamed, Mutua, et al. 2018) in the general population.  Though not demonstrated in this study, 
other  evidence suggests that the rates of hypertension in  patients with psychosis are likely  higher than 
the general population owing to  several shared etiological pathways between hypertension and mental 
illness (Rihmer, Gonda, and Döme 2017). For example,  a  nationwide survey in Japan amongst patients 
with schizophrenia found a prevalence of hypertension of  30% (Sugai et al. 2016b),  and  a multisite 
study  done in France among older patients   reported  a  prevalence of 43% (Abou Kassm et al. 2019). 
The lower prevalence of hypertension in the current study   might be accounted for by the relatively 
younger age of the participants. Current evidence suggests that blood pressure changes by 20 mm Hg 
systolic and 10 mm Hg diastolic increment from age 30 to 65 years (William B. Kannel 1996).  These 
changes in blood pressure with increasing age have been linked to the various changes at the cellular 
level that aging brings such as alterations  in second messengers  calcium and magnesium that affect 
the tone of the small arteries  (Barbagallo et al. 2000),  and the structural changes especially  large artery 
stiffness (Pinto 2007b).  
These findings indicate the need for monitoring blood pressure among patients with psychosis in similar 
setting, and a need to do for more studies among older patients with psychosis who might be more at 
risk than the young population that this study engaged. 
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Dyslipidaemia; This study found a high prevalence of dyslipidaemia (65% had elevated LDL, 47% had 
elevated triglycerides and 36% had low HDL) among patients with psychosis and both cholesterol and 
triglyceride levels were significantly higher among patients compared to controls.  These findings are 
higher than what would be expected in the general population in a similar setting as exemplified by a 
systematic review and meta-analysis of 177 studies (n=294063) from across that reported 28·6% 
elevated of LDL, 37·4% of low HDL, and 17·0% of triglycerides (Noubiap et al. 2018) , and findings of the 
Health and Demographic Surveillance System (HDSS) site in Western Kenya which reported that only 
15% of the population had elevated plasma lipids (Chege 2016). They are comparable to findings  of a 
Saudi Arabian cross sectional study that included  992 patients with mental illness reported that 32.8% 
had elevated  triglycerides and  52.5 % had low HDL cholesterol (Alosaimi et al. 2017). The high 
prevalence of dyslipidaemia in this study is a clear indicator for the need for continuous monitoring and 
management of lipids in patients with psychosis in this setup in order to reduce the associated risk of 
CVD.  
Obesity; This study found a high prevalence of elevated BMI (45%) This is higher than a meta-analysis 
of obesity in general population in Africa ( n=48,823) that estimated the prevalence to be 21.8% (Tulp et 
al. 2018).  A cross sectional study  done in Australia ( n=189) demonstrated higher prevalence  where 
most of the participants (78%)  were either overweight or obese (Nenke et al. 2015).In the current study, 
the prevalence of abnormal BMI was significantly higher among patients than controls. This is similar to 
study done in Yale that included  326 patients with schizophrenia and 1899 controls reported which 
reported that 58% of the patients were obese compared to 27% of the controls (Annamalai, Kosir, and 
Tek 2017).  This study established that abnormal BMI was positively associated with female Sex.  This 
is similar to findings of an ecological analysis of internationally comparable obesity prevalence for adult 
men and women from the 2010 WHO Global Infobase which reported that in 87% of the 151 countries 
involved, female prevalence exceeded that of males (Garawi et al. 2014). While data on mentally ill 
females patients is limited, evidence for excess obesity among females has  been reported in studies 
done in general populations in Turkey (Erem et al. 2004),  Spain (Martínez, Moreno, and Martínez‐
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González 2004), and Malawi (Alison J Price et al. 2018) and Kenya (Asiki et al. 2018). In addition to high 
rates of elevated BMI, the study also established a high prevalence of central obesity as indicated by 
abnormal waist circumference (35%). Similarly an observational study  done in China among patients 
with schizophrenia reported that almost half of the participants had central obesity (Bressington et al. 
2016) This has significance as abdominal obesity is believed to have the highest impact on metabolic 
profile in some populations such as Africans (Handlos et al. 2012). These findings indicate the need to 
screen for obesity bearing in mind the Sex differences, and the need to put mechanisms in place to lower 
these rates in order to promote cardiovascular health in similar settings.    
Metabolic syndrome; In this study we found that 28.6 % of the patients had MetS.  In a Kenyan setting, 
these findings are lower than 34.6% which was  reported  in  a cross-sectional study among  urban 
dwellers in Nairobi  (Kaduka et al. 2012) but higher than the prevalence of 19.2% among  HIV infected 
individuals in the same setting  (Kiama et al. 2018).  Among patients with mental illness, these findings 
are comparable to  an earlier South African study done among 276 patients with SMI which reported a 
prevalence of 23% (Saloojee, Burns, and Motala 2016a) an Ethiopian study which reported a prevalence 
of 28.9 (Asaye et al. 2018)  and a very recent  cross sectional study done in Uganda among 309 patients 
with SMI which reported a prevalence of 24% (Agaba et al. 2019). The prevalence in this  study  is  also 
comparable  to  cross- sectional studies done in  Taiwan  and Singapore which reported that 26% of 
patients with psychosis  had MetS (Tseng et al. 2014),(Seow et al. 2017)  and in  in Belgium  which 
reported a prevalence of 28.4% (Marc A de Heart et all 2006).  
 In this study the metabolic syndrome was associated with psychosis and increasing age. Of note is that 
males were more likely to have MetS than females which is contrary to other work in the field. For example  
a study done in South Africa reported  that the prevalence of MetS among black African women with SMI 
were more than three times more compared to men in the same setting (Saloojee, Burns, and Motala 
2017)  and a study done in Tanzania in the general  population reported that 13% of males and 35% of   
females had metabolic syndrome (Njelekela et al. 2009b).  Similarly data from the Clinical Antipsychotic 
Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial,  reported    higher rates of metabolic 
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syndrome among females,  (51.6 % females  vs 36%) (McEvoy et al. 2005). These findings indicate the 
need to consider sex differences in assessment and interventions for MetS. 
5.3: Trauma, Psychological distress and Comorbid medical conditions  
  5.3.1: Exposure to potentially traumatic events 
In this study, most participants (73% of patients and 80% of controls) reported   having experienced at 
least one potentially traumatic event in their life.  There were also several participants who reported 
having experienced potentially traumatic events in childhood. These findings of high prevalence of 
traumatic experiences among the patients is in agreement with other studies.   For example, one review 
of literature including 46 studies reported  that there is a wide range of  reported prevalence of  childhood 
trauma among patients with psychosis, ranging between 28% and 73% (Bendall et al. 2008).   Another 
study done among  schizophrenia patients in community mental health centres in central Indiana reported 
that 98% of the participants had at least one traumatic life event and 36% had childhood traumatic 
experiences(Resnick, Bond, and Mueser 2003). Similarly, a  study done in  New Yolk among patients 
with psychosis   reported that 69% had trauma exposure, with 29% being exposed to  at least three 
lifetime traumatic events, and 32.2% were exposed to childhood traumas before age 16 (Neria et al. 
2002).  Further, a Dutch study reported that 97.0% of the participants had experienced at least one 
traumatic event during their lifetime, 81.8% at least two, traumatic events  and 60.6% at least three 
traumatic events (Lommen and Restifo 2009). 
In our study, the commonest traumatic even experienced by patients was physical assault and may be 
partly related to high rates of Sex based violence in SSA settings (Melissa A. Smigelsky et al. 2014).. 
These findings are  similar to findings of a study done in Norway ( n=139) which also reported that 
physical assault and childhood neglect were among the commonest  traumas reported by patients in the  
acute ward of a public psychiatric hospital (Floen and Elklit 2007a). Similarly, a study done among 399 
patients with schizophrenia and schizoaffective disorder admitted in the Veterans Affairs inpatient 
psychiatric unit   endorsed physical trauma most, with war zone trauma coming second (Calhoun et al. 
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2007).  This is however different from a study done among patients with SMI  in  a community public 
mental health service in New Jersey (n=851) where the most endorsed traumatic events were childhood 
sexual abuse and sudden loss of a loved one  (Lu et al. 2013). 
Patients in this study recorded less traumatic events both in child hood and in their lifetime than controls. 
This is in contrast to the findings of the Genomics of Schizophrenia in the South African Xhosa people 
study, which reported that patients with schizophrenia had 2.44 odds of having experienced Childhood 
trauma compared to controls (Mall et al. 2020).  . Similarly a review of literature reported that trauma and 
post-traumatic stress disorder ( PTSD)  are highly prevalent among individuals with SMI relative to the 
general population, and that this is  associated with negative clinical functioning and increased healthcare 
burden (Grubaugh et al. 2011).  
Patients in this study endorsed physical neglect (wearing dirty clothes) much more than the controls.  
This finding is in agreement with a small study done in France which reported that almost a fifth of the 
patients on management for schizophrenia  had experienced physical neglect (Bennouna-Greene et al. 
2011) . On the contrary, a study done among 305, patients with psychotic disorders in Norway reported 
that 82% of the patients had experienced one or more Childhood traumatic events, the most frequent 
subtype of trauma being emotional neglect (Larsson et al. 2013) 
In the currents study, among the patients, there was an association between exposure to traumatic 
experiences and smoking. The association between smoking and traumatic experiences has been 
described in literature though mostly in the general population as demonstrated by the study done in 
Germany among 4075 participants (Hapke et al. 2005).  This has been attributed to the need to reduce 
the negative effects of trauma experienced by the victims of trauma (Feldner et al. 2007). In this study 
however there was no evidence of an association between trauma with psychosis status. Other literature 
has suggested a bilateral relationship between psychosis and exposure to trauma , where psychosis may  
increase the risk of trauma while traumatic experiences may contribute to psychopathology (Mayo et al. 
2017). On the same breadth, traumatic experiences have been reported to contribute to CVD risk by 
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promoting physiological changes such as dysregulation of the hypothalamic-pituitary-adrenal axis, 
autonomic nervous system dysfunction, and increased inflammation, which results in obesity, and 
hypertension. The findings of high rates of traumatic experiences in this study suggest the need to include 
trauma history in the diagnosis and management of patients with mental illness. 
5.3.2: Psychological distress and cardiovascular risk 
 Psychological distress was reported in 11.7% of controls and was found to be associated with reduced 
physical activity and lower education level, both potential contributors to increased CVD risk. This is in 
agreement with A Brazilian study done among 506 military officers which demonstrated that 
psychological distress was significantly associated with less sport and leisure exercises (Martins and 
Lopes 2013). A number of other observational studies have demonstrated association between 
cardiovascular risk and  psychological distress (Dimsdale 2008b), (McLachlan and Gale 2018).  Similarly, 
the Whitehall study that followed up participants of varying  social economic status in London  
demonstrated that social economic challenges such as  poor living environment would impact the 
cardiovascular risk significantly by increasing cholesterol, smoking, blood pressure, body mass index and 
blood glucose among the socially disadvantaged,(E. J. Brunner 2017).  A Finish Prospective study that 
followed up employee who were free from CVD at baseline for 25 years reported that psychological 
distress that results from job strain and effort-reward imbalance can be result in a doubling of the risk of 
CVD related death,  as well as contribute to  adverse changes in biological factors such as cholesterol 
concentration and body mass index among employees who were free from overt cardiovascular diseases 
at baseline (Kivimäki et al. 2002) . In line with this line of thought,  one South Korean study  including 
1071 workers study associated high work demand with low decision latitude with increased risk of 




5.3.3: Comorbid medical conditions.  
Patients in this study reported notably lower rates of most chronic disorders with significantly lower rates 
of HIV, TB, stomach ulcers and allergies.  
HIV: The  lower rates of HIV among patients compared to controls that were  reported in this study differ 
from that in other studies that have demonstrated an excess of HIV  in patients with mental illness (DE 
HERT et al. 2011).  For example a South African study   demonstrated that patients  with severe mental 
illness have an almost three times greater prevalence of HIV than the general population, after controlling 
for age and Sex (Singh, Berkman, and Bresnahan 2009).  This is agreement with  findings of a    
population based cohort study in Denmark that followed up more than two and a half million people 
demonstrated that HIV increased risk of schizophrenia 4 times and acute psychosis 7 times (Helleberg 
et al. 2015).  Similarly, a  descriptive study done in the US including 191,625 patients with severe mental 
illness and 100,000 participants without mental illnesses established that the crude odds of having an 
HIV diagnosis were twice as high among patients who had diagnoses of serious mental illness as among 
patients who did not have serious mental illness diagnoses (Himelhoch et al. 2007) .  The prevalence of 
HIV among mentally ill patients  has been attributed  to engagement in  risky sexual behaviour especially 
among bipolar patients , but may also be  due to the fact that there may be impairment  in understanding 
what safety entails or making decisions to promote safe Sex among mentally ill patients  (Mamabolo et 
al. 2012), (Henning, Krüger, and Fletcher 2012). 
 The unexpected findings of lower reported rates in this study could be due to the fact that we did not test 
but instead asked about HIV status. Stigma to report HIV status is possible (Hamra et al. 2005) (L. Li et 
al. 2013), but it is also likely that routine screening for HIV is less in patients with mental illness in Kenya 
than in the general population .  In the setting of the study one needs to be mentally stable to undergo 
the pre-test and post-test counselling in order to understand the test and appreciate the results, and this 
could have implications on the rates of diagnosis for HIV among patients with psychosis.  The low levels 
of reported HIV could also point to difficulties with sexual interaction either due to cognitive impairment 
or due to side effects of medication.    
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Tuberculosis: In this study patients with psychosis reported significantly lower rates of TB compared to 
those without psychosis again contrasting other published studies. For example, one review and meta-
analysis that included 40 studies from 20 different countries  reported that 25% of multidrug-resistant 
tuberculosis patients experienced depression 24% experienced anxiety 10% experienced psychosis 
(Alene et al. 2018).  Other  small studies have  also reported higher rates of mental illness among  
tuberculosis patients compared to the general population (Duko, Gebeyehu, and Ayano 2015) , (Ambaw 
et al. 2017). Further  Psychosis due to TB meningitis or   TB   medication such as Isoniazid therapy has 
also been documented (Masood et al. 2011), (R., Garg, and Verma 2008),(Gomes et al. 2019),(Deribew 
et al. 2010). The low rates in this study could indicate low levels of screening and diagnosis for physical 
disorders among patients with mental illness.  This may be  associated with cognitive impairments in 
patients with psychosis which impairs ability to appreciate, describe and report physical symptoms such 
as those of TB (L. S. Goldman 1999). It could also be an indicator  of failure of the existing the health 
systems to put mechanisms in place to screen and treat for physical disorders among the mentally ill 
patients (Fagiolini and Goracci 2009b).  Such challenges in screening and care for the comorbidity were 
demonstrated in a   global survey conducted in 26 different countries which reported low levels of 
screening for the comorbidity of mental health and TB and these were associated  with knowledge gap 
for need to screen , limited resources and social stigma for TB (c et al. 2019). 
Asthma:  Patients reported lower rates of asthma compared to controls.  Like all the other medical 
conditions above, this may be attributed to low screening of medical conditions in the study setting. Other 
studies have indicated that patients with asthma have an increased risk of developing psychosis.   For 
example, a nationwide  longitudinal study  in Taiwan involving 75,069 subjects reported that asthma was 
associated with significantly greater hazard ratio for incident schizophrenia 1.40  (W.-C. Wang et al. 
2017).  
In this study, we found no significant association between the presence of selected medical conditions 
and FRS, with Mets S or other CVD risk factors. This was unexpected given  existing evidence   that 
existing comorbid  infectious and non- infectious medical conditions among patients with psychosis  are 
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likely to impact on the cardiovascular risk  profile  through direct effects of the medical condition on the 
cardiovascular system or  due to medication prescribed for the comorbid medical condition (Young et al. 
2009b).  
These findings point to the need to interrogate further the practice of screening and treatment for these 
conditions among patients with mental illness.  
5.4:  Antipsychotic treatment and cardiovascular risk.  
 We found that 87% of the participants were on olanzapine with only a minority being on other 
antipsychotics.  This is likely due to the widespread availability of the agent in the study setting 
(Olanzapine is available as a donation to the hospital), in which cost and availability of a drug are very 
important consideration in prescribing.   
Contrary to existing evidence olanzapine use in this study was not associated with any of the 
cardiovascular risk factors nor did it significantly affect the estimated 10 year CVD risk.  A number of 
observational and longitudinal studies have reported that antipsychotics affect metabolism of patients on 
management of psychosis hence increasing the overall cardiovascular risk. (B. L. Lambert et al. 2005), 
(Emsley et al. 2015: Henderson 2002; Komossa et al. 2010).   For example, a one year prospective study 
comparing weight gain of patients initiated on neuroleptics and heathy controls  demonstrated  a higher 
weight gain among those on neuroleptics with majority of the weight gain being associated to olanzapine 
use (Strassnig et al. 2007). Similarly a  three year prospective cohort study   done in Belgium comparing 
patients with first and second generation antipsychotics  reported a 3 fold increase in MetS among 
patients with second generation antipsychotics compared to first generation antipsychotics (De Hert et 
al. 2008).   Even among the second generation antipsychotics, there are reported differences among the 
various drugs on the effect on metabolism. Specifically olanzapine and clozapine have been linked with 
the highest risk of metabolic side effects compared to other antipsychotics  (Haupt et al  2006), (R.-R. 
Wu et al. 2006). A Chinese prospective, comparative, longitudinal study with a minimum antipsychotic 
treatment period of 8 weeks and assessments of participants at baseline and 8 weeks after inclusion 
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demonstrated that antipsychotics are associated with an increase of insulin, C-peptide, and insulin  
resistance index , increased  cholesterol and triglyceride levels,  with the effects of clozapine and 
olanzapine on the glucose and lipid metabolism outweighing  those of risperidone and sulpiride (R.-R. 
Wu et al. 2006).  
In this study, lower prevalence of hypertension was found among patients treated with olanzapine 
compared those who were not on olanzapine.  This could be due to a switch from olanzapine for patients 
whose high blood pressure is noted to be high. Other studies have reported higher rates of hypertension 
in patients with antipsychotics that is believed to be due to the effect on dopamine on the renin 
angiotensin pathways (Gonsai et al. 2018), as well as its effect on the sympathetic nervous system  where  
D2 receptor blockade results in persistently  increased sympathetic tone, hence increase in blood 
pressure  (Scigliano and Ronchetti 2013). 
These findings imply the need for further studies to establish if olanzapine induced metabolic effects are 
different in the Kenyan/ SSA setting and whether there is need to reconsider safety warnings related to 
metabolic complication that has seen olanzapine loose favour as a first line treatment for at risk 
populations with psychosis. 
5.5:  Estimated 10 year cardiovascular risk  
The estimated 10 year risk of developing cardiovascular related events among the patients in this study 
was low. This may be partly explained by the  likelihood of generally low risk of CVD in the study setting 
as demonstrated by  a cross-sectional survey done among slum dwellers in Nairobi which established 
that the risk score was CVD was low with only 1.7% having a high risk (Vusirikala et al. 2019).  The 
findings of this study are similar to a study done in Brazil among patients with psychosis reported that 
only   1.2% had severe Framingham  risk scores (Benseñor et al. 2012).  However  in contrast to a study 
done among 363 Spanish patients with schizophrenia where 22% of the participants had  high 
Framingham risk scores, (Bobes et al. 2007). The lower FRS scores are likely related to the young age 
of the participants in this study, which could explain lower rates of most of the CVD risk factors like 
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hypertension, diabetes and obesity, all of which tend to increase with age (Jousilahti Pekka et al. 
1999).One Italian study done among  595 men and 748 women showed that  older age was associated 
with higher levels of interleukin-6 IL-1 receptor antagonist, C-reactive protein and fibrinogen, resulting in 
a pro-inflammatory state that increases the risk of CVD (Ferrucci et al. 2005) 
This study found that the absolute estimated 10 year risk of developing CVD between patients and control 
was comparable and that the female patients had higher risk scores compared to controls while there 
was no difference between male patients and controls. This in contrast with the findings that  the Clinical 
Trials of Antipsychotic Treatment Effectiveness (CATIE) study that reported significantly higher FRS 
between patients and controls generally and that both male and female patients had higher scores than 
male and female controls (Goff et al. 2005). 
In this study FRS scores were significantly associated with female Sex, smoking and MetS. These 
findings are comparable to the findings of a Chinese study that compared  83 patients with schizophrenia 
and 243 controls that reported that smoking and MetS were the leading contributors of increased CVD 
risk  (Tay, Nurjono, and Lee 2013). Similarly a study done in Malaysia among 270 patients with 
Schizophrenia reported FRS scores among patients with MetS compared to those without MetS (Said et 
al. 2012).The FRS were also associated with age,  in agreement with existing literature that indicate that 
the estimation of absolute CVD risk is highly dependent an age. As an example a study done among 179 
patients with psychosis in San Diego revealed that the FRS was increased by 50% due to age (H. Jin et 
al. 2011). These findings indicate a need to reconsider the best way to evaluate CVD risk in a setting with 
young participants. 
5.6 The treatment gap for metabolic disorders 
 In this study sample, most of patients with hypertension as well as diabetes were not previously 
diagnosed hence were not on medication. Further, no documentation of prevention or treatment for 
dyslipidaemia was found on review of patients’ files who had evidence of dyslipidaemia and obesity, 
suggesting a potential gap in the identification and management of CVD risk factors in the study setting. 
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This finding supports the fact that the rate of screening for CVD risk factors  is wanting in many settings  
as reported by  a study done in Durban South Africa among 331 patients who were treated with 
antipsychotics for SMI for at least 6 months which reported  very low rates of screening for components 
of MetS; 0.6% for abdominal obesity,, 3.9%  for hyperglycaemia and 1.8% for dyslipidaemia (Saloojee, 
Burns, and Motala 2014). Similar findings have been reported in developed countries such as the US, in 
which diabetes care and hypertension control was found to be 14-49% lower among patients with mental 
illness compared to unaffected controls (J. Liu et al. 2017). One review also reported that mentally ill 
persons are 30% less likely to  be investigated or to receive care for CVD risk factors, both before and 
after initiation of antipsychotics (D. Scott, Platania-Phung, and Happell 2012).  An observational study 
done among 76,799 patients with  DM and mental illness and  236,827  patients with DM but no mental 
illness reported lower DM care among patients with mental illness compared to those without mental 
illness(Frayne et al. 2005). Like in our study low treatment with statins among patients has also been 
documented.  For example, a study done among 40,992 patients with psychosis in Maryland reported 
that about half of patients with lipid derangements did not receive treatment with statins (Kreyenbuhl et 
al. 2008). A number of other studies have documented sub-optimal care for cardiovascular risk factors 
among patients with mental illness  - this could be due to individual factors such as stigma; de-
prioritisation of psychiatric (versus biomedical) symptoms; or patients’ inability to describe their symptoms 
due to their mental illness (Marc De Hert et al. 2011). Systemic  challenges such as lack of capacity (in 
terms of knowledge and infrastructure) for monitoring the physical illness; and limited time and human 
resources may also contribute to the treatment gap for CVD risk factors (M. De Hert et al. 2009).  This 
may ultimately result in increased costs related to treating complications (McIntyre et al. 2006). 
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5.7:  Relevance of the Study to Clinical Practice and Recommendations.  
This study established that patients with psychosis have high prevalence of CVD risk factors and that 
there are gaps in interventions to address these risk factors in the context of MTRH, Eldoret.  This is in 
agreement with the findings of the Lancet commission for protecting physical health in people with mental 
illness, which in summary, reported a 1.4 to 2 increased risk of obesity, and CVD as well as an increased 
risk of lifestyle factors such as smoking, sedentary behaviour and alcohol use among patients with mental 
illness, and  also observed that  that people with mental illness are likely to receive  lower quality of care 
compared to the general population , and gave several suggestions for addressing these risk factors 
using a multidisciplinary approach (Firth et al. 2019).   
To address the burden of specific CVD risk factors in the setting of Eldoret  there is a need to consider  
implementing  a number of suggested solutions put forward in the Lancet commission  as well as in earlier  
literature (Samele 2004). 
 Inclusion of simple strategies  that are  achievable even in resource limited setting  is a potentially good 
place to start , for example; active assessment of  physical health symptoms and  CVD risk factor 
symptoms by use of  checklists for physical health as well as  routine systematic questioning  (Phelan M 





 Table 24: Addressing the cardiovascular health of patients with psychosis 
Cardiovascular risk factors  Potential solution 
Biological,  genetics 
Immune factors 
Early screening and prevention 
Lifestyle: Smoking, Poor diet, Exercise, 
harmful alcohol use 
 
Individualised/ Flexible  interventions 
Education, 
Nicotine replacement therapy 
Nutritional education 
Prescribe and monitor exercise programs 
Motivational interviews as part of care 
 Addiction counselling 
Medication  induced CVD risk Risk assessment early on before initiation of medication 
Routine screening, avoid polypharmacy, use drugs with low 




Multidisciplinary  approach 
Integrated care 
Capacity building among health care workers 
Allocate finances to allow investigations and management 
Use of technology 
Putting in place appropriate policies 
Lack of Support systems 
Stigma 
Family education and involvement 




There is also need to consider incorporating into routine  care  lifestyle modification activities with 
attention to diet and exercise – both of which promote the mental wellbeing and cardiovascular health of 
patients with psychosis (Bonfioli et al. 2012) This may include targeted behavioural weight loss (Daumit 
et al. 2013),(Bartels et al. 2015), in which physicians collaboratively identify physical activity goals for a 
specific client, reinforce efforts to reach the targets, and  continuously address barriers to physical activity 
(Richardson et al. 2005). To demonstrate this, the Life Goal Corroborated Care Trial reported improved 
blood pressure and reduction  in mental symptoms associated with semi-structured guidance on 
managing physical and mental health symptoms through healthy behaviour changes augmented by 
ongoing care (Kilbourne et al. 2017), (Kilbourne et al. 2013).  Clinicians should routinely discuss  and 
encourage  healthy and culturally appropriate diets (such as fresh fruit and vegetables and meals made 
at home) and  discourage unhealthy foods  (such as fast foods and hotel foods) (Pérez-Martínez et al. 
2017). Early involvement of nutritionists for individual and group support  (where possible) is also key  in 
promoting healthy diets (Teasdale et al. 2017).  Strategies should be employed to  mitigate potential poor  
adherence to these lifestyle changes  such as psychoeducation group sessions and use of incentives 
(Andrade 2016) , as the lifestyle changes need to be   sustained over long periods in order  translate into 
long-term reduction in CVD  risk (Patnode et al. 2017). 
Prevention or cessation of alcohol consumption and cigarette smoking should also be incorporated into 
the care of patients with psychosis (Compton, Daumit, and Druss 2006). Although smoking cessation is 
an effective   and cost-effective way to improve cardiovascular health (H. Lee and Son 2019),  cessation 
therapies are not widely implemented partly  due to the perception that smoking is a “lifestyle choice”, or 
relapse is common (Erhardt 2009).  Medication to assist smoking cessation, such as bupropion, 
varenicline and nicotine replacement therapies - as well as group and individual psychotherapies - should 
also be routinely incorporated into care where feasible (Tsoi, Porwal, and Webster 2013). 
Antipsychotic treatment should also be optimised, by encouraging monotherapy, use of minimum 
effective doses and attention to increased risk. For vulnerable groups e.g. children, the elderly and 
patients with a genetic predisposition to metabolic disorders, medication with lower risk of metabolic side 
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effects should be considered e.g.  first-generation antipsychotics are often cost effective, as effective as 
second generation antipsychotics , but with a lower risk of metabolic adverse effects (Naber and Lambert 
2009), (Linmarie Sikich et al. 2008). Metformin may also be prescribed in cases of refractory metabolic 
symptoms as  this agent has demonstrated efficacy (Praharaj et al. 2011), (Zheng et al. 2015), and is 
available and affordable in most settings (Siskind et al. 2016). 
Mechanisms of early identification of high-risk patients, as well  as routine monitoring of  the metabolic 
effects of medication, should be implemented (Marc De Hert et al. 2009). When initiating antipsychotic 
treatment, baseline weight, blood pressure, and fasting triglycerides should be measured; and an 
electrocardiogram done due to the risk of arrhythmias in patients  with existing heart disease (Warnier et 
al. 2015), (Rabkin 2015). Patients should also be assessed for a family history of type 2 DM, hypertension 
and obesity, in order to avoid medications that increase risk of these disorders. Weight and BMI  should 
then be monitored at each follow-up visit; and fasting blood glucose and lipid profile should be checked 
at week 12 after treatment initiation, and annually thereafter (Jesus, Jesus, and Agius 2015) . 
Integration of care   for CVD  and psychosis, employing a multidisciplinary team approach, is a potential 
mechanism for addressing current treatment gaps globally (T. J. R. Lambert and Newcomer 2009), 
(Vreeland 2007).  Capacity building and skills development are also key, in order to ensure that health 
professionals treating patients with mental illness are equipped to screen for CVD risk factors, and to 
initiate care or refer adequately. Continuous evaluation of care (e.g. via audit-based, quality improvement 
programmes and customised feedback to participating mental health services) could also complement 
the strategies highlighted above (T R E Barnes et al. 2015).  A holistic approach that gives weight to both 
physical and mental wellbeing  is key in optimising outcomes (Seeman 2016). 
Finally, education and involvement of patients and their families are integral to optimising adherence to 
the prescribed health promotion activities (Khasawneh and Shankar 2014).  Provision of adequate 
motivation will also be vital in ensuring that patients remain committed to prescribed interventions 
(Mamakou et al. 2018). 
129 
 
5.8:  Strength and   limitations of the study, and suggestions for future research.  
 A number of methodological limitations should be borne in mind when interpreting these study findings. 
First, an observational study design was undertaken. As a result, potential causal relationships between 
psychosis and CVD risk could not be ascertained.  In future, longitudinal studies of patients with newly-
diagnosed psychosis would enable more reliable estimates of the incidence of cardiovascular risk factors 
in this patient group, as well as enabling tests of causality.  
Second, convenience sampling was employed mainly and this could have resulted in selection bias as 
those who were available to participate may have had a different risk profile from those who were not 
available.  
Third, most data collected were self-reported (e.g. chronic medical conditions, tobacco use, alcohol 
consumption, exercise and diet).  This is likely to have introduced a reporting bias.  Future studies utilizing 
objective measures such as laboratory testing for chronic disorders and pedometers for exercise could 
mitigate the latter bias. 
Fourth, random blood glucose measurement was used to establish the presence of DM. While this was 
undertaken in order to overcome the challenge of ascertaining a  fasted state among the patients, it is 
possible that  some participants were actually in a fasted state hence excluded from the random sugar 
cut off of DM , hence giving  a lower  prevalence. In future, glycated haemoglobin (HbA1c) measurement 
could be undertaken to get more accurate assessments of the prevalence of DM in the study setting. 
Fifth, most patients in our study sample were being treated with olanzapine.  Thus, we were unable to 
compare the impact of different antipsychotics on cardiovascular risk profile in the study setting. Future 
studies stratifying patients according to antipsychotic medication would allow for comparison.   
Sixth, the use of records to establish treatment for dyslipidaemia (as was the case in our study) is 
inherently limited by the documentation itself.  Thus, it may be that our study findings were reflective of 
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incomplete records, rather than a true treatment gap.  In future, qualitative patient discussions centred 
on interventions implemented could be undertaken to complement hospital records. 
Seventh, the use of absolute scores to describe CVD risk has its limitations. For example FRS our patient 
group is quite low and can give a false impression of CVD risk of the setting, yet it may only be explained 
by the young age of the participants. In addition Framingham risk scores represent average values 
without considering individual variability in risk. Further, several other factors not included in the 
Framingham scores potentially modify absolute risk for individual for example the social economic status. 
Future studies could assess the FRS among older participants in the same setting and also compare 
different risk score estimating formulae. 
Eighth, there are variations in recommended cut off for various metabolic parameters like DM and 
hypertension and this has potential to give varying prevalence of metabolic disorders in different studies. 
These limitations notwithstanding, the current study provides novel and clinically relevant preliminary 
data of cardiovascular risk profile among patients with psychosis in Eldoret, Kenya.  One of the strengths 
of this study is the assessment of several cardiovascular risk indicators, given that most studies focus 
one or two CVD risk factors.  The second novel thing is the inclusion of nonconventional CVD risk factors 
in assessing the cardiovascular risk profile.  Work such as this may ultimately provide insight into the 




5.9:  Conclusion 
In the LMIC setting of Eldoret, patients with psychosis exhibited a high burden of a number of key CVD 
risk factors. Of note the prevalence of MetS, smoking and obesity were found to be significantly more 
prevalent than in the general population.  In this setting smoking and MetS, as well as age and female 
Sex contributed significantly to increased Framingham risk scores. It is worth noting that in this study 
smoking was the only CVD risk factor that was associated with exposure to potentially traumatic 
experiences. However our study did not establish a relationship between psychological distress, 
comorbid medical conditions or use of olanzapine with CVD risk factors. A number of gaps in current 
practice – both in terms of undiagnosed and of untreated metabolic disorders – were also identified.  In 
future, routine screening for various CVD risk factors could improve early identification of high risk 
patients.  Thereafter, coordinated and integrated interventions, drawing on multidisciplinary approaches 
and guided by contextually appropriate standardized guidelines, could be effective in improving patient 
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Appendix 1 consent 
Appendix 1a:  Patient Consent 
You are being invited to participate in a research study on the things that increase the likelihood of 
developing heart-related problems among patients on management for mental illness as compared to the 
general population.  The study is important as it will be useful in developing treatments and strategies of 
improving the physical health of people with mental illness.  This study will involve 600 participants. There 
is no very special reason why you are being asked to participate except that you fit in the criteria required 
for the study.    
This work is being done as part of a PHD program for Dr Edith Kwobah who is a consultant psychiatrist 
at the MTRH.  
 If you agree to participate, the study will take at most 2 hours of your time. There will be an initial interview 
in which several questions concerning your physical and psychological health, including negative 
experiences in the past will be asked. Subsequently you will have your weight, height, waist 
circumference, and blood pressure taken. A blood sample will also be taken to measure your sugar and 
fat levels. We will also carry out an examination of the heart that involves putting several metallic knobs 
on your chest. It is called an electrocardiogram, it assesses how the heart functions and it is painless.  
The benefit of participating in this study to you as an individual, is to get to know your health status with 
respect to your sugar levels, blood pressure, blood fat levels, weight and heart function.  Your results will 
be communicated to you by Dr E Kwobah.  
Participating in this research is entirely voluntary. You may terminate your participation at any point during 
the study without losing any benefits. 
This research has minimal risk to you, it will cause no grave harm. You may experience mild discomfort 
and pain during drawing of your blood samples. The interview will contain some questions of a sensitive 
nature which may cause you psychological discomfort .You will also spend more time in the hospital than 
usual in order to complete these study activities. However, the research team is prepared to help you 
deal with any physical or psychological pain that may arise. This information will be confidential but should 
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you choose not to answer, it will in no way affect your relations with the clinic.  
There are no costs to you for participating in the study.  You will also not receive any payments for 
participating in the study. 
The blood samples drawn for this study will be stored for a minimum of the two years duration of the 
study. Any further study done using the sample will strictly be upon approval by the ethics committee. 
The results of the study will be stored in a computer that is password protected and only accessible by 
those conducting the study. No one will be able to identify you or your results. Should the results be 
published, none of your individual information will be disclosed. You will not get the results of the study 
individually. 
If you have any questions about the study, please contact Dr. Edith Kwobah (phone no: 0721763412) at 
Moi Teaching and Referral Hospital. The Institutional Review and Ethics Committee of Moi University 
and Moi Teaching & Referral Hospital has reviewed this request to conduct this project.   You may   also 
contact the ethics committee at Moi Teaching & Referral Hospital building, 2nd floor. Door No. 219, P.O. 
Box. 3-30100 Eldoret, Kenya, Office line: 0787723677, Email: irecmtrh@gmail.com or contact@irec.or.ke 
By signing this document, you are voluntarily agreeing to participate in this study.  
I have understood the explanation given to me regarding the study. ALL OF MY 
QUESTIONS HAVE BEEN SATISFACTORILY ANSWERED, AND I WANT TO 
TAKE PART IN THIS RESEARCH STUDY. By signing below, I agree to participate 
in this study and I also permit the publication of the results of the study. I also accept 
that future research may be conducted using the sample stored during this study, 
on condition that such a study is approved by the ethical committees involved. 
 
Signature of the participant ___________________     Date ____________________ 





Appendix 1b: Control Consent 
 
You are being invited to participate in a research study comparing the risk of developing heart-related 
problems among patients on management for mental illness and participants without mental illness. The 
study is important as it will be useful in developing treatments and strategies of improving the physical 
health of people with mental illness.  This study will involve 600 participants. There is no very special 
reason why you are being asked to participate except that you fit in the criteria required for the study.    
This work is being done as part of a PHD program for Dr Edith Kwobah who is a consultant psychiatrist 
at the MTRH.  
The study will take at most 2 hours of your time. There will be an initial interview in which questions 
concerning your physical and psychological health, including negative experiences in the past will be 
asked. Subsequently you will have your weight, height, waist circumference, and blood pressure taken. 
A blood sample will also be taken to measure your sugar and fat levels. We will also carry out an 
examination of the heart that involves putting several metallic knobs on your chest. It is called an 
electrocardiogram, it assesses how the heart functions and it is painless.  
The benefit of participating in this study to you as an individual, is to get to know your health status with 
respect to your sugar levels, blood pressure, blood fat levels, weight and heart function.  Your results will 
be communicated to you by Dr E Kwobah. If any of these is found to be abnormal, you will either be 
initiated on medication or be referred to the relevant clinic for help.  
Participating in this research is entirely voluntary. You may terminate your participation at any point during 
the study without affecting your relationship or interaction with the hospital. 
This research has minimal risk to you and will cause no grave harm. You will, however, experience mild 
discomfort and pain during drawing of your blood samples. The interview will contain some questions of 
a sensitive nature which may cause you psychological discomfort .You will also spend time in the hospital 
in order to complete these study activities. However, the research team is prepared to help you deal with 
any physical or psychological pain that may arise. This information will be confidential but should you 
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choose not to answer, it will in no way affect your future relations with the hospital or the staff.  
There are no costs to you for participating in the study.  You will also not receive any payments for 
participating in the study. 
The results of the study will be stored in a computer that is password protected and only accessible by 
those conducting the study. No one will be able to identify you or your results. Should the results be 
published, none of your individual information will be disclosed. You will not get the results of the study 
individually. 
If you have any questions about the study, please contact Dr Edith Kwobah (phone no: 0721763412) at 
Moi Teaching and Referral Hospital. The Institutional Review and Ethics Committee of Moi University 
and Moi Teaching & Referral Hospital has reviewed this request to conduct this project.  You may also 
contact the ethics committee at Moi Teaching & Referral Hospital building, 2nd floor. Door No. 219, P.O. 
Box. 3-30100 Eldoret, Kenya, Office line: 0787723677, Email: irecmtrh@gmail.com or contact@irec.or.ke 
By signing this document, you are voluntarily agreeing to participate in this study.  
I have understood the explanation given to me regarding the study. ALL OF MY 
QUESTIONS HAVE BEEN SATISFACTORILY ANSWERED, AND I WANT TO 
TAKE PART IN THIS RESEARCH STUDY. By signing below, I agree to participate 
in this study and I also permit the publication of the results of the study. I also accept 
that future research may be conducted using the sample stored during this study, 
on condition that such a study is approved by the ethical committees involved. 
 
Signature of the participant ___________________     Date ____________________ 








Appendix 1c : University of California Brief Assessment of Capacity to Consent (UBACC) 
1. What is the purpose of the study that was just described to you? 
 
Circle 
Response: Two key concepts (1) risk of heart diseases. (2) Look at causes of heart 
disease among patients with mental illness.  
Neither concept  
One concept – either (1) OR (2)  






2. What makes you want to consider participating in this study? 
 
 
Response: Two key concepts: (1) Increase people’s knowledge about heart disease 
among patients with mental OR (2) possibility of finding improved treatments in the 
future.  
Neither concept , Give my blood or time for money, or get treatment 
One concept  




































6. If you participate in this study, what will you be asked to do? 
 
 
Response: Two tasks: (1) Answer questions about myself; (2) give blood   
None of the above  
One task either 1) OR (2)  






7. Please describe some of the risks or discomforts that you may experience?    
Response: Two key concepts: (1) Answering questions about myself could be 
uncomfortable; (2) Pain when blood is being withdrawn  
None of the above  
One concept 






8. Please describe some of the possible benefits of this study  
Response: Two key concepts: (1) helping humanity – increase knowledge about 
heart disease  OR (2) improved treatments in the future  
Neither concept: I will be paid to participate   
One concept – (1) helping humanity 



















No; I don’t know   









Research staff to add up scores from right-hand column.   Write number in box 





NEXT STEPS FOR RESEARCH STAFF 
 
1. If participant scores less than 20, review the questions that were not fully 
understood and re-administer those questions. 
 
2. Continue to explain and re-administer the specific questions not understood 
up to four times or until the participant receives a perfect score.  
 
3. If after four times the participant scores above 14.5, he or she can continue 
with the study. If after four times the participant scores below 14.5, STOP! 
He or she may not fully understand the study and should therefore not be 





Appendix 2: Study Announcement 
 
A research team in MTRH is conducting a research study on the risks of developing heart-related 
diseases. 
The study is seeking adults above 18 years of age.  
The study will involve an interview of about 45 minutes asking questions on physical and psychological 
well-being. Blood with be taken to measure blood sugar and body fat. Interested participants will have 
their blood sample taken to give and an electrocardiogram (ECG), a test of the heart function, done. 
The benefit of participating is that you get to know if you have high blood sugar, abnormal body fat, high 
blood pressure and whether your  weight or body fat is increasing your  risk of getting a heart disease. 
Anyone who is found to have an abnormality will be referred appropriately for care. 
Any interested participant may call the research coordinator on 0700 675 961 from 8am to 5pm on any 





Appendix 3: Data Collection Tool 
                                                                                       
       Academic Model Providing Access to Healthcare 
Telephone: 254 53 2033471/2P.O. BOX 4606, ELDORET Fax: 254 53 2060727 
 
           CVD Data Collection Tool 
PARTICIPANTS        Category                           Control       Patient 
P ID CVD …………………….   P ID NGAP………………..         Telephone No…………………… 
Clinical diagnosis (Patients only) …………………………………. 
 
Demographics 
1. Age in years……………. 
2. Sex……… 
A) Male…….  
B) Female …………. 
3. Marital status 
A) Currently Married 




F) Other (Specify): ………………………………. 
4. Highest level of Education 
 A) No formal schooling  
 B) Less than primary school  
 C) Primary school completed  
 D) Secondary school completed  
 E) High school completed  
 F) College/University completed  
 G) Post graduate degree  
5. What kind of work do you do? 
 A) Unemployed (Unable to work)  
 B) Unemployed (Able to work) 
 C) Formal employment (permanent or contract, 8am-5pm jobs) 
 D) Self-employed (business and farming) 
 E) Retired 
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Kessler 10 (controls only) 
 
  All of the Most of Some of A little of None of 
Please tick the answer that is correct for time 
the 
time the time the time the time 
(score 5) 
(score 
4) (score 3) (score 2) (score 1) you:        
       
1. In the past 4 weeks, about how often did       
 you feel tired out for no good reason?      
       
2. In the past 4 weeks, about how often did      
 you feel nervous?      
       
3. In the past 4 weeks, about how often did      
 you feel so nervous that nothing could      
 calm you down?      
       
4. In the past 4 weeks, about how often did      
 you feel hopeless?      
       
5. In the past 4 weeks, about how often did      
 you feel restless or fidgety?      
       
6. In the past 4 weeks, about how often did      
 you feel so restless you could not sit still?      
       
7. In the past 4 weeks, about how often did      
 you feel depressed?      
       
8. In the past 4 weeks, about how often did      
 you feel that everything was an effort?      
       
9. In the past 4 weeks, about how often did      
 you feel so sad that nothing could cheer      
 you up?      
       
10. In the past 4 weeks, about how often did      
 you feel worthless?      




LIFE EVENTS Checklist 
 
Listed below are a number of difficult or stressful things that sometimes happen to people. For each event 
check one or more of the boxes to the right to indicate that: (a) it happened to you personally; (b) you 
witnessed it happen to someone else; (c) you learned about it happening to a close family member or close 
friend; (d) you were exposed to it as part of your job (for example, paramedic, police, military, or other first 
responder); or (e) you’re not sure if it fits. 
 
Be sure to consider your entire life (growing up as well as adulthood) as you go through the list of events.  
 
 Happened Witnessed Learned Part of   
Event to me it about it my job  Not Sure  
1. Natural disaster (for example, flood, 
hurricane, tornado, earthquake) 
  
2. Fire or explosion  
 
3. Transportation accident (for example, car 
accident, boat accident, train wreck, plane crash) 
 
4. Serious accident at work, home, or during  
 recreational activity   
5. Exposure to toxic substance (for 
example, dangerous chemicals, radiation) 
 
6. Physical assault (for example, being  
attacked, hit, slapped, kicked, beaten up)   
7. Assault with a weapon (for example, being 
shot, stabbed, threatened with a knife, gun, 
bomb)  
8. Sexual assault (rape, attempted rape, 
made to perform any type of sexual act through 
force or threat of harm) 
 
9. Other unwanted or uncomfortable 
sexual experience 
 
10. Combat or exposure to a war-zone (in the  
 military or as a civilian)   
11. Captivity (for example, being kidnapped, 
abducted, held hostage, prisoner of war) 
  
12. Life-threatening illness or injury  
 
13. Severe human suffering  
 
14. Sudden violent death (for example,  
 homicide, suicide)  
 
15. Sudden accidental death  
 
16. Serious injury, harm, or death you 
caused to someone else 
 




1. Do you currently use any tobacco products such as chewing tobacco, snuffing tobacco, smoking cigarettes, 
shisha, betel nuts or pipes? 
A) Yes, if yes specify the type used…… frequency          amount per day ……………… 
B) No 
 
2. In the past, did you ever use tobacco products such as chewing tobacco, snuffing tobacco, smoking 
cigarettes, shisha, betel nuts or pipes? 




Alcohol Use (Audit-C) 
I) How often do you have a drink containing alcohol? 
(0) Never (Skip the rest of the questions) 
(1) Monthly or less 
(2) 2 to 4 times a month 
(3) 2 to 3 times a week 
(4) 4 or more times a week 
 
II) How many drinks containing alcohol do you have on a typical day when you are drinking? 
(0) 1 or 2 
(1) 3 or 4 
(2) 5 or 6 
(3) 7, 8, or 9 
(4) 10 or more 
 
III) How often do you have six or more drinks on one occasion? 
(0) Never 
(1) Less than monthly 
(2) Monthly 
(3) Weekly 
(4) Daily or almost daily 
 
 Other substances used:……………………Frequency……………….. 
 
Diet 
1. A ) In a typical week, on how many days do you eat fruits?.................................... 
B)  What quantity of fruits do you eat (in terms of pieces of fruits, types of fruits). 
…………………………………………………………. 
 
2. 1. A ) In a typical week, on how many days do you eat  vegetables?.................................... 






CIDI-Chronic Disease  Screener  
Have you ever been admitted to the hospital for a general medical condition?  
Yes                   No  
 
How many previous hospitalizations have you had?      
1  2  3    4 5  
 




The next few questions are about health problems you might have had at any time in your life. Have you 
ever had any of the following?  
 
Arthritis or rheumatism?                    
Yes            No   Don't know    Refused to answer  
Chronic back or neck problems?  
Yes  No   Don't know   Refused to answer  
 
Frequent or severe headaches? 
Yes   No   Don't know   Refused to answer  
 
Any other chronic pain?        
Yes   No   Don't know  Refused to answer  
 
Seasonal allergies like hay fever?      
Yes  No   Don't know   Refused to answer  
A stroke?          
Yes   No   Don't know   Refused to answer  
A heart attack?         
Yes  No   Don't know   Refused to answer  
 
Did a doctor or other health professional ever tell you that you had any of the following illnesses?  
Heart disease?         
Yes   No   Don't know   Refused to answer  
 
High Blood Pressure?        
Yes   No   Don't know   Refused to answer  
 
Asthma?          
Yes   No   Don't know   Refused to answer 
 
Tuberculosis?         
Yes   No   Don't know   Refused to answer 
 
Any other chronic lung disease, like COPD or emphysema?   
Yes   No   Don't know   Refused to answer  
 
Diabetes or high blood sugar?   
Yes   No   Don't know   Refused to answer 
      
An ulcer in your stomach or intestine?    
Yes   No   Don't know   Refused to answer 
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HIV infection or AIDS?  
Yes   No   Don't know   Refused to answer        
Epilepsy or seizures?  
Yes   No   Don't know   Refused to answer 
 
Cancer?  
Yes   No   Don't know   Refused to answer 
         
Other conditions?   
Yes   No    
  




Neuroleptic use (for patients only) 
What medications are you currently using? [May confirm with the notes in the file] 
a) Olanzapine   dose   mg/24 hours           date of  onset_____________ 
b) Chropromazine   dose   mg/24 hours           date of onset_____________ 
c) Haloperidol   dose   mg/24 hours              date of  onset_____________ 
d) Fluphenazine decanoate dose   mg/24 hours             date of  onset_____________ 
e) Zuclopenthixol  dose   mg/24 hours           date of  onset_____________ 
f).Amitriptiline   dose   mg/24 hours           date of  onset_____________ 
g) Fluoxetine   dose   mg/24 hours             date of  onset_____________ 
 
h) Others:    
Name ……………………..       Dose …………………mg/24hrs                    date of onset_____________ 




Section E: Physical activity 
1. In a typical week, on how many days do you do vigorous-intensity activities that increase your breathing and 
heart rate, as part of your work? 
A) 3-7 days 
B) <3 days 
 
2. In a typical week, on how many days do you walk or bicycle for at least 10 minutes continuously to get to and 
from places? 
A) 3-7 days 
B) <3 days 
 
3. In a typical week, on how many days do you do vigorous-intensity sports, fitness or recreational (leisure) 
activities? 
A) 3-7 days 
B) <3 days 
 
4. How much time do you usually spend sitting or reclining  
A) Less than 3 hours in a day 




 Childhood Trauma Questionnaire – Short Form (CTQ-SF) 
 
 















































1. I didn’t have enough to eat. 1 2 3 4 5 
2. I knew there was someone to take care of me and protect me 1 2 3 4 5 
3. People in my family called me things like “stupid”, “lazy”, or “ugly”. 1 2 3 4 5 
4. My parents were too drunk or high to take care of me. 1 2 3 4 5 
5. There was someone in my family who helped me feel important or 
special. 
1 2 3 4 5 
6. I had to wear dirty clothes. 1 2 3 4 5 
7. I felt loved. 1 2 3 4 5 
8. I thought that my parents wished I had never been born. 1 2 3 4 5 
9. I got hit so hard by someone in my family that I had to see a doctor or 
go to the hospital. 
1 2 3 4 5 
10. There was nothing I wanted to change about my family. 1 2 3 4 5 
11. People in my family hit me so hard that it left bruises or marks. 1 2 3 4 5 
12. I was punished with a belt, a board, a cord, or some hard object. 1 2 3 4 5 
13. People in my family looked out for each other. 1 2 3 4 5 
14. People in my family said hurtful or insulting things to me. 1 2 3 4 5 
15. I believe that I was physically abused. 1 2 3 4 5 
16. I had the perfect childhood. 1 2 3 4 5 
17. I got hit or beaten so badly that it was noticed by someone like a 
teacher, neighbor, or doctor. 
1 2 3 4 5 
18. I felt that someone in my family hated me. 1 2 3 4 5 
19. People in my family felt close to each other. 1 2 3 4 5 
20. Someone tried to touch me in a sexual way, or tried to make me touch 
them. 
1 2 3 4 5 
21. Someone threatened to hurt me or tell lies about me unless I did 
something sexual with them. 
1 2 3 4 5 
22. I had the best family in the world. 1 2 3 4 5 
23. Someone tried to make me do sexual things or make me watch sexual 
things. 
1 2 3 4 5 
24. Someone molested me. 1 2 3 4 5 
25. I believe that I was emotionally abused. 1 2 3 4 5 
26. There was someone to take me to the doctor if I needed it. 1 2 3 4 5 
27. I believe that I was sexually abused 1 2 3 4 5 








Section I: Physical measurements 
 
Measurement   
1. Height in centimeters   
2. Weight in Kilograms   
3. Waist circumference in Centimeters   
4. Blood pressure in mmhg   
1st reading Systolic                           Diastolic 
2nd reading Systolic                           Diastolic 
3rd reading Systolic                           Diastolic 
Average blood pressure  
 
 
Section J: Biochemical measurements (units in mmol/l) 
2. Random Blood Sugar ________________ 
3. Total Cholesterol  ________________ 
4. Triglycerides  ________________ 
5. LDL    ________________ 






Appendix 4: Procedures for various study measurements 
a)  Random blood sugar, lipid profile 
The procedure of withdrawing blood will be as follows: 
• The participant will remain in sitting position for 15 minutes prior to blood collection. 
• The arm will be exposed to search for a vein. 
•  Tourniquet will be placed around the arm 
• Injection site will be sterilized using alcohol swab. 
• A 20 or 22 gauge needle will be inserted into the identified vein.  
• Immediately after the insertion, the tourniquet will be released. 
•  10 mls of blood will be drawn into a 10 ml plain vacutainer, 
• The needle will be removed and an adhesive bandage placed on the puncture site.  
The Vacutainer will be labelled appropriately. Blood will be taken to the laboratory for analysis by the research nurse. 
Analysis will be done on the same day so no need for storage. 
 
b) The weight of participants will be taken in order to calculate body mass index (BMI), i.e. Weight relative to the height. The 
weight will be measured with a 762 Dial Bathroom Floor Scale.  
Below are the steps that will be followed in measuring weight: 
• The scale will be placed on a firm, flat surface. 
• Participant will be asked to remove their footwear (shoes, slippers, sandals). 
• The participant will be asked to step onto scale with one foot on each side of the scale. 
• Participant will be asked to: stand still, face forward, place arms on the side and wait until they will be asked to step 
off. 
• The weight in kilograms will be recorded on the participant’s file. 
• The participant will be asked to step off the scale.  
 
c). The height of participants will be measured as a composite of body mass index (BMI). The height will be measured with 
a Mechanical roll-up measuring tape (Seca 260). 
The steps that will be followed in measuring height will be as follows: 
• The participant will be asked to remove their footwear (shoes, slippers, sandals, etc.) and head gear (hat, cap, hair 
bows, comb, and ribbons). However, those with a scarf or veil shall not be asked to remove them (measurement may be 
taken over light fabric). 
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• Participant will be asked stand next to the measuring wall facing the research assistant/ investigator. 
• Participant will be asked to stand with: feet together, heels against the measuring board/wall, knees straight. 
• Participant will be asked to look straight ahead and not tilt their head up. 
• The research assistant/ investigator will make sure eyes are the same level as the ears. 
• The measure arm will be moved gently down onto the head of the participant and the participant asked to breathe 
in and stand tall. 
• The height will be read in centimetres at the exact point. 
• The participant will be asked to step away from the measuring board/wall. 
• The height measurement in centimetres will be recorded in the participant’s file  
d) Waist circumference: A standard tape measure will be used. Patient will be instructed to expose the abdomen fully while 
standing and lift both arms. The RA will then measure the waist circumference in centimetres at the midpoint between the 
iliac crests and the lower rib laterally and passing over the umbilicus anteriorly. 
e) Blood pressure ; This will be taken using an Omron M2 compact upper arm blood pressure (BP) monitor (Omron 
Healthcare, Inc., 1200 Lakeside Drive, Bannockburn, Illinois 60015). Patients will be required to have had at least 15 minutes’ 
rest in a quiet place and in a relaxed sitting position with no tight fitting clothing on the upper arm, or any thick clothing such 
as a sweater. 
 Steps that will be followed are as follows: 
• Participant will be seated upright with the back straight and right arm placed on the table so that the cuff will be on 
the same level as the heart.  
• Cuff will be wrapped on the arm so that the bottom of the cuff will be at least 1cm above the elbow. The cuff will 
then be fastened snugly.  
• Start button will then be pressed and the cuff will automatically inflate to take the blood pressure reading.  
• Blood pressure and pulse rate results will be displayed on the on the screen of the machine.  
• Blood pressure readings will be recorded on the pro-forma.  
In case an error occur during the process, the cuff will be deflated and the process repeated.  




Appendix 5:  Management and referral of participants with positive results 
 
As soon as the results are out (immediately for blood pressure, and random blood sugar, and later for lipid profile), 
the research nurse will inform Dr Kwobah. 
 Dr Kwobah will contact the client face to face or on the provided contact. 
 She will inform the participants of the abnormal results.  
She will discuss the need for care.  
She will initiate treatment, in consultation with a physician, where urgent care is needed. She will also fill the MTRH 
consultation form for a booking to the appropriate clinic; general medical outpatient clinic or cardiology clinic.  
In case of psychological distress resulting from the study procedures or otherwise, Dr Kwobah will assess the client 
and determine the appropriate course of action.  She will either manage the patient or link them to a psychologist 
in the hospital for relevant psychological support. 
 
Appendix 6:  Sample handling and storage  
 (1) Blood will be collected into a Vacutainer by the research assistant (nurse or clinical officer). The vacutainer will 
be labelled appropriately sing the participants study ID. 
 (2)  The blood will be taken to the Laboratory  
3. It will be allowed to stand for a minimum of 45 min at room temperature to allow complete clotting and clot 
retraction.  
(3)  It will be centrifuged by the laboratory technician. 
4. Serum will be analyses for the lipids appropriately. 
5.  Any extra sample will be stored at -80°C for the period of the study which is 2 years. 
 
